Anti-garp antibody

ABSTRACT

The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody. It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like. An anti-GARP antibody that binds to GARP and exhibits inhibitory activity to Treg function and exhibits ADCC activity is obtained, and moreover a pharmaceutical composition for use in tumor therapy, comprising the aforementioned antibody, etc. is obtained.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 15/761,045, filed on Mar. 16, 2018, which is a U.S. national stage application of International Patent Application No. PCT/JP2016/078067, filed Sep. 23, 2016, which claims the benefit of priority to Japanese Patent Application No. 2015-187488, filed Sep. 24, 2015, the entireties of which are incorporated herein by reference.

TECHNICAL FIELD

The present invention relates to an antibody that binds to GARP and is useful as a therapeutic agent for a tumor, and a method for treating a tumor using the aforementioned antibody.

BACKGROUND ART

Regulatory T cells (Treg) are the main causative cells inducing immune tolerance that is observed in the tumor area of cancer patients. That is to say, in cancer patients, groups of immune cells that intrinsically work to kill tumors are rendered into a state of immune suppression by activated Treg in the tumor, and this leads to the malignant progression of the tumor [Non Patent Literature 1].

Glycoprotein-A Repetitions Predominant (GARP) is a protein with a single-pass transmembrane structure [Non Patent Literature 2], and this protein is expressed on the cell surface of activated Treg and forms a complex with latent TGF-β (a precursor of TGF-β which is an important molecule for inducing immune tolerance) [Non Patent Literature 3].

As a result of the cell-cell interaction between Treg and target cells to which the Treg induces immunosuppression, TGF-β is matured from latent TGF-β by GARP on the cell surface of Treg and secreted from Treg, and the immunosuppressive signals of TGF-β are directly transmitted to the target cells [Non Patent Literature 4, 5]. It has been demonstrated that the membrane-bound GARP expressed on the cell surface is necessary for such maturation of TGF-β [Non Patent Literature 5]. On the other hand, it has also been demonstrated that soluble GARP that lacks a transmembrane region suppresses proliferation of CD4 positive T cells when it is directly added to the cell culture [Non Patent Literature 6]. Thus, it cannot be ruled out that there is an immunosuppressive mechanism of GARP which does not require TGF-β maturation on the cell membrane.

GARP is not only expressed by Treg from peripheral blood when they get activated, but also in a clinical setting by tumor infiltrating T cells at tumor sites of cancer patients [Non Patent Literature 7], by Treg existing in ascites [Non Patent Literature 8], and also by Treg circulating in the peripheral blood of cancer patients [Non Patent Literature 9].

In a report investigating the effect of inhibition of GARP expression on the function of Treg, siRNA-targeting GARP inhibited the immunosuppressive function of Treg on the proliferative responses of helper T cells, but such an inhibitory effect was partial [Non Patent Literature 10].

In another report, anti-GARP antibodies (MHG-8 and LHG-10) which had been obtained for their abilities to inhibit TGF-β maturation inhibited the suppressive function of A1 cells, which is a Treg cell line [Non Patent Literature 11] established from hemochromatosis patients, on the proliferative responses of helper T cells [Patent Literature 1 and Non Patent Literature 12]. However, it is not known whether or not the aforementioned antibodies effectively exhibit such inhibitory effects on Treg in a tumor microenvironment, and to date, no anti-GARP antibody having such effects has been reported so far. An antibody recognizing both GARP and TGF-β is also known [Patent Literature 2].

It has been demonstrated that the excessive presence and the activation of Treg in patients having malaria and HIV infection exhibit a correlation with the disease state [Non Patent Literatures 13 and 14], and that the removal of Treg resulted in remission of the disease state in murine models for the diseases [Non Patent Literatures 15 and 16].

CITATION LIST Patent Literature

-   Patent Literature 1: WO2015/015003 -   Patent Literature 2: WO2016/125017

Non Patent Literature

-   Non Patent Literature: 1: Int J Cancer. 2010 Aug. 15; 127(4):     759-67. -   Non Patent Literature: 2: PLoS One. 2008; 3(7): e2705. -   Non Patent Literature: 3: Proc Natl Acad Sci USA. 2009; 106(32):     13445-50. -   Non Patent Literature: 4: Eur J Immunol. 2009; 39(12): 3315-22. -   Non Patent Literature: 5: Mol Biol Cell. 2012; 23(6): 1129-39. -   Non Patent Literature: 6: Blood. 2013; 122(7): 1182-91. -   Non Patent Literature: 7: Eur J Immunol. 2012 Jul; 42(7): 1876-85. -   Non Patent Literature: 8: Clin Immunol. 2013 October; 149(1):     97-110. -   Non Patent Literature: 9: Cancer Res. 2013; 73: 2435. -   Non Patent Literature: 10: Proc Natl Acad Sci USA. 2009 Aug. 11;     106(32): 13445-50. -   Non Patent Literature: 11: Eur J Immunol. 2009; 39(12): 869-82. -   Non Patent Literature: 12: Sci Transl Med. 2015 Apr. 22; 7(284) -   Non Patent Literature: 13: PLoS One. 2008 Apr. 30; 3(4): e2027. -   Non Patent Literature: 14: Clin Exp Immunol. 2014 June; 176(3):     401-9. -   Non Patent Literature: 15: J Immunol. 2012 Jun. 1; 188(11): 5467-77. -   Non Patent Literature: 16: PLoS Pathog. 2013; 9(12): e1003798.

SUMMARY OF INVENTION Technical Problem

It is an object of the present invention to provide an antibody, which inhibits the function of Treg in a tumor and is thereby used as a pharmaceutical product having therapeutic effects, a method for treating a tumor using the aforementioned antibody, and the like.

Solution to Problem

The present inventors have conducted intensive studies directed towards achieving the aforementioned object. As a result, the inventors have found an antibody that specifically binds to GARP and exhibits an activity of inhibiting the function of Treg via antibody-dependent cellular cytotoxicity, thereby completing the present invention. Specifically, the present invention includes the following aspects of the invention.

-   (1) An antibody having the following properties: -   (a) specifically binding to Glycoprotein-A Repetitions Predominant     (GARP); -   (b) having an inhibitory activity to the immunosuppressive function     of regulatory T cells; -   (c) having antibody-dependent cellular cytotoxic (ADCC) activity;     and -   (d) having in vivo antitumor activity. -   (2) The antibody according to the above (1), wherein the GARP is a     molecule consisting of the amino acid sequence shown in SEQ ID NO:     1. -   (3) The antibody according to the above (1) or (2), which binds to: -   (a) amino acid sequence portions at amino acid positions 366 to 377,     407 to 445 and 456 to 470 shown in SEQ ID NO: 1, -   (b) amino acid sequence portions at amino acid positions 54 to 112     and 366 to 392 shown in SEQ ID NO: 1, -   (c) amino acid sequence portions at amino acid positions 352 to 392     shown in SEQ ID NO: 1, or -   (d) amino acid sequence portions at amino acid positions 18 to 112     shown in SEQ ID NO: 1. -   (4) The antibody according to any one of the above (1) to (3), which     has competitive inhibitory activity, for binding to GARP, against an     antibody having: -   (a) a heavy chain consisting of the amino acid sequence shown in SEQ     ID NO: 2 and a light chain consisting of the amino acid sequence     shown in SEQ ID NO: 3, -   (b) a heavy chain consisting of the amino acid sequence shown in SEQ     ID NO: 4 and a light chain consisting of the amino acid sequence     shown in SEQ ID NO: 5, -   (c) a heavy chain consisting of the amino acid sequence shown in SEQ     ID NO: 25 and a light chain consisting of the amino acid sequence     shown in SEQ ID NO: 27, or -   (d) a heavy chain consisting of the amino acid sequence shown in SEQ     ID NO: 29 and a light chain consisting of the amino acid sequence     shown in SEQ ID NO: 31. -   (5) The antibody according to any one of the above (1) to (4),     wherein the tumor is a cancer. -   (6) The antibody according to the above (5), wherein the cancer is     lung cancer, kidney cancer, urothelial cancer, colon cancer,     prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic     cancer, breast cancer, melanoma, liver cancer, bladder cancer,     stomach cancer, esophageal cancer, or blood cancer. -   (7) The antibody according to any one of the above (1) to (6), which     has: -   (a) CDRH1 consisting of the amino acid sequence at amino acid     positions 26 to 35 shown in SEQ ID NO: 2, CDRH2 consisting of the     amino acid sequence at amino acid positions 50 to 66 shown in SEQ ID     NO: 2 and CDRH3 consisting of the amino acid sequence at amino acid     positions 99 to 107 shown in SEQ ID NO: 2, and CDRL1 consisting of     the amino acid sequence at amino acid positions 23 to 36 shown in     SEQ ID NO: 3, CDRL2 consisting of the amino acid sequence at amino     acid positions 52 to 58 shown in SEQ ID NO: 3 and CDRL3 consisting     of the amino acid sequence at amino acid positions 91 to 101 shown     in SEQ ID NO: 3, -   (b) CDRH1 consisting of the amino acid sequence at amino acid     positions 26 to 35 shown in SEQ ID NO: 4, CDRH2 consisting of the     amino acid sequence at amino acid positions 50 to 66 shown in SEQ ID     NO: 4 and CDRH3 consisting of the amino acid sequence at amino acid     positions 99 to 112 shown in SEQ ID NO: 4, and CDRL1 consisting of     the amino acid sequence at amino acid positions 23 to 36 shown in     SEQ ID NO: 5, CDRL2 consisting of the amino acid sequence at amino     acid positions 52 to 58 shown in SEQ ID NO: 5 and CDRL3 consisting     of the amino acid sequence at amino acid positions 91 to 100 shown     in SEQ ID NO: 5, -   (c) CDRH1 consisting of the amino acid sequence at amino acid     positions 45 to 54 shown in SEQ ID NO: 25, CDRH2 consisting of the     amino acid sequence at amino acid positions 69 to 78 shown in SEQ ID     NO: 25 and CDRH3 consisting of the amino acid sequence at amino acid     positions 118 to 125 shown in SEQ ID NO: 25, and CDRL1 consisting of     the amino acid sequence at amino acid positions 44 to 54 shown in     SEQ ID NO: 27, CDRL2 consisting of the amino acid sequence at amino     acid positions 70 to 76 shown in SEQ ID NO: 27 and CDRL3 consisting     of the amino acid sequence at amino acid positions 109 to 117 shown     in SEQ ID NO: 27, or -   (d) CDRH1 consisting of the amino acid sequence at amino acid     positions 45 to 54 shown in SEQ ID NO: 29, CDRH2 consisting of the     amino acid sequence at amino acid positions 69 to 77 shown in SEQ ID     NO: 29 and CDRH3 consisting of the amino acid sequence at amino acid     positions 117 to 128 shown in SEQ ID NO: 29, and CDRL1 consisting of     the amino acid sequence at amino acid positions 44 to 54 shown in     SEQ ID NO: 31, CDRL2 consisting of the amino acid sequence at amino     acid positions 70 to 76 shown in SEQ ID NO: 31 and CDRL3 consisting     of the amino acid sequence at amino acid positions 109 to 117 shown     in SEQ ID NO: 31. -   (8) The antibody according to any one of the above (1) to (7), which     has: -   (a) a heavy chain variable region consisting of the amino acid     sequence at amino acid positions 1 to 118 shown in SEQ ID NO: 2, and     a light chain variable region consisting of the amino acid sequence     at amino acid positions 1 to 112 shown in SEQ ID NO: 3, -   (b) a heavy chain variable region consisting of the amino acid     sequence at amino acid positions 1 to 123 shown in SEQ ID NO: 4, and     a light chain variable region consisting of the amino acid sequence     at amino acid positions 1 to 111 shown in SEQ ID NO: 5, -   (c) a heavy chain variable region consisting of the amino acid     sequence at amino acid positions 20 to 136 shown in SEQ ID NO: 25,     and a light chain variable region consisting of the amino acid     sequence at amino acid positions 21 to 129 shown in SEQ ID NO: 27,     or -   (d) a heavy chain variable region consisting of the amino acid     sequence at amino acid positions 20 to 139 shown in SEQ ID NO: 29,     and a light chain variable region consisting of the amino acid     sequence at amino acid positions 21 to 129 shown in SEQ ID NO: 31. -   (9) The antibody according to any one of the above (1) to (8),     wherein the constant region is a human-derived constant region.     (10)The antibody according to any one of the above (1) to (9), which     has: -   (a) a heavy chain consisting of the amino acid sequence shown in SEQ     ID NO: 2, and a light chain consisting of the amino acid sequence     shown in SEQ ID NO: 3, -   (b) a heavy chain consisting of the amino acid sequence shown in SEQ     ID NO: 4, and a light chain consisting of the amino acid sequence     shown in SEQ ID NO: 5, -   (c) a heavy chain consisting of the amino acid sequence at amino     acid positions 20 to 466 shown in SEQ ID NO: 25, and a light chain     consisting of the amino acid sequence at amino acid positions 21 to     234 shown in SEQ ID NO: 27, or -   (d) a heavy chain consisting of the amino acid sequence at amino     acid positions 20 to 469 shown in SEQ ID NO: 29, and a light chain     consisting of the amino acid sequence at amino acid positions 21 to     234 shown in SEQ ID NO: 31. -   (11) The antibody according to any one of the above (1) to (10),     which is humanized. -   (12) The antibody according to the above (11), which has:

a heavy chain variable region consisting of an amino acid sequence selected from the group consisting of:

-   (a) the amino acid sequence at amino acid positions 20 to 136 shown     in SEQ ID NO: 33, -   (b) the amino acid sequence at amino acid positions 20 to 136 shown     in SEQ ID NO: 35, -   (c) the amino acid sequence at amino acid positions 20 to 139 shown     in SEQ ID NO: 41, -   (d) an amino acid sequence having homology of at least 95% or more     to the sequence of a framework region other than at each CDR     sequence in the sequences of (a) to (c), and -   (e) an amino acid sequence comprising a deletion, substitution or     addition of one or several amino acids in the sequence of a     framework region other than at each CDR sequence in the sequences     of (a) to (c), and

a light chain variable region consisting of an amino acid sequence selected from the group consisting of:

-   (f) the amino acid sequence at amino acid positions 21 to 129 shown     in SEQ ID NO: 37, -   (g) the amino acid sequence at amino acid positions 21 to 129 shown     in SEQ ID NO: 39, -   (h) the amino acid sequence at amino acid positions 21 to 129 shown     in SEQ ID NO: 43, -   (i) an amino acid sequence having homology of at least 95% or more     to the sequence of a framework region other than at each CDR     sequence in the sequences of (f) to (h), and -   (j) an amino acid sequence comprising a deletion, substitution or     addition of one or several amino acids in the sequence of a     framework region other than at each CDR sequence in the sequences     of (f) to (h). -   (13) The antibody according to the above (11) or (12), which has: -   (a) a heavy chain variable region consisting of the amino acid     sequence at amino acid positions 20 to 136 shown in SEQ ID NO: 33,     and a light chain variable region consisting of the amino acid     sequence at amino acid positions 21 to 129 shown in SEQ ID NO: 37, -   (b) a heavy chain variable region consisting of the amino acid     sequence at amino acid positions 20 to 136 shown in SEQ ID NO: 35,     and a light chain variable region consisting of the amino acid     sequence at amino acid positions 21 to 129 shown in SEQ ID NO: 39,     or -   (c) a heavy chain variable region consisting of the amino acid     sequence at amino acid positions 21 to 139 shown in SEQ ID NO: 41,     and a light chain variable region consisting of the amino acid     sequence at amino acid positions 21 to 129 shown in SEQ ID NO: 43. -   (14) The antibody according to any one of the above (11) to (13),     which has: -   (a) a heavy chain selected from the group consisting of a heavy     chain having the amino acid sequence at amino acid positions 20 to     466 shown in SEQ ID NO: 33, a heavy chain having the amino acid     sequence at amino acid positions 20 to 466 shown in SEQ ID NO: 35,     and a heavy chain having the amino acid sequence at amino acid     positions 20 to 469 shown in SEQ ID NO: 41, and -   (b) a light chain selected from the group consisting of a light     chain having the amino acid sequence at amino acid positions 21 to     234 shown in SEQ ID NO: 37, a light chain having the amino acid     sequence at amino acid positions 21 to 234 shown in SEQ ID NO: 39,     and a light chain having the amino acid sequence at amino acid     positions 21 to 234 shown in SEQ ID NO: 43. -   (15) The antibody according to any one of the above (11) to (14),     which has: -   (a) a heavy chain having the amino acid sequence at amino acid     positions 20 to 466 shown in SEQ ID NO: 33, and a light chain having     the amino acid sequence at amino acid positions 21 to 234 shown in     SEQ ID NO: 37, -   (b) a heavy chain having the amino acid sequence at amino acid     positions 20 to 466 shown in SEQ ID NO: 35, and a light chain having     the amino acid sequence at amino acid positions 21 to 234 shown in     SEQ ID NO: 39, or -   (c) a heavy chain having the amino acid sequence at amino acid     positions 20 to 469 shown in SEQ ID NO: 41, and a light chain having     the amino acid sequence at amino acid positions 21 to 234 shown in     SEQ ID NO: 43. -   (16) A polynucleotide encoding the antibody according to any one of     the above (1) to (15). -   (17) The polynucleotide according to the above (16), which has: -   (a) a polynucleotide of CDRH1 consisting of the nucleotide sequence     at nucleotide positions 76 to 105 shown in SEQ ID NO: 6, a     polynucleotide of CDRH2 consisting of the nucleotide sequence at     nucleotide positions 148 to 198 shown in SEQ ID NO: 6 and a     polynucleotide of CDRH3 consisting of the nucleotide sequence at     nucleotide positions 295 to 321 shown in SEQ ID NO: 6, and a     polynucleotide of CDRL1 consisting of the nucleotide sequence at     nucleotide positions 67 to 108 shown in SEQ ID NO: 7, a     polynucleotide of CDRL2 consisting of the nucleotide sequence at     nucleotide positions 154 to 174 shown in SEQ ID NO: 7 and a     polynucleotide of CDRL3 consisting of the nucleotide sequence at     nucleotide positions 271 to 303 shown in SEQ ID NO: 7, -   (b) a polynucleotide encoding CDRH1 consisting of the nucleotide     sequence at nucleotide positions 76 to 105 shown in SEQ ID NO: 8, a     polynucleotide of CDRH2 consisting of the nucleotide sequence at     nucleotide positions 148 to 198 shown in SEQ ID NO: 8 and a     polynucleotide of CDRH3 consisting of the nucleotide sequence at     nucleotide positions 295 to 336 shown in SEQ ID NO: 8, and a     polynucleotide of CDRL1 consisting of the nucleotide sequence at     nucleotide positions 67 to 108 shown in SEQ ID NO: 9, a     polynucleotide of CDRL2 consisting of the nucleotide sequence at     nucleotide positions 154 to 174 shown in SEQ ID NO: 9 and a     polynucleotide of CDRL3 consisting of the nucleotide sequence at     nucleotide positions 271 to 300 shown in SEQ ID NO: 9, -   (c) a polynucleotide of CDRH1 consisting of the nucleotide sequence     at nucleotide positions 133 to 162 shown in SEQ ID NO: 24, a     polynucleotide of CDRH2 consisting of the nucleotide sequence at     nucleotide positions 205 to 234 shown in SEQ ID NO: 24 and a     polynucleotide of CDRH3 consisting of the nucleotide sequence at     nucleotide positions 352 to 375 shown in SEQ ID NO: 24, and a     polynucleotide of CDRL1 consisting of the nucleotide sequence at     nucleotide positions 130 to 162 shown in SEQ ID NO: 26, a     polynucleotide of CDRL2 consisting of the nucleotide sequence at     nucleotide positions 208 to 228 shown in SEQ ID NO: 26 and a     polynucleotide of CDRL3 consisting of the nucleotide sequence at     nucleotide positions 325 to 351 shown in SEQ ID NO: 26, or -   (d) a polynucleotide of CDRH1 consisting of the nucleotide sequence     at nucleotide positions 133 to 162 shown in SEQ ID NO: 28, a     polynucleotide of CDRH2 consisting of the nucleotide sequence at     nucleotide positions 205 to 231 shown in SEQ ID NO: 28 and a     polynucleotide of CDRH3 consisting of the nucleotide sequence at     nucleotide positions 349 to 384 shown in SEQ ID NO: 28, and a     polynucleotide of CDRL1 consisting of the nucleotide sequence at     nucleotide positions 130 to 162 shown in SEQ ID NO: 30, a     polynucleotide of CDRL2 consisting of the nucleotide sequence at     nucleotide positions 208 to 228 shown in SEQ ID NO: 30 and a     polynucleotide of CDRL3 consisting of the nucleotide sequence at     nucleotide positions 325 to 351 shown in SEQ ID NO: 30. -   (18) The polynucleotide according to the above (16) or (17), which     has: -   (a) a polynucleotide of a heavy chain variable region consisting of     the nucleotide sequence at nucleotide positions 1 to 354 shown in     SEQ ID NO: 6, and a polynucleotide of a light chain variable region     consisting of the nucleotide sequence at nucleotide positions 1 to     336 shown in SEQ ID NO: 7, -   (b) a polynucleotide of a heavy chain variable region consisting of     the nucleotide sequence at nucleotide positions 1 to 369 shown in     SEQ ID NO: 8, and a polynucleotide of a light chain variable region     consisting of the nucleotide sequence at nucleotide positions 1 to     333 shown in SEQ ID NO: 9, -   (c) a polynucleotide of a heavy chain variable region consisting of     the nucleotide sequence at nucleotide positions 58 to 408 shown in     SEQ ID NO: 24, and a polynucleotide of a light chain variable region     consisting of the nucleotide sequence at nucleotide positions 61 to     387 shown in SEQ ID NO: 26, or -   (d) a polynucleotide of a heavy chain variable region consisting of     the nucleotide sequence at nucleotide positions 58 to 417 shown in     SEQ ID NO: 28, and a polynucleotide of a light chain variable region     consisting of the nucleotide sequence at nucleotide positions 61 to     387 shown in SEQ ID NO: 30. -   (19) The polynucleotide according to any one of the above (16) to     (18), which has: -   (a) a polynucleotide of a heavy chain consisting of the nucleotide     sequence shown in SEQ ID NO: 6, and a polynucleotide of a light     chain consisting of the nucleotide sequence shown in SEQ ID NO: 7, -   (b) a polynucleotide of a heavy chain consisting of the nucleotide     sequence shown in SEQ ID NO: 8, and a polynucleotide of a light     chain consisting of the nucleotide sequence shown in SEQ ID NO: 9, -   (c) a polynucleotide of a heavy chain consisting of the nucleotide     sequence at nucleotide positions 58 to 1398 shown in SEQ ID NO: 24,     and a polynucleotide of a light chain consisting of the nucleotide     sequence at nucleotide positions 61 to 702 shown in SEQ ID NO: 26,     or -   (d) a polynucleotide of a heavy chain consisting of the nucleotide     sequence at nucleotide positions 58 to 1407 shown in SEQ ID NO: 28,     and a polynucleotide of a light chain consisting of the nucleotide     sequence at nucleotide positions 61 to 702 shown in SEQ ID NO: 30. -   (20) The polynucleotide according to the above (16) or (17), which     has: -   (a) a polynucleotide of a heavy chain variable region selected from     the group consisting of a polynucleotide of a heavy chain variable     region consisting of the nucleotide sequence at nucleotide positions     58 to 408 shown in SEQ ID NO: 32, a polynucleotide of a heavy chain     variable region consisting of the nucleotide sequence at nucleotide     positions 58 to 408 shown in SEQ ID NO: 34, and a polynucleotide of     a heavy chain variable region consisting of the nucleotide sequence     at nucleotide positions 58 to 417 shown in SEQ ID NO: 40, and (b) a     polynucleotide of a light chain variable region selected from the     group consisting of a polynucleotide of a light chain variable     region consisting of the nucleotide sequence at nucleotide positions     61 to 387 shown in SEQ ID NO: 36, a polynucleotide of a light chain     variable region consisting of the nucleotide sequence at nucleotide     positions 61 to 387 shown in SEQ ID NO: 38, and a polynucleotide of     a light chain variable region consisting of the nucleotide sequence     at nucleotide positions 61 to 387 shown in SEQ ID NO: 42. -   (21) The polynucleotide according to the above (16), (17) or (20),     which has: -   (a) a polynucleotide of a heavy chain variable region consisting of     the nucleotide sequence at nucleotide positions 58 to 408 shown in     SEQ ID NO: 32, and a polynucleotide of a light chain variable region     consisting of the nucleotide sequence at nucleotide positions 61 to     387 shown in SEQ ID NO: 36, -   (b) a polynucleotide of a heavy chain variable region consisting of     the nucleotide sequence at nucleotide positions 58 to 408 shown in     SEQ ID NO: 34, and a polynucleotide of a light chain variable region     consisting of the nucleotide sequence at nucleotide positions 61 to     387 shown in SEQ ID NO: 38, or -   (c) a polynucleotide of a heavy chain variable region consisting of     the nucleotide sequence at nucleotide positions 58 to 417 shown in     SEQ ID NO: 40, and a polynucleotide of a light chain variable region     consisting of the nucleotide sequence at nucleotide positions 61 to     387 shown in SEQ ID NO: 42. -   (22) The polynucleotide according to the above (16), (17), (20) or     (21), which has: -   (a) a polynucleotide of a heavy chain selected from the group     consisting of a polynucleotide of a heavy chain consisting of the     nucleotide sequence at nucleotide positions 58 to 1398 shown in SEQ     ID NO: 32, a polynucleotide of a heavy chain consisting of the     nucleotide sequence at nucleotide positions 58 to 1398 shown in SEQ     ID NO: 34, and a polynucleotide of a heavy chain consisting of the     nucleotide sequence at nucleotide positions 58 to 1407 shown in SEQ     ID NO: 40, and -   (b) a polynucleotide of a light chain selected from the group     consisting of a polynucleotide of a light chain consisting of the     nucleotide sequence at nucleotide positions 61 to 702 shown in SEQ     ID NO: 36, a polynucleotide of a light chain consisting of the     nucleotide sequence at nucleotide positions 61 to 702 shown in SEQ     ID NO: 38, and a polynucleotide of a light chain consisting of the     nucleotide sequence at nucleotide positions 61 to 702 shown in SEQ     ID NO: 42. -   (23)The polynucleotide according to any one of the above (16), (17)     and (20) to (22), which has: -   (a) a polynucleotide of a heavy chain consisting of the nucleotide     sequence at nucleotide positions 58 to 1398 shown in SEQ ID NO: 32,     and a polynucleotide of a light chain consisting of the nucleotide     sequence at nucleotide positions 61 to 702 shown in SEQ ID NO: 36, -   (b) a polynucleotide of a heavy chain consisting of the nucleotide     sequence at nucleotide positions 58 to 1398 shown in SEQ ID NO: 34,     and a polynucleotide of a light chain consisting of the nucleotide     sequence at nucleotide positions 61 to 702 shown in SEQ ID NO: 38,     or -   (c) a polynucleotide of a heavy chain consisting of the nucleotide     sequence at nucleotide positions 58 to 1407 shown in SEQ ID NO: 40,     and a polynucleotide of a light chain consisting of the nucleotide     sequence at nucleotide positions 61 to 702 shown in SEQ ID NO: 42. -   (24) An expression vector comprising the polynucleotide according to     any one of the above (16) to (23). -   (25) Host cells transformed with the expression vector according to     the above (24). -   (26) A method for producing an antibody of interest or a fragment     thereof, which comprises a step of culturing the host cells     according to the above (25), and a step of collecting an antibody of     interest from the culture obtained by the aforementioned step. -   (27) An antibody obtained by the production method according to the     above (26). -   (28) The antibody according to any one of the above (1) to (15) and     (27), comprising one or two or more modifications selected from the     group consisting of N-linked glycosylation, O-linked glycosylation,     N-terminal processing, C-terminal processing, deamidation,     isomerization of aspartic acid, oxidation of methionine, addition of     a methionine residue to the N-terminus, amidation of a proline     residue, and a heavy chain comprising a deletion of one or two amino     acids at the carboxyl terminus. -   (29) The antibody according to the above (28), wherein one or two     amino acids are deleted at the carboxyl terminus of a heavy chain     thereof. -   (30) The antibody according to the above (29), wherein one amino     acid is deleted at each of the carboxyl termini of both of the heavy     chains thereof. -   (31) The antibody according to any one of the above (28) to (30),     wherein a proline residue at the carboxyl terminus of a heavy chain     thereof is further amidated. -   (32) The antibody according to any one of the above (1) to (15)     and (27) to (31), wherein sugar chain modification is regulated in     order to enhance antibody-dependent cellular cytotoxicity. -   (33) A pharmaceutical composition comprising at least one of the     antibodies according to the above (1) to (15) and (27) to (32). -   (34) The pharmaceutical composition according to the above (33),     which is for use in tumor therapy. -   (35) The pharmaceutical composition according to the above (34),     wherein the tumor is a cancer. -   (36) The pharmaceutical composition according to the above (35),     wherein the cancer is lung cancer, kidney cancer, urothelial cancer,     colon cancer, prostate cancer, glioblastoma multiforme, ovarian     cancer, pancreatic cancer, breast cancer, melanoma, liver cancer,     bladder cancer, stomach cancer, esophageal cancer, or blood cancer. -   (37) A method for treating a tumor, which comprises administering at     least one of the antibodies according to the above (1) to (15)     and (27) to (32) to an individual. -   (38) The treatment method according to the above (37), wherein the     tumor is a cancer. -   (39) The treatment method according to the above (38), wherein the     cancer is lung cancer, kidney cancer, urothelial cancer, colon     cancer, prostate cancer, glioblastoma multiforme, ovarian cancer,     pancreatic cancer, breast cancer, melanoma, liver cancer, bladder     cancer, stomach cancer, esophageal cancer, or blood cancer.

Advantageous Effects of Invention

According to the present invention, there can be obtained a therapeutic agent for cancer comprising an antibody binding to GARP and having an antitumor activity caused by ADCC-mediated inhibition of Treg. In addition, the excessive presence and the activation of Treg in patients having malaria and HIV infection exhibit a correlation with that disease state, and the removal of Treg induces remission of the disease state in murine models for the diseases. Accordingly, it can be expected that effective inhibition of Treg function will have therapeutic effects also on refractory infectious diseases such as those caused by malaria and HIV.

BRIEF DESCRIPTION OF DRAWINGS

FIG. 1 shows the amino acid sequence (SEQ ID NO: 1) of GARP.

FIG. 2 shows the amino acid sequence (SEQ ID NO: 2) of a 105F antibody heavy chain.

FIG. 3 shows the amino acid sequence (SEQ ID NO: 3) of a 105F antibody light chain.

FIG. 4 shows the amino acid sequence (SEQ ID NO: 4) of a 110F antibody heavy chain.

FIG. 5 shows the amino acid sequence (SEQ ID NO: 5) of a 110F antibody light chain.

FIG. 6 shows the nucleotide sequence (SEQ ID NO: 6) of a 105F antibody heavy chain.

FIG. 7 shows the nucleotide sequence (SEQ ID NO: 7) of a 105F antibody light chain.

FIG. 8 shows the nucleotide sequence (SEQ ID NO: 8) of a 110F antibody heavy chain.

FIG. 9 shows the nucleotide sequence (SEQ ID NO: 9) of a 110F antibody light chain.

FIG. 10 shows the binding of antibodies to GARP. The 105F antibody and the 110F antibody exhibited the binding thereof to GARP according to an ELISA method.

FIG. 11 shows the specific binding of antibodies to GARP. The 105F antibody did not bind to HEK293T cells, into which an empty vector had been introduced, and exhibited the binding thereof to HEK293T cells, in which GARP had been transiently expressed.

FIG. 12 shows the specific binding of an antibody to GARP. The 105F antibody exhibited a binding activity to L428 cells endogenously expressing GARP.

FIG. 13 shows the specific binding of antibodies to GARP. The 105F antibody exhibited a binding activity to activated Treg.

FIG. 14 shows the ADCC activity of antibodies. When L428 cells endogenously expressing GARP were targeted, an increase in the ADCC activity was found in a 105F antibody concentration-dependent manner.

FIG. 15 shows the inhibitory activity of an antibody to the Treg function. The 105F antibody (50 μg/mL) inhibited the proliferation-suppressive function of Treg against helper T cells.

FIG. 16 shows the inhibitory activity of antibody to the Treg function. The 105F antibody (10 μg/mL) inhibited the proliferation-suppressive function of Treg against helper T cells. On the other hand, the MHG-8 and LHG-10 antibodies did not exhibit the effect on the proliferation-suppressive function of Treg against helper T cells.

FIG. 17 shows the amino acid sequence (SEQ ID NO: 25) of a c151D antibody heavy chain.

FIG. 18 shows the amino acid sequence (SEQ ID NO: 27) of a c151D antibody light chain.

FIG. 19 shows the amino acid sequence (SEQ ID NO: 29) of a c198D antibody heavy chain.

FIG. 20 shows the amino acid sequence (SEQ ID NO: 31) of a c198D antibody light chain.

FIG. 21 shows the amino acid sequence (SEQ ID NO: 33) of an h151D-H1 heavy chain.

FIG. 22 shows the amino acid sequence (SEQ ID NO: 37) of an h151D-L1 light chain.

FIG. 23 shows the amino acid sequence (SEQ ID NO: 35) of an h151D-H4 heavy chain.

FIG. 24 shows the amino acid sequence (SEQ ID NO: 39) of an h151D-L4 light chain.

FIG. 25 shows the amino acid sequence (SEQ ID NO: 41) of an h198D-H3 heavy chain.

FIG. 26 shows the amino acid sequence (SEQ ID NO: 43) of an h198D-L4 light chain.

FIG. 27 shows the nucleotide sequence (SEQ ID NO: 24) of a c151D antibody heavy chain.

FIG. 28 shows the nucleotide sequence (SEQ ID NO: 26) of a c151D antibody light chain.

FIG. 29 shows the nucleotide sequence (SEQ ID NO: 28) of a c198D antibody heavy chain.

FIG. 30 shows the nucleotide sequence (SEQ ID NO: 30) of a c198D antibody light chain.

FIG. 31 shows the nucleotide sequence (SEQ ID NO: 32) of a h151D-H1 antibody heavy chain.

FIG. 32 shows the nucleotide sequence (SEQ ID NO: 36) of a h151D-L1 antibody heavy chain.

FIG. 33 shows the nucleotide sequence (SEQ ID NO: 34) of an h151D-H4 heavy chain.

FIG. 34 shows the nucleotide sequence (SEQ ID NO: 38) of an h151D-L4 light chain.

FIG. 35 shows the nucleotide sequence (SEQ ID NO: 40) of an h198D-H3 heavy chain.

FIG. 36 shows the nucleotide sequence (SEQ ID NO: 42) of an h198D-L4 light chain.

FIG. 37 shows the binding activity of each antibody to GARP-expressing cells. h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited a specific binding activity to GARP.

FIG. 38 shows the binding activity of each antibody to GARP-TGF β1 co-expressing cells. Individual antibodies 105F, h151D-H1L1, h151D-H4L4 and h198D-H3L4 bound to both GARP and a GARP mutant, which were co-expressed with TGFβ1, and these antibodies exhibited a binding activity to a different region in GARP from the case of known antibodies MHG8 and LHG10.

FIG. 39 shows the binding activity of each antibody to L428 cells. Individual antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited a binding activity to endogenously expressed GARP.

FIG. 40 shows the binding activity of each antibody to Treg. Individual antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited a binding activity to FoxP3-positive Treg.

FIG. 41 shows the ADCC activity of each antibody. Individual antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited an ADCC activity.

FIG. 42 shows inhibitory activity of each antibody to the Treg function. Individual antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited inhibitory activity to the Treg function.

FIG. 43 shows suppressive activity of Treg on the target cell lysis activity of CTL.

FIG. 44 shows an increase in antitumor activity of each antibody. Individual antibodies 105F, h151D-H1L1, h151D-H4L4, and h198D-H3L4 inhibited the suppressive function of Treg on cell lysis activity of CTL.

FIG. 45 shows the in vivo antitumor activity of each antibody. Individual antibodies 105F, h151D-H1L1, h151D-H4L4, and h198D-H3L4 exhibited an antitumor activity in in vivo models.

DESCRIPTION OF EMBODIMENTS

In the present description, the term “cancer” is used to have the same meaning as that of the term “tumor”.

In the present description, the term “gene” is used to include, not only DNA but also its mRNA and cDNA, and the cRNA thereof.

In the present description, the term “polynucleotide” is used to have the same meaning as that of a nucleic acid, and it includes DNA, RNA, a probe, an oligonucleotide, and a primer.

In the present description, the term “polypeptide” is used such that it is not distinguished from the term “protein.”

In the present description, the term “cell” includes cells in an individual animal, and cultured cells.

In the present description, the term “GARP” is used to have the same meaning as that of GARP protein.

In the present description, the term “cytotoxicity” is used to mean that a pathologic change is caused to cells in any given way. It does not only mean a direct trauma, but also means all types of structural or functional damage caused to cells, such as DNA cleavage, formation of a base dimer, chromosomal cleavage, damage to cell mitotic apparatus, and a reduction in the activities of various types of enzymes.

In the present description, the term “cytotoxic activity” is used to mean an activity that causes the above described cytotoxicity.

In the present description, the term “antibody-dependent cellular cytotoxicity” is used to mean an “antibody dependent cellular cytotoxic (ADCC) activity,” and this activity means the effect or the activity of damaging target cells such as tumor cells by NK cells mediated by an antibody.

In the present description, the term “epitope” is used to mean the partial peptide or partial three-dimensional structure of GARP, to which a specific anti-GARP antibody binds. Such an epitope, which is a partial peptide of the above described GARP, can be determined by a method well known to a person skilled in the art, such as an immunoassay, for example, by the following method. First, various partial structures of an antigen are produced. As regards production of such partial structures, a known oligopeptide synthesis technique can be applied. For example, a series of peptides, in which an antigen has been successively truncated at an appropriate length from the C-terminus or N-terminus thereof, are produced by a genetic recombination technique well known to a person skilled in the art, and thereafter, the reactivity of an antibody to such polypeptides is studied, and recognition sites are roughly determined. Thereafter, further shorter peptides are synthesized, and the reactivity thereof to the aforementioned peptides is then studied, so as to determine an epitope. Moreover, an epitope, which is a partial three-dimensional structure of an antigen that binds to a specific antibody, can be determined by specifying the amino acid residues of an antigen adjacent to the above-described antibody by X-ray structural analysis.

In the present description, the phrase “antibodies binding to the same epitope” is used to mean different antibodies that bind to a common epitope. If a second antibody binds to a partial peptide or a partial three-dimensional structure, to which a first antibody binds, it can be determined that the first antibody and the second antibody bind to the same epitope. In addition, by confirming that a second antibody competes with a first antibody for the binding of a first antibody to an antigen (i.e., a second antibody interferes with the binding of a first antibody to an antigen), it can be determined that the first antibody and the second antibody bind to the same epitope, even if the specific sequence or structure of the epitope has not been determined. Furthermore, when a first antibody and a second antibody bind to the same epitope and further, the first antibody has special effects such as antitumor activity, the second antibody can be expected to have the same activity as that of the first antibody. Accordingly, if a second anti-GARP antibody binds to a partial peptide to which a first anti-GARP antibody binds, it can be determined that the first antibody and the second antibody bind to the same epitope of GARP. In addition, by confirming that the second anti-GARP antibody competes with the first anti-GARP antibody for the binding of the first anti-GARP antibody to GARP, it can be determined that the first antibody and the second antibody are antibodies binding to the same epitope of GARP.

In the present description, the term “CDR” is used to mean a complementarity determining region. It is known that the heavy chain and light chain of an antibody molecule each have three CDRs. Such a CDR is also referred to as a hypervariable domain, and is located in the variable region of the heavy chain and light chain of an antibody. These regions have a particularly highly variable primary structure and are separated into three sites on the primary structure of the polypeptide chain in each of the heavy chain and light chain. In the present description, with regard to the CDR of an antibody, the CDRs of a heavy chain are referred to as CDRH1, CDRH2 and CDRH3, respectively, from the amino-terminal side of the amino acid sequence of the heavy chain, whereas the CDRs of a light chain are referred to as CDRL1, CDRL2 and CDRL3, respectively, from the amino-terminal side of the amino acid sequence of the light chain. These sites are located close to one another on the three-dimensional structure, and determine the specificity of the antibody to an antigen, to which the antibody binds.

In the present invention, the phrase “to hybridize under stringent conditions” is used to mean that hybridization is carried out in the commercially available hybridization solution ExpressHyb Hybridization Solution (manufactured by Clontech) at 68° C., or that hybridization is carried out under conditions in which hybridization is carried out using a DNA-immobilized filter in the presence of 0.7-1.0 M NaCl at 68° C., and the resultant is then washed at 68° C. with a 0.1- to 2-fold concentration of SSC solution (wherein 1×SSC consists of 150 mM NaCl and 15 mM sodium citrate) for identification, or conditions equivalent thereto.

1. GARP

GARP used in the present invention can be directly purified from the GARP-expressing cells of a human or a non-human mammal (e.g., a rat, a mouse, etc.) and can then be used, or a cell membrane faction of the aforementioned cells can be prepared and can be used as the GARP. Alternatively, GARP can also be obtained by synthesizing it in vitro, or by allowing host cells to produce GARP by genetic manipulation. According to such genetic manipulation, the GARP protein can be obtained, specifically, by incorporating GARP cDNA into an expression vector capable of expressing the GARP cDNA, and then synthesizing GARP in a solution comprising enzymes, substrate and energetic materials necessary for transcription and translation, or by transforming the host cells of other prokaryotes or eukaryotes, so as to allow them to express GARP.

The amino acid sequence of human GARP is shown in SEQ ID NO: 1 in the sequence listing. In addition, the sequence of SEQ ID NO: 1 is shown in FIG. 1.

Moreover, a protein, which consists of an amino acid sequence comprising a substitution, deletion and/or addition of one or several amino acids in the above-described amino acid sequence of GARP, and has a biological activity equivalent to that of the GARP protein, is also included in GARP.

Mature human GARP, from which a signal sequence has been removed, corresponds to an amino acid sequence consisting of the amino acid residues at positions 20 to 662 in the amino acid sequence shown in SEQ ID NO: 1.

Furthermore, a protein, which consists of an amino acid sequence comprising a substitution, deletion and/or addition of one or several amino acids in the amino acid sequence shown in SEQ ID NO: 1, or in the amino acid sequence shown in SEQ ID NO: 1 from which a signal sequence has been removed, and which has a biological activity equivalent to that of GARP, is also included in GARP. Further, a protein, which consists of an amino acid sequence encoded by a splicing variant transcribed from a human GARP gene locus or an amino acid sequence comprising a substitution, deletion and/or addition of one or several amino acids in the aforementioned amino acid sequence, and which has a biological activity equivalent to that of GARP, is also included in GARP.

2. Production of Anti-GARP Antibody

An example of the antibody against GARP of the present invention can be an anti-GARP human antibody. The anti-GARP human antibody means a human antibody having only the gene sequence of an antibody derived from human chromosomes.

The anti-GARP human antibody can be obtained by a method using a human antibody-producing mouse having a human chromosomal fragment comprising the heavy chain and light chain genes of a human antibody (see Tomizuka, K. et al., Nature Genetics (1997) 16, p. 133-143,; Kuroiwa, Y. et al., Nucl. Acids Res. (1998) 26, p. 3447-3448; Yoshida, H. et al., Animal Cell Technology: Basic and Applied Aspects vol. 10, p. 69-73 (Kitagawa, Y., Matsuda, T. and Iijima, S. eds.), Kluwer Academic Publishers, 1999.; Tomizuka, K. et al., Proc. Natl. Acad. Sci. USA (2000) 97, p. 722-727; etc.).

Such a human antibody-producing mouse can be specifically produced by using a genetically modified animal, the gene loci of endogenous immunoglobulin heavy chain and light chain of which have been disrupted and instead the gene loci of human immunoglobulin heavy chain and light chain have been then introduced using a yeast artificial chromosome (YAC) vector or the like, and then producing a knock-out animal and a transgenic animal from such a genetically modified animal, and then breeding such animals with one another.

Otherwise, the anti-GARP human antibody can also be obtained by transforming eukaryotic cells with cDNA encoding each of the heavy chain and light chain of such a human antibody, or preferably with a vector comprising the cDNA, according to genetic recombination techniques, and then culturing the transformed cells producing a genetically modified human monoclonal antibody, so that the antibody can be obtained from the culture supernatant. As host cells, eukaryotic cells, and preferably, mammalian cells such as CHO cells, lymphocytes or myelomas can, for example, be used.

Alternatively, the antibody can also be obtained by a method of obtaining a phage display-derived human antibody that has been selected from a human antibody library (see Wormstone, I. M. et al., Investigative Ophthalmology & Visual Science. (2002) 43 (7), p. 2301-2308; Carmen, S. et al., Briefings in Functional Genomics and Proteomics (2002), 1 (2), p. 189-203; Siriwardena, D. et al., Ophthalmology (2002) 109 (3), p. 427-431; etc.). For example, a phage display method, which comprises allowing the variable region of a human antibody to express as a single chain antibody (scFv) on the surface of a phage, and then selecting a phage binding to an antigen, can be applied (Nature Biotechnology (2005), 23, (9), p. 1105-1116).

By analyzing the phage gene that has been selected because of its binding ability to the antigen, a DNA sequence encoding the variable region of a human antibody binding to the antigen can be determined. Once the DNA sequence of scFv binding to the antigen is determined, a DNA sequence of a constant region of an antibody is allowed to bind thereto to produce an IgG expression vector having the aforementioned sequences, and the produced expression vector is then introduced into suitable host cells and is allowed to express therein, thereby obtaining a human antibody (WO92/01047, WO92/20791, WO93/06213, WO93/11236, WO93/19172, WO95/01438, WO95/15388, Annu. Rev. Immunol (1994) 12, p. 433-455, Nature Biotechnology (2005) 23 (9), p. 1105-1116).

Moreover, the antibody against GARP of the present invention can be obtained by immunizing an animal with GARP or any given polypeptide selected from the amino acid sequence of GARP, and then collecting and purifying an antibody produced in a living body thereof. The species of the organism of the GARP used as an antigen is not limited to human, and thus, an animal can also be immunized with GARP derived from an animal other than a human, such as a mouse or a rat. In this case, an antibody applicable to the disease of a human can be selected by examining the cross-reactivity of the obtained antibody binding to heterologous GARP with human GARP.

Furthermore, antibody-producing cells that produce an antibody against GARP are fused with myeloma cells according to a known method (e.g., Kohler and Milstein, Nature (1975) 256, p. 495-497, Kennet, R. ed., Monoclonal Antibodies, p. 365-367, Plenum Press, N. Y. (1980)) to establish hybridomas, so as to obtain a monoclonal antibody.

It is to be noted that GARP used as an antigen can be obtained by allowing host cells to produce GARP genes according to genetic manipulation.

Specifically, a vector capable of expressing a GARP gene is produced, and the vector is then introduced into host cells, so that the gene is expressed therein, and thereafter, the expressed GARP may be purified. Hereafter, a method of obtaining an antibody against GARP will be specifically described.

(1) Preparation of Antigen

Examples of an antigen used to produce an anti-GARP antibody can include GARP, a polypeptide consisting of at least 6 consecutive partial amino acid sequences thereof, and a derivative prepared by adding any given amino acid sequence or carrier to such GARP or a polypeptide thereof.

GARP can be directly purified from the tumor tissues or tumor cells of a human and can then be used. Alternatively, GARP can also be obtained by synthesizing it in vitro or by allowing host cells to produce it by genetic manipulation.

According to such genetic manipulation, an antigen can be obtained, specifically, by incorporating GARP cDNA into an expression vector capable of expressing the GARP cDNA, and then synthesizing GARP in a solution comprising enzymes, substrate and energetic materials necessary for transcription and translation, or by transforming the host cells of other prokaryotes or eukaryotes, so as to allow them to express GARP.

It is also possible to obtain an antigen as a secretory protein by allowing a fusion protein formed by ligating DNA encoding the extracellular region of GARP as a membrane protein to DNA encoding the constant region of an antibody, to express in a suitable host and/or vector system.

GARP cDNA can be obtained by what is called a PCR method, which comprises performing a polymerase chain reaction (hereinafter referred to as “PCR”), for example, using a cDNA library expressing the cDNA of GARP as a template, and also using primers for specifically amplifying the GARP cDNA (see Saiki, R. K., et al. Science (1988) 239, p. 487-489).

An example of the in vitro synthesis of a polypeptide can be the Rapid Translation System (RTS) manufactured by Roche Diagnostics, but it is not limited thereto.

Examples of prokaryotic cells used as host cells can include Escherichia coli and Bacillus subtilis . In order to transform the host cells with a gene of interest, the host cells are transformed with a plasmid vector comprising a replicon derived from species compatible with the host, namely, a replication origin, and a regulatory sequence. As a vector, a vector having a sequence capable of imparting the selectivity of a phenotype to the cells to be transformed is preferable.

Examples of eukaryotic cells used as host cells can include the cells of vertebrate, insects and yeasts. Examples of the vertebrate cells that can frequently be used include COS cells which are monkey cells (Gluzman, Y., Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblasts NIH3T3 (ATCC No. CRL-1658), and a dihydrofolate reductase-deficient cell line of Chinese hamster ovary cells (CHO cells, ATCC CCL-61) (Urlaub, G. and Chasin, L. A. Proc. Natl. Acad. Sci. U.S.A. (1980) 77, p. 4126-4220), but are not limited thereto.

The thus obtained transformant can be cultured according to ordinary methods, and a polypeptide of interest can be produced inside or outside of the cells of the culture.

As media used in the culture, various types of commonly used media can be selected, as appropriate, depending on the type of the adopted host cells. If the host cells are Escherichia coli , for example, antibiotics such as ampicillin or IPMG can be added to an LB medium, as necessary, and the resulting medium can then be used.

A recombinant protein produced inside or outside of the cells of a transformant as a result of the above described culture can be separated and/or purified by various types of known separation methods, utilizing the physical properties or chemical properties of the protein.

Specific examples of the method can include a treatment using an ordinary protein precipitant, ultrafiltration, various types of liquid chromatography such as molecular sieve chromatography (gel filtration), absorption chromatography, ion exchange chromatography or affinity chromatography, a dialysis method, and a combination thereof.

In addition, by attaching a histidine tag consisting of 6 residues to a recombinant protein to be expressed, the protein can be efficiently purified using a nickel affinity column. Otherwise, by connecting the Fc region of IgG to a recombinant protein to be expressed, the protein can be efficiently purified using a Protein A column.

By combining the above described methods with one another, a polypeptide of interest can be produced at a large scale, with a high yield and with high purity.

(2) Production of Anti-GARP Monoclonal Antibody

An example of an antibody specifically binding to GARP can be a monoclonal antibody specifically binding to GARP. A method of obtaining such a monoclonal antibody is as follows.

For the production of a monoclonal antibody, the following working steps are generally necessary.

Specifically, the necessary working steps include:

-   (a) purification of a biopolymer used as an antigen, -   (b) a step of immunizing an animal with the antigen by injection,     collecting the blood from the animal, examining the antibody titer     to determine the period for excision of the spleen from the animal,     and then preparing antibody-producing cells, -   (c) preparation of myeloma cells (hereinafter referred to as     “myelomas”), -   (d) cell fusion between the antibody-producing cells and the     myelomas, -   (e) selection of a hybridoma group producing an antibody of     interest, -   (f) division into single cell clones (cloning), -   (g) optionally, the culture of hybridomas for the mass production of     monoclonal antibodies, or the breeding of animals into which the     hybridomas are transplanted, and -   (h) the analysis of the physiological activity and binding     specificity of the thus produced monoclonal antibody, or examination     of the properties of the antibody as a labelling reagent.

Hereafter, a method for producing a monoclonal antibody will be described in detail along with the above described steps. However, the method of producing the aforementioned antibody is not limited thereto, and, for example, antibody-producing cells other than splenic cells and myelomas can also be used.

(a) Purification of Antigen

As an antigen, GARP prepared by the above described method, or a portion thereof, can be used.

Alternatively, a membrane fraction prepared from GARP-expressing recombinant somatic cells, or such GARP-expressing recombinant somatic cells themselves, or further, a partial peptide of the protein of the present invention, which is chemically synthesized according to a method well known to a person skilled in the art, can also be used as an antigen.

(b) Preparation of Antibody-Producing Cells

The antigen obtained in step (a) is mixed with an auxiliary agent, such as a Freund complete or incomplete adjuvant, or potassium alum, to prepare an immunogen, and thereafter, an experimental animal is immunized with the immunogen. As such an experimental animal, an animal used in known methods for producing hybridomas can be used without any problems. Specific examples of such an animal that can be used herein include a mouse, a rat, a goat, sheep, a bovine, and a horse. From the viewpoint of the availability of myeloma cells to be fused with the excised antibody-producing cells, etc., a mouse or a rat is preferably used as the animal to be immunized.

The strains of actually used mice and rats are not particularly limited. In the case of mice, examples of the strain that can be used herein include A, AKR, BALB/c, BDP, BA, CE, C3H, 57BL, C57BL, C57L, DBA, FL, HTH, HT1, LP, NZB, NZW, RF, R III, SJL, SWR, WB, and 129. On the other hand, in the case of rats, examples of the strain that can be used herein include Wistar, Low, Lewis, Sprague Dawley, ACI, BN, and Fischer.

These mice and rats are available from experimental animal breeders and distributors, such as CLEA Japan, Inc. and CHARLES RIVER LABORATORIES JAPAN, INC.

Among others, taking into consideration fusion compatibility with the myeloma cells discussed below, the BALB/c strain in the case of mice, and the Wistar and Low strains in the case of rats, are particularly preferable as animals to be immunized.

Moreover, taking into consideration the homology between the antigens of humans and mice, it is also preferable to use mice whose biological mechanism for removing autoantibodies has been reduced, namely, autoimmune disease mice.

The age of these mice or rats upon immunization is preferably 5 to 12 weeks old, and more preferably 6 to 8 weeks old.

In order to immunize animals with GARP or a recombinant thereof, known methods, which are described in detail, for example, in Weir, D. M., Handbook of Experimental Immunology, Vol. I. II. III., Blackwell Scientific Publications, Oxford (1987), Kabat, E. A. and Mayer, M. M., Experimental Immunochemistry, Charles C Thomas Publisher Springfield, Illinois (1964), etc. can be applied.

Among these immunization methods, a method preferably applied in the present invention is specifically the following method, for example.

That is to say, first, cells, in which a membrane protein fraction used as an antigen, or an antigen has been expressed, are intradermally or intraperitoneally administered to an animal.

In order to enhance immunization efficiency, the combined use thereof is preferable. If intradermal administration is carried out in a first half of an administration regime, and intraperitoneal administration is carried out in a latter half thereof or only in the final instance of administration, immunization efficiency can be particularly enhanced.

The administration schedule of the antigen is different depending on the type of animal to be immunized, individual differences, etc. In general, 3 to 6 antigen doses and a dosing interval of 2 to 6 weeks are preferable, and 3 or 4 antigen doses and a dosing interval of 2 to 4 weeks are more preferable.

The applied dose of an antigen is different depending on the type of animal to be immunized, individual differences, etc. It is generally 0.05 to 5 mg, and preferably approximately 0.1 to 0.5 mg.

The booster is carried out 1 to 6 weeks, preferably 2 to 4 weeks, and more preferably 2 to 3 weeks, after the above described administration of the antigen.

The applied dose of the antigen, when the booster is carried out, is different depending on the type of animal, the size thereof, etc. In the case of a mouse for example, the applied dose of the antigen is generally 0.05 to 5 mg, preferably 0.1 to 0.5 mg, and more preferably approximately 0.1 to 0.2 mg.

1 to 10 days, preferably 2 to 5 days, and more preferably 2 or 3 days after completion of the above described booster, splenic cells or lymphocytes comprising antibody-producing cells are aseptically removed from the immunized animal. At that time, the antibody titer is measured. An animal, in which the antibody titer has been sufficiently increased, is used as a supply source of antibody-producing cells, so that the efficiency of the subsequent operations can be enhanced.

Examples of the method of measuring an antibody titer used herein can include a RIA method and an ELISA method, but are not limited thereto.

With regard to the measurement of an antibody titer in the present invention, the ELISA method can, for example, be carried out according to the following procedures.

First, a purified or a partially purified antigen is adsorbed on the surface of a solid phase, such as a 96-well plate for ELISA, and another solid surface, on which such an antigen is not adsorbed, is covered with a protein irrelevant to the antigen, such as bovine serum albumin (hereinafter referred to as “BSA”). The surfaces are washed, and are then allowed to come into contact with a serially diluted sample used as a primary antibody (e.g., mouse serum), so that an antibody in the sample is allowed to bind to the above described antigen.

Thereafter, an enzyme-labeled antibody against the mouse antibody is added as a secondary antibody, so that it is allowed to bind to the mouse antibody, followed by washing. After that, a substrate of the enzyme is added thereto, and a change in the absorbance due to color development based on the substrate decomposition, etc., is then measured, so that the antibody titer is calculated.

Antibody-producing cells can be separated from the splenic cells or lymphocytes of the immunized animal according to known methods (e.g., Kohler et al., Nature (1975) 256, p. 495,; Kohler et al., Eur. J. Immunol. (1977) 6, p. 511,; Milstein et al., Nature (1977), 266, p. 550,; Walsh, Nature, (1977) 266, p. 495). For example, in the case of splenic cells, there can be adopted a common method which comprises mincing the spleen, then filtrating the cells through a stainless steel mesh, then suspending the filtrate in Eagle's minimal essential medium (MEM) to separate antibody-producing cells.

(c) Preparation of Myeloma Cells (Hereinafter Referred to as “Myelomas”)

Myeloma cells used in cell fusion are not particularly limited, and the cells can be selected from known cell lines, as appropriate, and can then be used. Taking into consideration issues of convenience in the selection of hybridomas from fused cells, HGPRT (Hypoxanthine-GUANINE phosphoribosyl transferase)-deficient cell lines, the selection procedures of which have been established, is preferably used.

That is, examples of such HGPRT-deficient cell lines include: mouse-derived X63-Ag8 (X63), NS1-ANS/1 (NS1), P3X63-Ag8. U1 (P3U1), X63-Ag8.653 (X63.653), SP2/0-Ag14 (SP2/0), MPC11-45.6TG1.7 (45.6TG), FO, S149/5XXO, and BU. 1; rat-derived 210. RSY3. Ag. 1. 2.3 (Y3); and human-derived U266AR (SKO-007), GM1500-GTG-A12 (GM1500), UC729-6, LICR-LOW-HMy2 (HMy2), and 8226AR/NIP4-1 (NP41). These HGPRT-deficient cell lines are available from, for example, American Type Culture Collection (ATCC).

These cell lines are sub-cultured in a suitable medium, such as an 8-azaguanine medium [a medium prepared by adding 8-azaguanine to an RPMI-1640 medium comprising glutamine, 2-mercaptoethanol, gentamicin, and fetal calf serum (hereinafter referred to as “FCS”)], Iscove's Modified Dulbecco's Medium (hereinafter referred to as “IMDM”), or Dulbecco's Modified Eagle Medium (hereinafter referred to as “DMEM”). Three or four days before cell fusion, the cells are sub-cultured in a normal medium [e.g., ASF104 medium comprising 10% FCS (manufactured by Ajinomoto Co., Inc.)] to ensure not less than 2×10⁷ cells on the day of cell fusion.

(d) Cell Fusion

Antibody-producing cells can be fused with myeloma cells, as appropriate, according to known methods (Weir, D. M., Handbook of Experimental Immunology, Vol. I. II. III., Blackwell Scientific Publications, Oxford (1987), Kabat, E. A. and Mayer, M. M., Experimental Immunochemistry, Charles C Thomas Publisher Springfield, Illinois (1964), etc.) under conditions in which the survival rate of cells is not excessively reduced.

Examples of such a method that can be used herein include a chemical method comprising mixing antibody-producing cells with myeloma cells in a high-concentration polymer solution such as polyethylene glycol, and a physical method utilizing electric stimulation. Among these methods, a specific example of the above described chemical method is as follows.

That is, when polyethylene glycol is used as a high-concentration polymer solution, antibody-producing cells are mixed with myeloma cells in a polyethylene glycol solution with a molecular weight of 1500 to 6000, preferably 2000 to 4000, at a temperature of 30° C. to 40° C., preferably 35° C. to 38° C., and for 1 to 10 minutes, preferably for 5 to 8 minutes.

(e) Selection of Hybridoma Group

The method of selecting hybridomas obtained by the above described cell fusion is not particularly limited. In general, a HAT (hypoxanthine-aminopterin-thymidine) selection method (Kohler et al., Nature (1975) 256, p. 495; Milstein et al., Nature (1977) 266, p. 550) is applied.

This method is effective, when hybridomas are obtained using myeloma cells of an HGPRT-deficient cell line that cannot survive in aminopterin.

Specifically, unfused cells and hybridomas are cultured in a HAT medium, so that only the hybridomas that are resistant to aminopterin are allowed to remain and grow selectively.

(f) Division into Single Cell Clones (Cloning)

As hybridoma cloning methods, known methods such as a methyl cellulose method, a soft agarose method, or a limiting dilution method can, for example, be applied (see, for example, Barbara, B. M. and Stanley, M. S.: Selected Methods in Cellular Immunology, W. H. Freeman and Company, San Francisco (1980)). Among these methods, three-dimensional culture methods, such as a methyl cellulose method, are particularly preferable. For example, a hybridoma group formed by cell fusion is suspended in a methyl cellulose medium such as ClonaCell-HY Selection Medium D (manufactured by StemCell Technologies, #03804), and is then cultured. Thereafter, the formed hybridoma colonies are harvested, so that monoclonal hybridomas can be obtained. The harvested hybridoma colonies are each cultured, and the obtained hybridoma culture supernatant, in which a stable antibody titer is observed, is selected as a GARP monoclonal antibody-producing hybridoma strain.

Examples of the thus established hybridoma strain can include GARP hybridomas 151D and 198D. In the present description, an antibody produced by GARP hybridomas 151D and 198D is referred to as a “151D antibody” or “198D antibody,” or it is simply referred to as “151D” or “198D.”

The heavy chain variable region of the 151D antibody has the amino acid sequence shown in SEQ ID NO: 15 in the sequence listing. In addition, the light chain variable region of the 151D antibody has the amino acid sequence shown in SEQ ID NO: 17 in the sequence listing. It is to be noted that the amino acid sequence of the heavy chain variable region shown in SEQ ID NO: 15 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 14 in the sequence listing. It is also to be noted that the amino acid sequence of the light chain variable region shown in SEQ ID NO: 17 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 16 in the sequence listing.

The heavy chain variable region of the 198D antibody has the amino acid sequence shown in SEQ ID NO: 19 in the sequence listing. In addition, the light chain variable region of the 198D antibody has the amino acid sequence shown in SEQ ID NO: 21 in the sequence listing. It is to be noted that the amino acid sequence of the heavy chain variable region shown in SEQ ID NO: 19 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 18 in the sequence listing. It is also to be noted that the amino acid sequence of the light chain variable region shown in SEQ ID NO: 21 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 20 in the sequence listing.

(g) Preparation of Monoclonal Antibody by Culturing Hybridomas

The thus selected hybridomas are cultured, so that monoclonal antibodies can be efficiently obtained. Before performing the culture, it is desirable to screen for hybridomas that produce a monoclonal antibody of interest.

For this screening, known methods can be adopted.

The antibody titer can be measured in the present invention by, for example, the ELISA method described in the above section (b).

The hybridomas obtained by the aforementioned methods can be preserved in liquid nitrogen or in a freezer at a temperature of −80° C. or lower in the form of a frozen state.

After completion of the cloning, the hybridomas are cultured, while replacing the HT medium with a normal medium.

Mass culture is carried out by rotary culture or spinner culture, using a large culture bottle. A supernatant obtained from this mass culture is purified according to methods well known to a person skilled in the art, such as gel filtration, so as to obtain a monoclonal antibody specifically binding to the protein of the present invention.

Moreover, hybridomas are injected into the abdominal cavity of a mouse of the same strain (e.g., the above described BALB/c), or a Nu/Nu mouse, and the hybridomas are allowed to grow therein, so as to obtain ascites comprising a large amount of the monoclonal antibody of the present invention.

When the hybridomas are administered into the abdominal cavity of such a mouse, a larger amount of ascites can be obtained if mineral oil such as 2,6,10,14-tetramethylpentadecane (pristane) has previously been administered to the mouse (3 to 7 days before administration of the hybridomas).

For instance, suppose that an immunosuppressive agent has previously been administered into the abdominal cavity of a mouse of the same strain as the hybridomas, so that T cells are deactivated. Twenty days after the injection, 10⁶ to 10⁷ hybridomas and/or clonal cells are suspended in a medium comprising no serum (0.5 ml), and the suspension is then administered into the abdominal cavity. When the normal abdomen has swollen and ascites has gathered, the ascites is collected from the mouse. According to this method, a monoclonal antibody in a concentration that is about 100 times or more than in a culture solution can be obtained.

The monoclonal antibody obtained by the above described method can be purified, for example, by the method described in Weir, D. M.: Handbook of Experimental Immunology, Vol. I, II, III, Blackwell Scientific Publications, Oxford (1978).

The thus obtained monoclonal antibody has high antigen specificity to GARP.

(h) Assay of Monoclonal Antibody

The isotype and subtype of the obtained monoclonal antibody can be determined as follows.

First, examples of the assay method can include an ouchterlony method, an ELISA method, and a RIA method.

The Ouchterlony method is simple, but when the concentration of a monoclonal antibody is low, a concentration procedure is necessary.

On the other hand, when the ELISA method or the RIA method is used, a culture supernatant is directly reacted with an antigen-adsorbed solid phase, and an antibody corresponding to various immunoglobulin isotypes or subclasses is used as a secondary antibody, so that the isotype and subtype of the monoclonal antibody can be identified.

As a simpler method, a commercially available identification kit (e.g., Mouse Typer Kit; manufactured by BioRad), etc. can also be utilized.

Moreover, quantification of a protein can be carried out by a Folin Lowry method and a method of calculating the value from the absorbance at 280 nm [1.4 (OD 280)=1 mg/ml immunoglobulin].

Furthermore, also in a case where the steps (a) to (h) in the above (2) are carried out again and a monoclonal antibody is independently obtained separately, an antibody having properties equivalent to those of an 105F antibody, an 110F antibody, a 151D-derived antibody (humanized 151D antibody) and a 198D-derived antibody (humanized 198D antibody) can be obtained. An example of such an antibody can be an antibody binding to the same epitope, to which each of the above described antibodies binds. The 105F antibody recognizes the amino acid sequence portions at amino acid positions 366 to 377, 407 to 445, and 456 to 470 in the amino acid sequence (SEQ ID NO: 1) of GARP, and binds thereto; the 110F antibody recognizes the amino acid sequence portions at amino acid positions 54 to 112 and 366 to 392 in the amino acid sequence (SEQ ID NO: 1) of GARP, and binds thereto; the 151D-derived antibody (humanized 151D antibody) recognizes the amino acid sequence at amino acid positions 352 to 392 in the amino acid sequence (SEQ ID NO: 1) of GARP, and binds thereto; and the 198D-derived antibody (humanized 198D antibody) recognizes the amino acid sequence at amino acid positions 18 to 112 in the amino acid sequence (SEQ ID NO: 1) of GARP, and binds thereto. Accordingly, particular examples of the aforementioned epitope can include the aforementioned regions in the amino acid sequence of GARP.

If a newly prepared monoclonal antibody binds to a partial peptide or a partial three-dimensional structure to which the above described 105F antibody, etc. binds, it can be determined that the monoclonal antibody binds to the same epitope, to which the above described 105F antibody, etc. binds. Moreover, by confirming that the monoclonal antibody competes with the above described antibodies such as the 105F antibody in the binding of the antibodies to GARP (i.e., the monoclonal antibody interferes with the binding of the above described antibodies such as the 105F antibody to GARP), it can be determined that the monoclonal antibody binds to the same epitope, to which the above described 105F antibody, etc. binds, even if the specific sequence or structure of the epitope has not been determined. When it is confirmed that the monoclonal antibody binds to the same epitope to which the 105F antibody, etc. binds, then it is strongly expected that the monoclonal antibody should have properties equivalent to the above described antibodies such as the 105F antibody.

(3) Other Antibodies

The antibody of the present invention also includes genetically recombinant antibodies that have been artificially modified for the purpose of reducing heterogenetic antigenicity to humans, such as a chimeric antibody, a humanized antibody and the above described human antibodies, as well as the above described monoclonal antibody against GARP. These antibodies can be produced by known methods.

The obtained antibody can be purified to a homogenous state. For separation and purification of the antibody, separation and purification methods used for ordinary proteins may be used. For example, column chromatography, filtration, ultrafiltration, salting-out, dialysis, preparative polyacrylamide gel electrophoresis, isoelectric focusing, etc. are appropriately selected and combined with one another, so that the antibody can be separated and purified (Strategies for Protein Purification and Characterization: A Laboratory Course Manual, Daniel R. Marshak et al. eds., Cold Spring Harbor Laboratory Press (1996); Antibodies: A Laboratory Manual. Ed Harlow and David Lane, Cold Spring Harbor Laboratory (1988)), but examples of the separation and purification methods are not limited thereto.

Examples of the chromatography can include affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration chromatography, reverse phase chromatography, and absorption chromatography.

These chromatographic techniques can be carried out using liquid chromatography such as HPLC or FPLC.

Examples of the column used in the affinity chromatography can include a Protein A column and a Protein G column. Examples of the column involving the use of Protein A can include Hyper D, POROS, and Sepharose F. F. (Pharmacia).

Also, using an antigen-immobilized carrier, an antibody can be purified by utilizing the binding activity of the antibody to the antigen.

The obtained antibodies are evaluated, in terms of their binding activity to the antigen, according to the method described in the Examples discussed below, etc., so that a preferred antibody can be selected.

The stability of an antibody can be used as an indicator for comparison of the properties of antibodies. A differential scanning calorimeter (DSC) is a device capable of promptly and exactly measuring a thermal denaturation midpoint (Tm) that is a good indicator for the relative structural stability of a protein. By using DSC to measure Tm values and making a comparison regarding the obtained values, differences in the thermal stability can be compared. It is known that the preservation stability of an antibody has a certain correlation with the thermal stability of the antibody (Lori Burton, et al., Pharmaceutical Development and Technology (2007) 12, pp. 265-273), and thus, a preferred antibody can be selected using thermal stability as an indicator. Examples of other indicators for selection of an antibody can include high yield in suitable host cells and low agglutination in an aqueous solution. For example, since an antibody with the highest yield does not always exhibit the highest thermal stability, it is necessary to select an antibody most suitable for administration to a human by comprehensively determining it based on the aforementioned indicators.

An example of the anti-GARP human antibody of the present invention can be an anti-GARP human antibody obtained by the above described phage display method, and preferred examples of the present anti-GARP human antibody can include a 105F antibody and a 110F antibody, each of which has the following structure.

The heavy chain of the 105F antibody has the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing. In the heavy chain amino acid sequence shown in SEQ ID NO: 2 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 118 is a variable region, whereas the amino acid sequence consisting of the amino acid residues at positions 119 to 448 is a constant region. In SEQ ID NO: 2 in the sequence listing, this variable region has CDRH1 consisting of the amino acid sequence at amino acid positions 26 to 35, CDRH2 consisting of the amino acid sequence at amino acid positions 50 to 66, and CDRH3 consisting of the amino acid sequence at amino acid positions 99 to 107. In addition, the sequence of SEQ ID NO: 2 is shown in FIG. 2.

The light chain of the 105F antibody has the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing. In the light chain amino acid sequence shown in SEQ ID NO: 3 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 112 is a variable region, whereas the amino acid sequence consisting of the amino acid residues at positions 113 to 217 is a constant region. In SEQ ID NO: 3 in the sequence listing, this variable region has CDRL1 consisting of the amino acid sequence at amino acid positions 23 to 36, CDRL2 consisting of the amino acid sequence at amino acid positions 52 to 58, and CDRL3 consisting of the amino acid sequence at amino acid positions 91 to 101. In addition, the sequence of SEQ ID NO: 3 is shown in FIG. 3.

The heavy chain of the 110F antibody has the amino acid sequence shown in SEQ ID NO: 4 in the sequence listing. In the heavy chain amino acid sequence shown in SEQ ID NO: 4 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 123 is a variable region, whereas the amino acid sequence consisting of the amino acid residues at positions 124 to 453 is a constant region. In SEQ ID NO: 4 in the sequence listing, this variable region has CDRH1 consisting of the amino acid sequence at amino acid positions 26 to 35, CDRH2 consisting of the amino acid sequence at amino acid positions 50 to 66, and CDRH3 consisting of the amino acid sequence at amino acid positions 99 to 112. In addition, the sequence of SEQ ID NO: 4 is shown in FIG. 4.

The light chain of the 110F antibody has the amino acid sequence shown in SEQ ID NO: 5 in the sequence listing. In the light chain amino acid sequence shown in SEQ ID NO: 5 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 111 is a variable region, whereas the amino acid sequence consisting of the amino acid residues at positions 112 to 216 is a constant region. In SEQ ID NO: 5 in the sequence listing, this variable region has CDRL1 consisting of the amino acid sequence at amino acid positions 23 to 36, CDRL2 consisting of the amino acid sequence at amino acid positions 52 to 58, and CDRL3 consisting of the amino acid sequence at amino acid positions 91 to 100. In addition, the sequence of SEQ ID NO: 5 is shown in FIG. 5.

The amino acid sequence of the 105F antibody heavy chain shown in SEQ ID NO: 2 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 6 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 354 in the nucleotide sequence shown in SEQ ID NO: 6 in the sequence listing encodes the heavy chain variable region of the 105F antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 355 to 1344 encodes the heavy chain constant region of the 105F antibody. As shown in SEQ ID NO: 6, the nucleotide sequence encoding the variable region has a polynucleotide consisting of the nucleotide sequence at nucleotide positions 76 to 105 encoding CDRH1, a polynucleotide consisting of the nucleotide sequence at nucleotide positions 148 to 198 encoding CDRH2, and a polynucleotide consisting of the nucleotide sequence at nucleotide positions 295 to 321 encoding CDRH3. In addition, the sequence of SEQ ID NO: 6 is shown in FIG. 6.

The amino acid sequence of the 105F antibody light chain shown in SEQ ID NO: 3 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 7 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 336 in the nucleotide sequence shown in SEQ ID NO: 7 in the sequence listing encodes the light chain variable region of the 105F antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 337 to 651 encodes the light chain constant region of the 105F antibody. As shown in SEQ ID NO: 7, the nucleotide sequence encoding the variable region has a polynucleotide consisting of the nucleotide sequence at nucleotide positions 67 to 108 encoding CDRL1, a polynucleotide consisting of the nucleotide sequence at nucleotide positions 154 to 174 encoding CDRL2, and a polynucleotide consisting of the nucleotide sequence at nucleotide positions 271 to 303 encoding CDRL3. In addition, the sequence of SEQ ID NO: 7 is shown in FIG. 7.

The amino acid sequence of the 110F antibody heavy chain shown in SEQ ID NO: 4 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 8 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 369 in the nucleotide sequence shown in SEQ ID NO: 8 in the sequence listing encodes the heavy chain variable region of the 110F antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 370 to 1359 encodes the heavy chain constant region of the 110F antibody. As shown in SEQ ID NO: 8, the nucleotide sequence encoding the variable region has a polynucleotide consisting of the nucleotide sequence at nucleotide positions 76 to 105 encoding CDRH1, a polynucleotide consisting of the nucleotide sequence at nucleotide positions 148 to 198 encoding CDRH2, and a polynucleotide consisting of the nucleotide sequence at nucleotide positions 295 to 336 encoding CDRH3. In addition, the sequence of SEQ ID NO: 8 is shown in FIG. 8.

The amino acid sequence of the 110F antibody light chain shown in SEQ ID NO: 5 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 9 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 333 in the nucleotide sequence shown in SEQ ID NO: 9 in the sequence listing encodes the light chain variable region of the 110F antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 334 to 648 encodes the light chain constant region of the 110F antibody. As shown in SEQ ID NO: 9, the nucleotide sequence encoding the variable region has a polynucleotide consisting of the nucleotide sequence at nucleotide positions 67 to 108 encoding CDRL1, a polynucleotide consisting of the nucleotide sequence at nucleotide positions 154 to 174 encoding CDRL2, and a polynucleotide consisting of the nucleotide sequence at nucleotide positions 271 to 300 encoding CDRL3. In addition, the sequence of SEQ ID NO: 9 is shown in FIG. 9.

With regard to the antibody of the present invention, in addition to the above described anti-GARP human antibody, even in a case where an antibody is independently obtained, separately, according to a method other than the above described method of obtaining an antibody, antibodies having cytotoxicity equivalent to that of the 105F antibody or the 110F antibody can be obtained. An example of such an antibody can be an antibody binding to the same epitope to which the 105F antibody or the 110F antibody binds.

If a newly produced human antibody binds to a partial peptide or a partial three-dimensional structure, to which the 105F antibody or the 110F antibody binds, it can be determined that the produced antibody binds to the same epitope, to which the 105F antibody or the 110F antibody binds. In addition, by confirming that the concerned antibody competes with the 105F antibody or the 110F antibody for the binding thereof to GARP (i.e., the concerned antibody interferes with the binding of the 105F antibody or the 110F antibody to GARP), it can be determined that the concerned antibody binds to the same epitope, to which the 105F antibody or the 110F antibody binds, even if the specific sequence or structure of the epitope has not been determined. If it is confirmed that the concerned antibody binds to the same epitope to which the 105F antibody or the 110F antibody binds, then it is strongly expected that the concerned antibody should have cytotoxicity equivalent to that of the 105F antibody or the 110F antibody.

Moreover, the antibody of the present invention includes artificially modified, genetically recombinant antibodies. These antibodies can be produced using known methods. The antibody concerned is preferably an antibody having, at least, the same 6 CDRs as the heavy chain and light chain of the above described 105F antibody or 110F antibody, and also having ADCC activity and inhibitory activity on the immunosuppressive function of Treg. The concerned antibody is not limited to a specific antibody, as long as it has the aforementioned properties. The antibody is more preferably an antibody having the heavy chain variable region and light chain variable region of the above described 105F antibody or 110F antibody.

Furthermore, by combining sequences showing a high homology to the heavy chain amino acid sequence and light chain amino acid sequence of the 105F antibody or the 110F antibody with each other, it is possible to select an antibody having an activity equivalent to the above described antibody. Such a homology is a homology of generally 80% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more (however, each CDR is identical to that of each of the above described antibodies). Further, it is also possible to select an antibody having an activity equivalent to each of the above described antibodies by incorporating an amino acid sequence comprising a substitution, deletion or addition of one or several amino acid residues to the amino acid sequence of the above described heavy chain or light chain (excluding each CDR site).

Still further, examples of the anti-GARP antibody according to the present invention can include the following chimeric antibodies and humanized antibodies.

Example of a chimeric antibody can include antibodies in which a variable region and a constant region are heterologous to each other, such as a chimeric antibody formed by conjugating the variable region of a mouse- or rat-derived antibody to a human-derived constant region (see Proc. Natl. Acad. Sci. U. S. A., 81, 6851-6855, (1984)).

A chimeric antibody derived from rat anti-human GARP antibody 151D is an antibody consisting of a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 1 to 117 shown in SEQ ID NO: 15, and a light chain comprising a light chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 1 to 109 shown in SEQ ID NO: 17, and this chimeric antibody may have a constant region derived from any given human.

Moreover, a chimeric antibody derived from a rat anti-human GARP antibody 198D is an antibody consisting of a heavy chain comprising a heavy chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 1 to 120 shown in SEQ ID NO: 19, and a light chain comprising a light chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 1 to 109 shown in SEQ ID NO: 21, and this chimeric antibody may have a constant region derived from any given human.

Examples of such a chimeric antibody can include: an antibody consisting of a heavy chain having the amino acid sequence consisting of the amino acid residues at positions 20 to 466 shown in SEQ ID NO: 25 in the sequence listing, and a light chain having the amino acid sequence consisting of the amino acid residues at positions 21 to 234 shown in SEQ ID NO: 27 therein; and an antibody consisting of a heavy chain having the amino acid sequence consisting of the amino acid residues at positions 20 to 469 shown in SEQ ID NO: 29 in the sequence listing, and a light chain having the amino acid sequence consisting of the amino acid residues at positions 21 to 234 shown in SEQ ID NO: 31 therein.

It is to be noted that, in the heavy chain sequence shown in SEQ ID NO: 25 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 136 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 137 to 466 is a constant region.

It is also to be noted that, in the light chain sequence shown in SEQ ID NO: 27 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 21 to 129 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 130 to 234 is a constant region.

It is further to be noted that, in the heavy chain sequence shown in SEQ ID NO: 29 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 139 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 140 to 469 is a constant region.

It is further to be noted that, in the light chain sequence shown in SEQ ID NO: 31 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 21 to 129 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 130 to 234 is a constant region.

The amino acid sequence of the heavy chain of the c151D antibody shown in SEQ ID NO: 25 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 24 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 57 in the nucleotide sequence shown in SEQ ID NO: 24 in the sequence listing encodes the heavy chain signal sequence of the c151D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 408 therein encodes the heavy chain variable region of the c151D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 409 to 1398 therein encodes the heavy chain constant region of the c151D antibody.

Moreover, the amino acid sequence of the light chain of the c151D antibody shown in SEQ ID NO: 27 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 26 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 60 in the nucleotide sequence shown in SEQ ID NO: 26 in the sequence listing encodes the light chain signal sequence of the c151D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 387 therein encodes the light chain variable region of the c151D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 388 to 702 therein encodes the light chain constant region of the c151D antibody.

Furthermore, the amino acid sequence of the heavy chain of the c198D antibody shown in SEQ ID NO: 29 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 28 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 57 in the nucleotide sequence shown in SEQ ID NO: 28 in the sequence listing encodes the heavy chain signal sequence of the c198D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 417 therein encodes the heavy chain variable region of the c198D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 418 to 1407 therein encodes the heavy chain constant region of the c198D antibody.

Further, the amino acid sequence of the light chain of the c198D antibody shown in SEQ ID NO: 31 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 30 in the sequence listing. The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 60 in the nucleotide sequence shown in SEQ ID NO: 30 in the sequence listing encodes the light chain signal sequence of the c198D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 387 therein encodes the light chain variable region of the c198D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 388 to 702 therein encodes the light chain constant region of the c198D antibody.

Examples of the humanized antibody include a humanized antibody formed by incorporating only a complementarity determining region (CDR) into a human-derived antibody (see Nature (1986) 321, p. 522-525), and a humanized antibody formed by transplanting the amino acid residues in some frameworks, as well as CDR sequences, into a human antibody according to a CDR grafting method (International Publication No. WO90/07861).

However, a humanized antibody derived from the 151D antibody is not limited to a specific humanized antibody, as long as it retains all 6 CDR sequences of the 151D antibody and has an antitumor activity.

It is to be noted that the heavy chain variable region of the 151D antibody has CDRH1 (GFTFSNYYMA) consisting of the amino acid sequence consisting of the amino acid residues at positions 26 to 35 in SEQ ID NO: 15 in the sequence listing, CDRH2 (SIGTVGGNTY) consisting of the amino acid sequence consisting of the amino acid residues at positions 50 to 59 in SEQ ID NO: 15 therein, and CDRH3 (EDYGGFPH) consisting of the amino acid sequence consisting of the amino acid residues at positions 99 to 106 in SEQ ID NO: 15 therein.

In addition, the light chain variable region of the 151D antibody has CDRL1 (KASQNVGTNVD) consisting of the amino acid sequence consisting of the amino acid residues at positions 24 to 34 in SEQ ID NO: 17 in the sequence listing, CDRL2 (GASNRYT) consisting of the amino acid sequence consisting of the amino acid residues at positions 50 to 56 in SEQ ID NO: 17 therein, and CDRL3 (LQYKYNPYT) consisting of the amino acid sequence consisting of the amino acid residues at positions 89 to 97 in SEQ ID NO: 17 therein.

Moreover, the heavy chain variable region of the 198D antibody has CDRH1 (GFSLTSFHVS) consisting of the amino acid sequence consisting of the amino acid residues at positions 26 to 35 in SEQ ID NO: 19 in the sequence listing, CDRH2 (TISSGGGTY) consisting of the amino acid sequence consisting of the amino acid residues at positions 50 to 58 in SEQ ID NO: 19 therein, and CDRH3 (ISGWGHYYVMDV) consisting of the amino acid sequence consisting of the amino acid residues at positions 98 to 109 in SEQ ID NO: 19 therein.

Furthermore, the light chain variable region of the 198D antibody has CDRL1 (QASEDIYSGLA) consisting of the amino acid sequence consisting of the amino acid residues at positions 24 to 34 in SEQ ID NO: 21 in the sequence listing, CDRL2 (GAGSLQD) consisting of the amino acid sequence consisting of the amino acid residues at positions 50 to 56 in SEQ ID NO: 21 therein, and CDRL3 (QQGLKFPLT) consisting of the amino acid sequence consisting of the amino acid residues at positions 89 to 97 in SEQ ID NO: 21 therein.

A concrete example of a humanized antibody of the rat antibody 151D can be any given combination of: a heavy chain comprising a heavy chain variable region consisting of any one of (1) an amino acid sequence consisting of the amino acid residues at positions 20 to 136 shown in SEQ ID NO: 33 (h151D-H1) or 35 (h151D-H4) in the sequence listing, (2) an amino acid sequence having a homology of at least 95% or more to the sequence of a framework region other than at each CDR sequence in the sequence of the above (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the sequence of a framework region other than at each CDR sequence in the sequence of the above (1); and a light chain comprising a light chain variable region consisting of any one of (4) an amino acid sequence consisting of the amino acid residues at positions 21 to 129 shown in SEQ ID NO: 37 (h151D-L1) or 39 (h151D-L4), (5) an amino acid sequence having a homology of at least 95% or more to the sequence of a framework region other than at each CDR sequence in the sequence of the above (4), and (6) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the sequence of a framework region other than at each CDR sequence in the sequence of the above (4).

On the other hand, a concrete example of a humanized antibody of the rat antibody 198D can be any given combination of: a heavy chain comprising a heavy chain variable region consisting of any one of (1) an amino acid sequence consisting of the amino acid residues at positions 20 to 139 shown in SEQ ID NO: 41 (h198D-H3) in the sequence listing, (2) an amino acid sequence having a homology of at least 95% or more to the sequence of a framework region other than at each CDR sequence in the sequence of the above (1), and (3) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the sequence of a framework region other than at each CDR sequence in the sequence of the above (1); and a light chain comprising a light chain variable region consisting of any one of (4) an amino acid sequence consisting of the amino acid residues at positions 21 to 129 shown in SEQ ID NO: 43 (h198D-L4) in the sequence listing, (5) an amino acid sequence having a homology of at least 95% or more to the sequence of a framework region other than at each CDR sequence in the sequence of the above (4), and (6) an amino acid sequence comprising a deletion, substitution or addition of one or several amino acids in the sequence of a framework region other than at each CDR sequence in the sequence of the above (4).

Examples of a preferred combination of a heavy chain and a light chain of the humanized 151D antibody can include: an antibody consisting of a heavy chain having a heavy chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 20 to 136 shown in SEQ ID NO: 33, and a light chain having a light chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 21 to 129 shown in SEQ ID NO: 37; and an antibody consisting of a heavy chain having a heavy chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 20 to 136 shown in SEQ ID NO: 35, and a light chain having a light chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 21 to 129 shown in SEQ ID NO: 39.

Examples of a more preferred combination thereof can include: an antibody (h151D-H1L1) consisting of a heavy chain having the amino acid sequence shown in SEQ ID NO: 33 and a light chain having the amino acid sequence shown in SEQ ID NO: 37; and an antibody (h151D-H4L4) consisting of a heavy chain having the amino acid sequence shown in SEQ ID NO: 35 and a light chain having the amino acid sequence shown in SEQ ID NO: 39.

An example of a preferred combination of the heavy chain and light chain of the humanized 198D antibody can be an antibody consisting of a heavy chain having a heavy chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 20 to 139 shown in SEQ ID NO: 41, and a light chain having a light chain variable region consisting of the amino acid sequence consisting of the amino acid residues at positions 21 to 129 shown in SEQ ID NO: 43.

An example of a more preferred combination thereof can be an antibody (h198D-H3L4) consisting of a heavy chain having the amino acid sequence shown in SEQ ID NO: 41 and a light chain having the amino acid sequence shown in SEQ ID NO: 43.

By combining together sequences showing a high homology to the above described heavy chain amino acid sequences and light chain amino acid sequences, it is possible to select an antibody having cytotoxicity equivalent to each of the above described antibodies. Such a homology is a homology of generally 80% or more, preferably 90% or more, more preferably 95% or more, and most preferably 99% or more. Moreover, also by combining with one another, amino acid sequences comprising a substitution, deletion or addition of one or several amino acid residues with respect to the amino acid sequence of a heavy chain or a light chain, it is possible to select an antibody having cytotoxicity equivalent to each of the above described antibodies.

It is to be noted that the term “several” is used in the present description to mean 1 to 10, 1 to 9, 1 to 8, 1 to 7, 1 to 6, 1 to 5, 1 to 4, 1 to 3, or 1 or 2.

The amino acid substitution in the present description is preferably a conservative amino acid substitution. The conservative amino acid substitution is a substitution occurring within an amino acid group associated with certain amino acid side chains. Preferred amino acid groups are the following: acidic group=aspartic acid and glutamic acid; basic group=lysine, arginine, and histidine; non-polar group=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, and tryptophan; and uncharged polar group=glycine, asparagine, glutamine, cysteine, serine, threonine, and tyrosine. Other preferred amino acid groups are the following: aliphatic hydroxy group=serine and threonine; amide-containing group=asparagine and glutamine; aliphatic group=alanine, valine, leucine and isoleucine; and aromatic group=phenylalanine, tryptophan and tyrosine. Such amino acid substitution is preferably carried out to the extent that the properties of a substance having the original amino acid sequence are not impaired.

Homology between two types of amino acid sequences can be determined using default parameters of Blast algorithm version 2.2.2 (Altschul, Stephen F., Thomas L. Madden, Alejandro A. Schaffer, Jinghui Zhang, Zheng Zhang, Webb Miller, and David J. Lipman (1997), “Gapped BLAST and PSI-BLAST: a new generation of protein database search programs,” Nucleic Acids Res. 25: 3389-3402). The Blast algorithm can also be used by accessing www.ncbi.nlm.nih.gov/blast through the internet. It is to be noted that homology between the nucleotide sequence of the antibody of the present invention and the nucleotide sequence of another antibody can also be determined using the Blast algorithm.

In the amino acid sequence of the heavy chain of the humanized 151D antibody shown in SEQ ID NO: 33 or 35 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 136 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 137 to 466 is a constant region.

Moreover, in the amino acid sequence of the light chain of the humanized 151D antibody shown in SEQ ID NO: 37 or 39 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 21 to 129 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 130 to 234 is a constant region.

Furthermore, in the amino acid sequence of the heavy chain of the humanized 198D antibody shown in SEQ ID NO: 41 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 19 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 20 to 139 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 140 to 469 is a constant region.

Further, in the amino acid sequence of the light chain of the humanized 198D antibody shown in SEQ ID NO: 43 in the sequence listing, the amino acid sequence consisting of the amino acid residues at positions 1 to 20 is a signal sequence, the amino acid sequence consisting of the amino acid residues at positions 21 to 129 is a variable region, and the amino acid sequence consisting of the amino acid residues at positions 130 to 234 is a constant region.

The amino acid sequence of the heavy chain of the humanized 151D antibody shown in SEQ ID NO: 33 or 35 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 32 or 34 in the sequence listing, respectively. In addition, the sequence of SEQ ID NO: 33 is shown in FIG. 21, the sequence of SEQ ID NO: 35 is shown in FIG. 23, the sequence of SEQ ID NO: 32 is shown in FIG. 31, and the sequence of SEQ ID NO: 34 is shown in FIG. 33, respectively.

The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 57 in each nucleotide sequence encodes the heavy chain signal sequence of the humanized 151D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 408 therein encodes the heavy chain variable region of the humanized 151D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 409 to 1398 therein encodes the heavy chain constant region of the humanized 151D antibody

The amino acid sequence of the heavy chain of the humanized 198D antibody shown in SEQ ID NO: 41 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 40 in the sequence listing. In addition, the sequence of SEQ ID NO: 41 is shown in FIG. 25, and the sequence of SEQ ID NO: 40 is shown in FIG. 35.

The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 57 in the aforementioned nucleotide sequence encodes the heavy chain signal sequence of the humanized 198D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 417 therein encodes the heavy chain variable region of the humanized 198D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 418 to 1407 therein encodes the heavy chain constant region of the humanized 198D antibody.

The amino acid sequence of the light chain of the humanized 151D antibody shown in SEQ ID NO: 37 or 39 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 36 or 38 in the sequence listing, respectively. In addition, the sequence of SEQ ID NO: 37 is shown in FIG. 22, the sequence of SEQ ID NO: 39 is shown in FIG. 24, the sequence of SEQ ID NO: 36 is shown in FIG. 32, and the sequence of SEQ ID NO: 38 is shown in FIG. 34, respectively.

The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 60 in each nucleotide sequence encodes the light chain signal sequence of the humanized 151D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 387 therein encodes the light chain variable region of the humanized 151D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 388 to 702 therein encodes the light chain constant region of the humanized 151D antibody.

The amino acid sequence of the light chain of the humanized 198D antibody shown in SEQ ID NO: 43 in the sequence listing is encoded by the nucleotide sequence shown in SEQ ID NO: 42 in the sequence listing. In addition, the sequence of SEQ ID NO: 43 is shown in FIG. 26, and the sequence of SEQ ID NO: 42 is shown in FIG. 36.

The nucleotide sequence consisting of the nucleotides at nucleotide positions 1 to 60 in the aforementioned nucleotide sequence encodes the light chain signal sequence of the humanized 198D antibody, the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 387 therein encodes the light chain variable region of the humanized 198D antibody, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 388 to 702 therein encodes the light chain constant region of the humanized 198D antibody.

Homology between these nucleotide sequences and the nucleotide sequences of other antibodies can also be determined using the Blast algorithm.

A further example of the antibody of the present invention can be a human antibody binding to the same epitope, to which the humanized 151D antibody or the humanized 198D antibody also binds. An anti-GARP human antibody means a human antibody having only the gene sequence of a human chromosome-derived antibody. The anti-GARP human antibody can be obtained by the aforementioned method.

If a newly produced human antibody binds to a partial peptide or a partial three-dimensional structure, to which the humanized 151D antibody or the humanized 198D antibody binds, it can be determined that the human antibody binds to the same epitope, to which the humanized 151D antibody or the humanized 198D antibody binds. In addition, by confirming that the human antibody competes with the humanized 151D antibody or the humanized 198D antibody for the binding thereof to GARP (i.e., the human antibody interferes with the binding of the humanized 151D antibody or the humanized 198D antibody to GARP), it can be determined that the human antibody binds to the same epitope, to which the humanized 151D antibody or humanized 198D antibody binds, even if the specific sequence or structure of the epitope has not been determined. If it is confirmed that the concerned human antibody binds to the same epitope to which the humanized 151D antibody or the humanized 198D antibody binds, then, it is strongly expected that the human antibody should have cytotoxicity equivalent to that of the humanized 151D antibody or the humanized 198D antibody.

The chimeric antibody, humanized antibody, or human antibody obtained by the aforementioned methods is evaluated by the methods described later in the Examples, etc., in terms of binding activity to an antigen, and thus, a preferred antibody can be selected.

The present invention also includes a modification of an antibody. The term “modification” is used herein to mean the antibody of the present invention, which is chemically or biologically modified. Examples of such a chemical modification include the binding of a chemical moiety to an amino acid skeleton, and the chemical modification of an N-linked or O-linked carbohydrate chain. Examples of such a biological modification include antibodies which have undergone a posttranslational modification (e.g., an N-linked or O-linked sugar chain modification, N-terminal or C-terminal processing, deamidation, isomerization of aspartic acid, and oxidation of methionine), and antibodies, to the N-terminus of which a methionine residue is added as a result of having been allowed to be expressed using prokaryote host cells. In addition, such a modification also includes labeled antibodies for enabling detection or isolation of the antibody of the present invention or an antigen, such as, for example, an enzyme labeled antibody, a fluorescent-labeled antibody, and an affinity-labeled antibody. Such a modification of the antibody of the present invention is useful for the improvement of the stability and retention in blood of the original antibody of the present invention, a reduction in antigenicity, detection or isolation of such an antibody or antigen, etc.

Moreover, by regulating a sugar chain modification (glycosylation, de-fucosylation, etc.) that binds to the antibody of the present invention, antibody-dependent cellular cytotoxicity can be enhanced. As techniques of regulating the sugar chain modification of an antibody, those described in WO99/54342, WO2000/61739, WO2002/31140, etc. are known, but the techniques are not limited thereto. The antibody of the present invention also includes antibodies in which the aforementioned sugar chain modification has been regulated.

After an antibody gene has been isolated, the gene is introduced into a suitable host to produce an antibody, using a suitable combination of a host and an expression vector. A specific example of the antibody gene can be a combination of a gene encoding the heavy chain sequence of the antibody described in the present description and a gene encoding the light chain sequence of the antibody described therein. Upon transformation of host cells, a heavy chain sequence gene and a light chain sequence gene can be inserted into a single expression vector, or these genes can instead each be inserted into different expression vectors.

When eukaryotic cells are used as hosts, animal cells, plant cells or eukaryotic microorganisms can be used. Examples of animal cells include mammalian cells such as COS cells which are monkey cells (Gluzman, Y., Cell (1981) 23, p. 175-182, ATCC CRL-1650), mouse fibroblasts NIH3T3 (ATCC No. CRL-1658), and a dihydrofolate reductase-deficient cell line of Chinese hamster ovary cells (CHO cells, ATCC CCL-61) (Urlaub, G. and Chasin, L. A. Proc. Natl. Acad. Sci. U.S.A. (1980) 77, p. 4126-4220).

When prokaryotic cells are used as hosts, Escherichia coli or Bacillus subtilis can be used, for example.

An antibody gene of interest is introduced into these cells for transformation, and the transformed cells are then cultured in vitro to obtain an antibody. In the aforementioned culture, there are cases where yield is different depending on the sequence of the antibody, and thus, it is possible to select an antibody, which is easily produced as a medicament, from antibodies having equivalent binding activity, using the yield as an indicator. Accordingly, the antibody of the present invention also includes an antibody obtained by the above described method for producing an antibody, which is characterized in that it comprises a step of culturing the transformed host cells and a step of collecting an antibody of interest from the culture obtained in the aforementioned step.

It is known that the lysine residue at the carboxyl terminus of the heavy chain of an antibody produced in cultured mammalian cells is deleted (Journal of Chromatography A, 705: 129-134 (1995)), and also, it is known that the two amino acid residues at the heavy chain carboxyl terminus, glycine and lysine, are deleted, and that the proline residue positioned at the carboxyl terminus is newly amidated (Analytical Biochemistry, 360: 75-83 (2007)). However, such deletion and modification of these heavy chain sequences do not have an influence on the antigen-binding activity and effector function (activation of complement, antibody-dependent cellular cytotoxicity, etc.) of an antibody. Accordingly, the present invention also includes an antibody that has undergone the aforementioned modification, and specific examples of such an antibody include a deletion mutant comprising a deletion of 1 or 2 amino acids at the heavy chain carboxyl terminus, and a deletion mutant formed by amidating the aforementioned deletion mutant (e.g., a heavy chain in which the proline residue at the carboxyl terminal site is amidated). However, deletion mutants involving a deletion at the carboxyl terminus of the heavy chain of the antibody according to the present invention are not limited to the above described deletion mutants, as long as they retain antigen-binding activity and effector function. Two heavy chains constituting the antibody according to the present invention may be any one type of heavy chain selected from the group consisting of a full length antibody and the above described deletion mutants, or a combination of any two types selected from the aforementioned group. The ratio of individual deletion mutants can be influenced by the types of cultured mammalian cells that produce the antibody according to the present invention, and the culture conditions. The main ingredient of the antibody according to the present invention can be antibodies where one amino acid residue is deleted at each of the carboxyl termini of the two heavy chains.

Examples of the isotype of the antibody of the present invention can include IgG (IgG1, IgG2, IgG3, and IgG4). Among others, IgG1 and IgG2 are preferable.

Examples of the general function of an antibody can include antigen-binding activity, activity of neutralizing the activity of an antigen, activity of enhancing the activity of an antigen, ADCC activity, antibody dependent cellular phagocytosis (ADCP) activity, and complement-dependent cytotoxic (CDC) activity. The function of the antibody according to the present invention is binding activity to GARP, preferably ADCC activity, and more preferably cytotoxicity (antitumor activity) caused by ADCC-mediated inhibition of Treg function. Moreover, the antibody of the present invention may have ADCP activity and/or CDC activity, as well as ADCC activity. In particular, with regard to medicaments comprising existing antitumor antibodies, it has been reported that the medicaments directly act on tumor cells to block growth signals, that they directly act on tumor cells to induce cell death signals, that they suppress angiogenesis, that they cause ADCC activity via NK cells, and that they induce CDC activity via complement to suppress the growth of tumor cells (J Clin Oncol 28: 4390-4399. (2010), Clin Cancer Res; 16 (1); 11-20. (2010)). However, with regard to the ADCP activity of the anti-GARP antibody according to the invention of the present application, at least, the present inventors have not known that the ADCP activity had been reported as an activity of a medicament comprising an existing anti-GARP antitumor antibody.

The antibody of the present invention may be an antibody that has been multimerized to enhance affinity for an antigen. The antibody to be multimerized may be either a single type of antibody, or multiple antibodies recognizing multiple epitopes of a single antigen. Examples of a method of multimerizing an antibody can include the binding of an IgG CH3 domain to two scFv (single-chain antibodies), the binding of an antibody to streptavidin, and introduction of a helix-turn-helix motif.

The antibody of the present invention may also be a polyclonal antibody that is a mixture of multiple types of anti-GARP antibodies having different amino acid sequences. An example of the polyclonal antibody can be a mixture of multiple types of antibodies having different CDRs. As such a polyclonal antibody, an antibody obtained by culturing a mixture of cells producing different antibodies and then purifying the obtained culture can be used (see WO2004/061104).

As a modification of the antibody, an antibody binding to various types of molecules such as polyethylene glycol (PEG) can be used.

The antibody of the present invention may further be a conjugate formed by such an antibody and another drug (Immunoconjugate). Such an antibody can be, for example, an antibody that binds to a radioactive substance or a compound having pharmacological action (Nature Biotechnology (2005) 23, p. 1137-1146). Examples of such an antibody can include Indium (¹¹¹In) Capromab pendetide, Technetium (^(99m)Tc) Nofetumomab merpentan, Indium (¹¹¹In) Ibritumomab, Yttrium (⁹⁰Y) Ibritumomab, and Iodine (¹³¹I) Tositumomab.

3. Medicament Containing Anti-GARP Antibody

Since the antibody obtained by the method described in the above section “2. Production of anti-GARP antibody” exhibits cytotoxicity on Treg, it can be used as a medicament, and in particular, as a therapeutic agent for cancer and infectious disease (in particular, malaria and HIV infection).

Cytotoxicity caused by an antibody in vitro can be measured based on the activity of suppressing the proliferative responses of cells.

For example, a cancer cell line overexpressing GARP is cultured, and antibodies having different concentrations are added to the culture system. Thereafter, the inhibitory activity of the antibody on focus formation, colony formation and spheroid growth can be measured.

The in vivo therapeutic effects of an antibody on the cancer of an experimental animal can be measured, for example, by administering the antibody to a nude mouse into which a tumor cell line overexpressing GARP has been transplanted, and then measuring a change in the cancer cells.

Examples of the cancer type can include lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, and blood cancer. However, the cancer type is not limited to the aforementioned examples, as long as the cancer cells, as therapeutic targets, express GARP.

As a substance used in a medicament acceptable for the pharmaceutical composition of the present invention, a substance that is non-toxic to a subject, to whom the pharmaceutical composition is to be administered, is preferable, in terms of an applied dose or an applied concentration.

The pharmaceutical composition of the present invention can comprise a pharmaceutical substance for altering or retaining pH, osmotic pressure, viscosity, transparency, color, isotonicity, sterility, stability, solubility, sustained release rate, absorptivity, and permeability. Examples of the pharmaceutical substance can include the following substances, but are not limited thereto: amino acids such as glycine, alanine, glutamine, asparagine, arginine or lysine; antibacterial agents; antioxidants such as ascorbic acid, sodium sulfate or sodium hydrogen sulfite; buffers such as a phosphate, citrate or borate buffer, sodium hydrogen carbonate, or a Tris-HCl solution; fillers such as mannitol or glycine; chelating agents such as ethylenediaminetetraacetic acid (EDTA); complexing agents such as caffeine, polyvinylpyrrolidine, β-cyclodextrin or hydroxypropyl-β-cyclodextrin; bulking agents such as glucose, mannose or dextrin; other carbohydrates such as monosaccharides or disaccharides; a coloring agent; a flavor agent; a diluent; an emulsifier; hydrophilic polymers such as polyvinylpyrrolidine; a low-molecular-weight polypeptide; salt-forming counterions; antiseptics such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide; solvents such as glycerin, propylene glycol or polyethylene glycol; sugar alcohols such as mannitol or sorbitol; polysorbates such as a suspending agent, sorbitan ester, polysorbate 20 or polysorbate 80; surfactants such as Triton, tromethamine, lecithin or cholesterol; stability enhancers such as sucrose or sorbitol; a suspending agent; elasticity enhancers such as sodium chloride, potassium chloride, mannitol or sorbitol; transporting agents; excipients; and/or pharmaceutical adjuvants. Such a pharmaceutical substance is preferably added to an anti-GARP antibody in an amount of 0.001 to 100 times, in particular, 0.1 to 10 times higher than the weight of the anti-GARP antibody. The preferred composition of a pharmaceutical composition in a formulation can be determined, as appropriate, by a person skilled in the art, depending on the target disease, the applied administration route, etc.

An excipient or a carrier in the pharmaceutical composition may be a liquid or a solid. A suitable excipient or carrier may be water for injection, normal saline, an artificial cerebrospinal fluid, or other substances commonly used in parenteral administration. Neutral normal saline or normal saline comprising serum albumin can also be used as a carrier. The pharmaceutical composition can comprise a Tris buffer with pH 7.0-8.5, an acetate buffer with pH 4.0-5.5, or a citrate buffer with pH 3.0-6.2. In addition, these buffers can also comprise sorbitol or other compounds.

Examples of the pharmaceutical composition of the present invention can include a pharmaceutical composition comprising an anti-GARP antibody and a pharmaceutical composition comprising an anti-GARP antibody and at least one cancer therapeutic agent. The pharmaceutical composition of the present invention is prepared as a drug having a selected composition and a necessary purity in the form of a freeze-dried product or a liquid. Such a pharmaceutical composition comprising an anti-GARP antibody and a pharmaceutical composition comprising an anti-GARP antibody and at least one cancer therapeutic agent can also be molded into a freeze-dried product comprising a suitable excipient such as sucrose.

A cancer therapeutic agent comprised, together with an anti-GARP antibody, in the above described pharmaceutical composition may be administered to an individual, simultaneously, separately, or continuously, together with the anti-GARP antibody. Otherwise, the cancer therapeutic agent and the anti-GARP antibody may each be administered to the subject at different administration intervals. Examples of such a cancer therapeutic agent can include abraxane, carboplatin, cisplatin, gemcitabine, irinotecan (CPT-11), paclitaxel, pemetrexed, sorafenib, vinblastin, the drugs described in International Publication No. WO2003/038043, LH-RH analogs (leuprorelin, goserelin, etc.), estramustine-phosphate, estrogen antagonists (tamoxifen, raloxifene, etc.), and aromatase inhibitors (anastrozole, letrozole, exemestane, etc.). However, examples of the cancer therapeutic agent are not limited to the above described drugs, as long as the agents have antitumor activity.

The subject to be the target for administration is not particularly limited. It is preferably a mammal, and more preferably a human.

The pharmaceutical composition of the present invention can be prepared for use in parenteral administration, or for use in gastrointestinal absorption involving oral administration. The composition and concentration of a formulation can be determined depending on the administration method. With regard to the affinity of an anti-GARP antibody comprised in the pharmaceutical composition of the present invention for GARP, namely, the dissociation constant (Kd value) of the anti-GARP antibody to GARP, as the affinity increases (i.e., the Kd value is low), the pharmaceutical composition can exhibit medicinal effects, even if the applied dose thereof to a human is decreased. Based on these results, the applied dose of the pharmaceutical composition of the present invention to a human can also be determined. When a human-type anti-GARP antibody is administered to a human, the antibody may be administered at a dose of from about 0.001 to 100 mg/kg once or several times at intervals of 1 to 180 days. Examples of the form of the pharmaceutical composition of the present invention can include an injection including a drip infusion, a suppository, a transnasal agent, a sublingual agent, and a transdermal absorption agent.

Hereinafter, the present invention will be specifically described in the following examples. However, these examples are not intended to limit the scope of the present invention.

EXAMPLES

In the following examples, unless otherwise specified, individual operations regarding genetic manipulation have been carried out according to the method described in “Molecular Cloning” (Sambrook, J., Fritsch, E. F. and Maniatis, T., published by Cold Spring Harbor Laboratory Press in 1989) or other methods described in experimental manuals used by persons skilled in the art, or when commercially available reagents or kits have been used, the examples have been carried out in accordance with the instructions included in the commercially available products.

Hereinafter, the present invention will be specifically described in the following examples. However, these examples are not intended to limit the scope of the present invention.

Example 1 Obtaining Antibody

1)-1 Separation of Anti-GARP Fab by Panning in Phage Display

An n-CoDeR Fab phage library (Biolnvent) was used in separation of Fab binding to GARP. Using EZ-Link NHS-Chromogenic-Biotin reagent (Thermo Scientific), GARP (R&D Systems) was biotinylated. For liquid-phase panning, the biotinylated GARP was solid-phased on Dynabeads Streptavidin M-280 (Life Technologies), and phages were then added. Unbound phages were removed by a washing operation using a magnet (DynaMag-2, Life Technologies). Thereafter, GARP-bound phages were collected by treating them with trypsin (Sigma-Aldrich), and were then amplified using Escherichia coli . In total, panning operations were carried out three times, and, using restriction enzymes, a DNA fragment encoding Fab was cut from a polyclonal phagemid, and was then loaded on an expression vector for Escherichia coli . Thereafter, Escherichia coli TOP10F′ (Life Technologies) was transformed with the expression vector, and Fab was then allowed to express in the presence of IPTG (Sigma-Aldrich). The obtained Fab was subjected to screening by ELISA.

1)-2 Screening for GARP-binding Fab by ELISA

50 μL GARP, which had been diluted to 2 μg/mL with PBS (0.01 M phosphate buffered saline (pH 7.4) containing 0.138 M sodium chloride and 0.0027 M potassium chloride; Sigma-Aldrich), was added to each well of a 384-well Maxi-sorp plate (Black, Nunc), and it was then incubated overnight at 4° C. for coating the plate. Alternatively, 50 μL of NeutrAvidin (Life Technologies) which had been diluted to 1 μg/mL with PBS was added to such a 384-well Maxi-sorp plate for coating the plate (by incubating overnight at 4° C.). Thereafter, the plate was washed with an ELISA buffer (PBS (Sigma-Aldrich) supplemented with 0.05% Tween-20 (Bio-RAD)) three times, and biotinylated GARP was then added thereto (1 pmol/50 μL PBS/well), followed by incubation at room temperature for 1 hour with mixing. The plate was washed with ELISA buffer three times, was then blocked with Blocker Casein (Thermo Scientific), and was further washed with the ELISA buffer three times. Thereafter, a culture supernatant containing Fab produced by Escherichia coli was added, and the plate was then incubated at room temperature for 1 hour with mixing. The plate was washed with the ELISA buffer three times, and 50 μL of 2500-fold diluted Horseradish peroxidase (HRP)-labeled anti-human F (ab′)₂ antibody (R&D Systems) was added. The plate was further incubated at room temperature for 1 hour with mixing. The reaction mixture was washed with the ELISA buffer three times, and SuperSignal Pico ELISA Chemiluminescent substrate (Thermo Scientific) was then added to the wells. Ten minutes later, chemiluminescence was measured using a plate reader (Envision 2104 Multilabel Reader, Perkin Elmer), and GARP-bound Fab was isolated.

1)-3 Determination of Nucleotide Sequence of ELISA-positive Clone

The heavy chain and light chain variable regions of ELISA-positive clones (105F and 110F) were analyzed by a Dye Terminator method (BigDye (registered trademark) Terminator v3.1, Life Technologies). The sequences of the main primers used in sequencing are as follows.

-   Primer A: 5′-GAA ACA GCT ATG AAA TAC CTA TTG C-3′ (SEQ ID NO: 10) -   Primer B: 5′-GCC TGA GCA GTG GAA GTC C-3′ (SEQ ID NO: 11) -   Primer C: 5′ -TAG GTA TTT CAT TAT GAC TGT CTC-3′ (SEQ ID NO: 12) -   Primer D: 5′-CCC AGT CAC GAC GTT GTA AAA CG-3′ (SEQ ID NO: 13)

As a result of the above described analysis, the nucleotide sequences of the variable regions of the 105F antibody and 110F antibody genes were determined.

The nucleotide sequence of the heavy chain variable region of the 105F antibody was a sequence consisting of the nucleotides at nucleotide positions 1 to 354 in the nucleotide sequence shown in SEQ ID NO: 6 in the sequence listing, and the nucleotide sequence of the light chain variable region of the 105F antibody was a sequence consisting of the nucleotides at nucleotide positions 1 to 336 in the nucleotide sequence shown in SEQ ID NO: 7 in the sequence listing.

The nucleotide sequence of the heavy chain variable region of the 110F antibody was a sequence consisting of the nucleotides at nucleotide positions 1 to 369 in the nucleotide sequence shown in SEQ ID NO: 8 in the sequence listing, and the nucleotide sequence of the light chain variable region of the 110F antibody was a sequence consisting of the nucleotides at nucleotide positions 1 to 333 in the nucleotide sequence shown in SEQ ID NO: 9 in the sequence listing.

1)-4: Preparation of Full-length IgG, and Expression and Purification of IgG

Full-length IgG of ELISA-positive clones including 105F and 110F was prepared by the following method.

A nucleotide sequence encoding Fab was determined, and thereafter, nucleotide sequences corresponding to the variable regions of the heavy chain and light chain of each antibody specified in the above 1)-3 were specified.

According to a common method, the nucleotide sequence of the variable region of the above described heavy chain was ligated to a nucleotide sequence encoding the constant region of the heavy chain of human IgG₁ (CH1+Fc region: the amino acid sequence at amino acid positions 119 to 448 in the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing), and also, the nucleotide sequence of the variable region of the above described light chain was ligated to a nucleotide sequence encoding the constant region of the light chain of human IgG₁ (CL: the amino acid sequence at amino acid positions 113 to 217 in the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing). Thereafter, the obtained ligate was inserted into an expression vector for animal cells, such as pcDNA3.3 (Invitrogen), to construct an IgG expression vector for animal cells.

The nucleotide sequence of the constructed IgG expression vector was analyzed again, so that it was confirmed that the nucleotide sequence of the full-length heavy chain of the 105F antibody was the nucleotide sequence shown in SEQ ID NO: 6 in the sequence listing, and that the nucleotide sequence of the full-length light chain of the 105F antibody was the nucleotide sequence shown in SEQ ID NO: 7 in the sequence listing.

It was also confirmed that the nucleotide sequence of the full-length heavy chain of the 110F antibody was the nucleotide sequence shown in SEQ ID NO: 8 in the sequence listing, and that the nucleotide sequence of the full-length light chain of the 110F antibody was the nucleotide sequence shown in SEQ ID NO: 9 in the sequence listing.

Moreover, based on the above described nucleotide sequences, the amino acid sequences of the full-length heavy chain and full-length light chain of the 105F antibody encoded by the nucleotide sequences, and the amino acid sequences of the full-length heavy chain and full-length light chain of the 110F antibody encoded by the nucleotide sequences, were determined.

The amino acid sequence of the heavy chain of the 105F antibody was the amino acid sequence shown in SEQ ID NO: 2 in the sequence listing, and the amino acid sequence of the light chain thereof was the amino acid sequence shown in SEQ ID NO: 3 in the sequence listing.

The amino acid sequence of the heavy chain of the 110F antibody was the amino acid sequence shown in SEQ ID NO: 4 in the sequence listing, and the amino acid sequence of the light chain thereof was the amino acid sequence shown in SEQ ID NO: 5 in the sequence listing.

The IgG of the 105F antibody or the 110F antibody was transiently expressed by inserting the above described IgG expression vector for animal cells into FreeStyle 293F cells (Life Technologies), and then the resulting IgGs were purified using a Protein A Affinity column (HiTrap Mab Select SuRe, GE Healthcare), as necessary. Thereafter, the buffer in which IgG was dissolved was replaced with PBS using Vivaspin 20 (7k MWCO, GE Healthcare) and the resultant was then subjected to the following step “1)-5.”

1)-5 Confirmation of Binding of Purified IgG to GARP According to ELISA

100 μL of human GARP (R&D Systems, catalog number: 6055-LR) diluted to 1 μg/mL with PBS was added to each well of a 96-well Maxi-sorp plate (Black, Nunc), and the plate was then incubated overnight at 4° C. for coating the plate.

The plate was washed with ELISA buffer three times, and then blocked with Blocker Casein at room temperature for 1 hour. The plate was washed with the ELISA buffer three times, and 100 μL of 50 nM 105F antibody, 50 nM 110F antibody, 50 nM human IgG (Jackson Immuno Research), 50 nM mouse anti-GARP antibody (Plato-1, ENZO Life Science) or 50 nM mouse IgG (Jackson Immuno Research) was added to the wells, and the plate was incubated at room temperature for 1 hour with mixing.

The plate was washed with the ELISA buffer three times. After that, 100 μL of HRP-labeled anti-human Fc antibody (R&D Systems), which had been 5000-fold diluted with PBS, was added to wells treated with 105F antibody, 110F antibody or human IgG. On the other hand, 100 μL of HRP-labeled anti-mouse Fc antibody (R&D Systems), which had been 5000-fold diluted with PBS, was added to the wells treated with mouse anti-GARP antibody and mouse IgG. The plate was incubated at room temperature for 1 hour with mixing.

The plate was washed with the ELISA buffer five times, and 0.1 mL of SuperSignal Pico ELISA Chemiluminescent substrate was then added to the wells. Ten minutes later, chemiluminescence was measured using a plate reader (Envision 2104 Multilabel Reader, Perkin Elmer).

As a result, it was demonstrated that the 105F antibody and the 110F antibody bound to GARP (FIG. 10) as commercially available anti-GARP antibody did.

Example 2 Binding to Antigen Gene-expressing Cells

Regarding a GARP expression vector, a cDNA clone of human GARP (Origene) was purchased, and it was then cloned into a pcDNA3.1 (+) vector (Invitrogen) according to a common method. Thereafter, the nucleotide sequence thereof was confirmed.

The GARP expression vector and a pcDNA3.1 vector used as a control were each transfected into HEK-293T cells (ATCC: CRL-11268), using Lipofectamine 2000 (Invitrogen). The resulting cells were cultured in a DMEM medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS, Hyclone) overnight in 5% CO₂ at 37° C. Thereafter, the cells were harvested from the plate by TrypLE Express (Invitrogen) treatment, and the cells were washed with MACS buffer (PBS containing 0.5% BSA and 2 mM EDTA; Miltenyi Biotec) twice and were then suspended in the same solution as described above. The 105F antibody and control human IgG (ENZO Life Science) were each added to the cell suspension, and the cells were incubated for 15 minutes at 4° C. The cells were washed twice with MACS buffer. Fluorescein isothiocyanate (FITC)-labeled anti-IgG antibody (Jackson ImmunoResearch Laboratories) was added and suspended, and the cells were further incubated at 4° C. for 15 minutes. The cells were washed twice with MACS buffer, and the cells were then fixed with 1% PFA (prepared from Paraformaldehyde 32% solution (ELECTRON MICROSCOPY SCIENCES)), and measured by using a flow cytometer (FACS Canto II; Becton Dickinson). The data was analyzed using Flowjo (TreeStar). Dead cells were removed from the analysis by gating out cells stained with Horizon FVS450 (Becton Dickinson). Thereafter, a histogram of the FITC fluorescence intensity of live cells was generated.

In terms of HEK-293T cells transfected with the control vector alone a histogram of fluorescence intensity for the 105F antibody was similar to that for the control IgG. On the other hand, in terms of GARP-expressing HEK-293T cells, it was confirmed that the histogram for the 105F antibody shifted to a strong fluorescence intensity side, in comparison to the histogram for the control IgG (FIG. 11). From the aforementioned results, it was found that the 105F antibody specifically bound to GARP expressed by HEK-293T cells.

Example 3 Binding to Endogenous GARP-expressing Cells

3)-1 Flow Cytometric Analysis Using L428 Cells

A fluorescent-labeled form of the 105F antibody was prepared using an Alexa Fluor 647 monoclonal antibody labeling kit (Invitrogen). L428 cells (obtained from DSMZ) were washed twice with MACS buffer, and were suspended in the same solution. The labeled 105F antibody was added to the cell suspension, and the cells were incubated for 30 minutes at 4° C. The cells were washed twice with MACS buffer, and the cells were then fixed with 1% PFA, and measured by using a flow cytometer (FACS Canto II, Becton Dickinson). The data was analyzed using FlowJo (TreeStar). Dead cells were removed by gating out cells stained with Horizon FVS450. Thereafter, a histogram of the FITC fluorescence intensity of live cells was generated. In comparison to the histogram of fluorescence intensity for L428 cells alone, the histogram of L428 cells to which the 105F antibody had been added shifted to the strong fluorescence intensity side. Thus, it was confirmed that the 105F antibody bound to GARP endogenously expressed by the cells (FIG. 12).

3)-2 Flow Cytometric Analysis Using Human Treg

Peripheral blood mononuclear cells (PBMC) from a healthy subject were separated using Ficoll-Paque PLUS (GE Healthcare), and the separated cells were then seeded at 2×10⁶ cells/mL in RPMI1640 medium (Invitrogen) supplemented with 10% FBS (hereinafter referred to as “RP-F10 medium”) in a low-adhesion 24-well plate (Costar). An anti-CD3 antibody (BD Pharmingen) and an anti-CD28 antibody (BD Pharmingen) were added to the wells, and the cells were cultured for 20 hours. Thereafter, the cells were suspended in FACS buffer (HBSS (Invitrogen) supplemented with 10 mM HEPES (Invitrogen), 2 mM EDTA (Invitrogen), and 2% FBS), and the labeled 105F antibody prepared in the above 3)-1 and an Alexa Fluor 647-labeled anti-GARP antibody (G14D9, eBioscience) were added to the suspension. The cells were incubated on ice for 30 minutes. The cells were washed with FACS buffer, and Fixation/Permeabilization working solution (eBioscience) was added. The cells were further incubated on ice for 30 minutes, and the cells were washed with Permeabilization buffer (eBioscience). After that, 2% rat serum (eBioscience) was added to the cells. The cells were incubated at room temperature for 15 minutes, and PE-labeled anti-Foxp3 antibody (eBioscience) was added, followed by further incubation at room temperature for 30 minutes. The cells were washed and fixed with a tissue-fixing solution which was prepared by two-fold diluting 4% Paraformaldehyde phosphate buffer solution (Wako Pure Chemical Industries, Ltd.) with D-PBS (Invitrogen) at 4° C. for 15 minutes or more. After the cells were washed with the FACS buffer, the cells were measured by using a flow cytometer (FACS Canto II; Becton Dickinson) and were analyzed using FlowJo (Tree Star). As a result, the 105F antibody bound to FoxP3-positive Treg as commercially available anti-GARP antibody did (FIG. 13).

Example 4 Properties of Anti-GARP Antibody

4)-1 ADCC Activity

4)-1-1 Preparation of Effector Cells

Frozen human PBMC (Cellular Technology) was thawed in accordance with the protocols. NK cells were purified from the PBMC, using an NK cell isolation kit (Miltenyi Biotec). The obtained NK cells were incubated overnight in an RP-F10 medium supplemented with 100 IU/mL rhlL-2 (Novartis). Thereafter, the number of live cells was counted by a trypan blue-exclusion test, and the cells were then re-suspended in an RP-F10 medium at a cell density of 2×10⁵ cells/mL. The obtained cells were used as effector cells.

4)-1-2 Preparation of Target Cells

30 μL (1110 kBq) of Chromium-51 (⁵¹Cr) was mixed with 0.6×10⁶ L428 cells described in Example 3)-1,in RPMI1640 medium (Invitrogen) supplemented with 10% FBS, and the cells were incubated for 2 hours in 5% CO₂ at 37° C., so that the cells were radio-labeled. The labeled cells were washed three times with RPMI1640 medium (Invitrogen) supplemented with 10% FBS, and the cells were then re-suspended in the same medium at 4×10⁴ cells/mL. The obtained cells were used as target cells.

4)-1-3 ⁵¹Cr Release Assay

The 105F antibody, which had been diluted with an RP-F10 medium so that final concentration would be at 1, 10, 100, or 1000 ng/mL, was dispensed in an amount of 50 μL/well into a 96-well U-bottom microplate (Costar), and the target cells were added to the wells (50 μL/well). The plate was incubated at 4° C. for 30 minutes. Subsequently, the effector cells were added to the wells (100 μL/well), and the plate was incubated in 5% CO₂ at 37° C. for 4 hours. Thereafter, 50 μL/well of supernatant was collected and applied to LumaPlate (PerkinElmer), and the released gamma-ray dose was measured by using a gamma counter. The cell lysis rate caused by ADCC activity was calculated according to the following formula. Cell lysis rate (%)=(A-B)/(C-B)×100

-   A: Count of sample well -   B: Mean value (n=3) of count of spontaneous release (well without     antibody and effector cells). Upon addition of the antibody and upon     addition of the effector cells, 50 μL and 100 μL of RP-F10 media     were added, respectively. The same operations as those for the     sample wells were carried out other than the above. -   C: Mean value (n=3) of count of maximum release (well in which the     target cells were dissolved with a surfactant). Upon addition of the     antibody, 50 μL of RP-F10 medium was added. Upon addition of the     effector cells, 100 μL of RP-F10 medium supplemented with 2% (v/v)     Triton-X100 (Sigma) was added. The same operations as those for the     sample wells were carried out other than the above.

The results are shown in FIG. 14. The 105F antibody exhibited cytolytic activity on L428 cells in an antibody concentration dependent manner. On the other hand, the control human IgG did not exhibit such cytolytic activity. Thus, the 105F antibody had ADCC activity on L428 cells expressing endogenous GARP. It is to be noted that the human IgG1 anti-GARP antibodies (MHG8 and LHG10) produced based on the sequence information described in Patent Literature 1 did not exhibit ADCC activity.

4)-2 Inhibitory Activity to Treg Function

4)-2-1 Preparation of Treg, Teff (Effector T Cells: CD4-positive CD25-negative Helper T cells), and Accessory Cells

CD4-positive T cells were separated from PBMC that were prepared in the same manner as in the above 4)-1-1, using CD4 T cell ISOLATION Kit (Miltenyi Biotec), and an FITC-labeled anti-CD4 antibody (Miltenyi Biotec) and an APC-labeled anti-CD25 antibody (Miltenyi Biotec) were added to the CD4-positive T cells. The cells were incubated at 4° C. for 30 minutes. After the cells were washed, the cells were suspended in MACS buffer, and CD4-positive CD25-negative cells (Teff) and CD4-positive CD25-strongly-positive cells (Treg) were separated using FACS Aria IIu (Becton Dickinson).

On the other hand, CD3-positive cells were removed from PBMC using CD3 Microbeads (Miltenyi Biotec) and the cells were irradiated at a dose of 1 C/kg (absorbed dose: 38.76 Gy/kg (3876 Rad/kg)) using an X-ray irradiator (Hitachi Medical Corporation) to prepare accessory cells.

4)-2-2 Co-culture Method and Assay for Inhibitory Activity to Treg Function

As a culture medium, RPMI1640 medium (Invitrogen) supplemented with Penicillin and Streptomycin (Invitrogen), 1×MEM NEAA (Invitrogen), 1×Sodium pyruvate (Invitrogen), 5 mM Hepes and 5% Human male AB serum (Sigma) was used. Teff (2000 cells/well) and accessory cells (20000 cells/well) were mixed and added into each well of a 96-well U-bottom microplate, and Treg were further added and seeded to wells at 500 cells/well. In addition, control wells without Treg were also prepared. An anti-CD3 antibody, an anti-CD28 antibody, and a 105F antibody were added to the wells at a final concentration of 50 or 10 μg/mL, and the plate was incubated for 5 days in 5% CO₂ at 37° C. Thereafter, [³H]-thymidine (PerkinElmer) at 18.5 kBq/mL was prepared, and added to each well at 20 μL/well. The cells were further incubated for 18 hours. The cells were harvested in Filtermat A (PerkinElmer) by using a cell harvester (Mach II, Tomtech), and the radioactivity of [³H]-thymidine incorporated into the cells was measured using a scintillation counter (MicroBeta, PerkinElmer). The measured data were expressed as corrected count per minute (CCPM).

Human IgG1 anti-GARP antibodies (MHG8 and LHG10) produced based on the sequence information described in Patent Literature 1 were also subjected to the present experiment system.

4)-2-3 Calculation of Inhibitory Activity

A mean value of three wells under individual co-culture conditions was calculated. Diminished value of proliferation in co-culturing Teff with Treg when compared with that of Teff alone, was defined as a “Suppression rate of Teff proliferation caused by Treg” (=1−[CCPM of co-culture/CCPM of Teff alone]).

The inhibitory activity of each antibody to the Treg function was determined by subtracting suppression rate of Teff proliferation by Treg in the presence of antibody from that in the absence of antibody (=[suppression rate upon non-addition of the antibody]−[suppression rate upon addition of each antibody]). It is to be noted that this inhibitory activity of a sample is calculated every time in each experiment.

The results of the inhibitory activity of the 105F antibody to the Treg function at 50 μg/mL (inhibitory rate: 72.6%) are shown in FIG. 15, and the results of the 105F antibody and the MHG-8 and LHG-10 antibodies (10 μg/mL each) are shown in FIG. 16. The MHG-8 and LHG-10 antibodies did not have inhibitory activity to the Treg function (inhibitory rates: 0.8% and 0.0%, respectively), whereas the 105F antibody significantly inhibited Treg function (inhibitory rate: 65.8%). The inhibitory rate caused by transducing siRNA to GARP into Treg was about 15%, when calculated roughly by using values in FIG. 5A (CD4+CD25−(Teff): Treg=4:1) of Non Patent Literature 10.

Example 5 Production of Rat Antibody

5)-1 Preparation of GARP Expression Vector

The expression vector described in Example 2 was used as a GARP expression vector, and an EndoFree Plasmid Giga Kit (QIAGEN) was used for mass production.

5)-2 Immunization of Rats

For immunization, WKY/Izm female rats (Japan SLC, Inc.) were used. First, the lower limbs of each rat were pre-treated with Hyaluronidase (SIGMA-ALDRICH) and a GARP expression vector was intramuscularly injected into the same sites. Subsequently, employing ECM830 (BTX), in vivo electroporation was performed on the same sites using two-needle electrode. Once every two weeks, the same in vivo electroporation was repeated, and lymph nodes or spleen was collected from the rat, and was used in production of hybridomas.

5)-3 Production of Hybridomas

The lymph nodes or splenic cells were fused with mouse myeloma SP2/0-ag14 cells (ATCC, No.CRL-1581) according to electrical cell fusion, using LF301 Cell Fusion Unit (BEX), and the cells were then diluted with ClonaCell-HY Selection Medium D (StemCell Technologies) and incubated. Hybridoma colonies that appeared in culture were picked and selected as monoclonal hybridomas. Every hybridoma colony was cultured, and culture supernatant from each hybridoma was used to screen for anti-GARP antibody-producing hybridomas.

5)-4 Antibody Screening According to Cell-ELISA Method

5)-4-1 Preparation of Antigen Gene-expressing Cells for Use in Cell-ELISA

293α cells (a stable expression cell line derived from HEK-293 cells (ATCC: CRL-1573) expressing integrin αv and integrin β3) were prepared at 7.5×10⁵ cells/mL in DMEM medium (Invitrogen) supplemented with 10% FBS. In accordance with transduction procedures for using Lipofectamine 2000 (Life Technologies), a GARP expression vector or a pcDNA3.1 (+) vector used as a negative control was transfected into the cells, and the cells were dispensed in an amount of 50 μl each to a 96-Half area well plate (Corning). Thereafter, the cells were cultured in DMEM medium supplemented with 10% FBS for 24 to 27 hours in 5% CO₂ at 37° C. The obtained transfected cells were used for Cell-ELISA in an adhesive state.

5)-4-2 Cell-ELISA

The culture supernatant of the 293α cells transfected with expression vectors prepared in Example 5)-4-1 was removed, and culture supernatant from each hybridoma was added to the 293α cells transfected either with GARP expression vector or pcDNA3.1 (+) vector. The cells were incubated at 4° C. for 1 hour. The cells in the wells were washed once with PBS (+) supplemented with 5% FBS, and thereafter, Anti-Rat IgG-Peroxidase antibody produced in rabbits (SIGMA) that had been 500-fold diluted with PBS (+) supplemented with 5% FBS was added to the wells. The cells were incubated at 4° C. for 1 hour. The cells in the wells were washed three times with PBS (+) supplemented with 5% FBS, and OPD coloring solution (which had been prepared by dissolving o-phenylenediamine dihydrochloride (Wako Pure Chemical Industries, Ltd.) and H₂O₂ in an OPD solution (0.05 M trisodium citrate, 0.1 M disodium hydrogen phosphate 12-water; pH 4.5), so that the substances became 0.4 mg/ml and 0.6% (v/v), respectively) was added in an amount of 50 μl/well to the wells. While the plate was incubated with mixing for a time, a coloring reaction was carried out. Thereafter, 1M HCl was added to the plate (50 μl/well) to terminate the coloring reaction, and the absorbance at 490 nm was measured using a plate reader (ENVISION: PerkinElmer). In order to select hybridomas that produce an antibody specifically binding to human GARP expressed on the surface of a cell membrane, hybridomas that produced a culture supernatant exhibiting higher absorbance in 293α cells transfected with GARP expression vector than that in cells transfected with the control pcDNA3.1 (+)vector were selected as positive cells that produce anti-human GARP antibody.

5)-5 Antibody Screening According to Flow Cytometric Method

5)-5-1 Preparation of Antigen Gene-expressing Cells for Use in Flow Cytometric Analysis

HEK-293T cells (obtained from ATCC) were seeded in a 225-cm² flask (Sumitomo Bakelite Co., Ltd.) at 5×10⁴ cells/cm², and the cells were then cultured in DMEM medium supplemented with 10% FBS overnight in 5% CO₂ at 37° C. On the following day, HEK-293T cells were transfected with a GARP expression vector or a pcDNA3.1 (+) vector used as a negative control using Lipofectamine 2000, and the cells were further incubated overnight in 5% CO₂ at 37° C. On the following day, the transfected HEK-293T cells were treated with TrypLE Express (Life Technologies), were washed with DMEM medium supplemented with 10% FBS, and were re-suspended in PBS supplemented with 5% FBS. The obtained cell suspension was used in a flow cytometric analysis.

5)-5-2 Flow Cytometric Analysis

The binding specificity to human GARP of an antibody produced from hybridomas that had been determined to be positive by Cell-ELISA in Example 5)-4-2 was further confirmed by a flow cytometric analysis.

A suspension of the transiently expressing HEK-293T cells prepared in Example 5)-5-1 was centrifuged, and a supernatant was then removed. Thereafter, culture supernatant from each hybridoma was added to cells and suspended. The cells were incubated at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and FITC-conjugated anti-Rat IgG (SIGMA) that had been 500-fold diluted with PBS supplemented with 5% FBS was added to the cells and suspended. The cells were incubated at 4° C. for 1 hour. The cells were washed twice with PBS supplemented with 5% FBS, and were then re-suspended in PBS supplemented with 5% FBS and 2 μg/ml 7-aminoactinomycin D (Molecular Probes). The cells were measured using a flow cytometer (FC500: manufactured by Beckman Coulter). The data was analyzed using Flowjo (TreeStar). After dead cells were removed from analysis by gating out 7-Aminoactinomycin D-positive cells, a histogram of the FITC fluorescence intensity of live cells was generated. Hybridomas producing human GARP-binding antibodies (113 clones) were selected based on results where the histogram for the antibody shifted to the strong fluorescence intensity side in HEK-293T cells transfected with GARP-expressing vector compared with cells transfected with control pcDNA3.1 vector.

5)-6 Preparation of Monoclonal Antibody

5)-6-1 Culture of Hybridomas 151D and 198D

From the rat anti-human GARP antibody-producing hybridomas obtained in the above 5)-5-2, hybridomas 151D and 198D, which had been suggested to bind strongly to human GARP, were selected.

A rat anti-GARP monoclonal antibody was purified from a hybridoma culture supernatant.

First, the volume of rat anti-GARP monoclonal antibody-producing hybridomas was sufficiently increased with ClonaCell-HY Selection Medium E, and thereafter, the medium was exchanged with Hybridoma SFM (Life Technologies) to which 20% of Ultra Low IgG FBS (Life Technologies) had been added. Thereafter, the hybridomas (8 to 9×10⁷ cells) were seeded in a 1272-cm² flask (Corning), and were then cultured for 7 days. The present culture supernatant was harvested by centrifugation, and it was sterilized by passing through a 0.8-μm filter, and through a 0.45-μm filter (Corning).

5)-6-2 Purification of Monoclonal Antibody

An antibody was purified from the culture supernatant of hybridomas prepared in Example 5)-6-1 according to Protein G affinity chromatography. The antibody was adsorbed on a Protein G column (GE Healthcare Bioscience), the column was then washed with PBS, and the antibody was then eluted with a 0.1 M glycine/HCl aqueous solution (pH 2.7). 1 M Tris-HCl (pH 9.0) was added to the eluant, so that the pH was adjusted to pH 7.0 to 7.5. Thereafter, the solution was dialyzed (Thermo Scientific, Slide-A-Lyzer Dialysis Cassette), so that the buffer was replaced with PBS. Using Centrifugal UF Filter Device VIVASPIN20 (molecular weight cutoff: UF30K, Sartorius), the antibody was concentrated, so that the concentration of the antibody was adjusted to 0.7 mg/mL or more. Finally, the antibody was filtrated through a Minisart-Plus filter (Sartorius) to obtain a purified sample.

Example 6 Cloning of Rat Antibody and Production of Human Chimeric Antibody

6)-1 Cloning and Sequencing of cDNA of Rat Antibody 151D

6)-1-1 Preparation of Total RNA from 151D-producing Hybridomas

In order to amplify cDNA comprising the variable region of 151D, total RNA was prepared from 151D-producing hybridomas using TRIzol Reagent (Ambion).

6)-1-2 Amplification of cDNA Comprising 151D Heavy Chain Variable Region According to 5′-RACE PCR, and Sequencing Thereof

cDNA comprising a heavy chain variable region was amplified using approximately 1 μg of the total RNA prepared in Example 6)-1-1 and a SMARTer RACE cDNA Amplification Kit (Clontech).

As primers used to amplify the cDNA of the variable region of a 151D heavy chain gene according to PCR, UPM (Universal Primer A Mix: included with SMARTer RACE cDNA Amplification Kit) and primers designed from the sequences of the constant regions of known rat heavy chains were used.

cDNA comprising the variable region of the heavy chain amplified by 5′-RACE PCR was cloned into a plasmid, and thereafter, the nucleotide sequence of the cDNA of the heavy chain variable region was subjected to sequence analysis.

The determined nucleotide sequence of the cDNA encoding the variable region of the 151D heavy chain is shown in SEQ ID NO: 14, and the amino acid sequence thereof is shown in SEQ ID NO: 15.

6)-1-3 Amplification of cDNA Comprising 151D Light Chain Variable Region According to 5′-RACE PCR, and Sequencing Thereof

Amplification and sequencing were carried out by the same method as that applied in Example 6)-1-2. However, as primers used to amplify the cDNA of the variable region of a 151D light chain gene according to PCR, UPM (Universal Primer A Mix: included with SMARTer RACE cDNA Amplification Kit) and primers designed from the sequences of the constant regions of known rat light chains were used.

The determined nucleotide sequence of the cDNA encoding the variable region of the 151D light chain is shown in SEQ ID NO: 16, and the amino acid sequence thereof is shown in SEQ ID NO: 17.

6)-2 Cloning and Sequencing of cDNA of Rat Antibody 198D

The sequences were determined by the same method as that applied in Example 6)-1.

The determined nucleotide sequence of the cDNA encoding the variable region of the 198D heavy chain is shown in SEQ ID NO: 18, and the amino acid sequence thereof is shown in SEQ ID NO: 19. The determined nucleotide sequence of the cDNA encoding the variable region of the 198D light chain is shown in SEQ ID NO: 20, and the amino acid sequence thereof is shown in SEQ ID NO: 21.

6)-3 Production of Human Chimeric Antibody Expression Vector

6)-3-1 Construction of human Chimeric Light Chain Expression Vector pCMA-LK

An approx. 5.4-kb fragment, which had been obtained by digesting a plasmid pcDNA3.3-TOPO/LacZ (Invitrogen) with the restriction enzymes XbaI and PmeI, was bound to a DNA fragment comprising the human light chain signal sequence shown in SEQ ID NO: 22 and a DNA sequence encoding a human κ chain constant region, using an In-Fusion Advantage PCR cloning kit (CLONTECH), to produce pcDNA3.3/LK.

A neomycin expression unit was removed from the pcDNA3.3/LK to construct pCMA-LK.

6)-3-2 Construction of Human Chimeric IgG1 Type Heavy Chain Expression Vector pCMA-G1

A DNA fragment, which had been obtained by digesting pCMA-LK with Xbal and Pmel to remove the light chain signal sequence and the human κ chain constant region therefrom, was bound to a DNA fragment comprising the human heavy chain signal sequence shown in SEQ ID NO: 23 and a DNA sequence encoding the amino acids in a human IgG1 constant region, using an In-Fusion Advantage PCR cloning kit (CLONTECH), to construct pCMA-G1.

6)-3-3 Construction of Human Chimeric 151D Heavy Chain Expression Vector

Using, as a template, the cDNA encoding the variable region of a rat antibody 151D heavy chain obtained in Example 6)-1, PCR was carried out with primers designed for In-fusion cloning, so as to amplify a DNA fragment comprising cDNA encoding the heavy chain variable region. Using an In-Fusion HD PCR cloning kit (Clontech), the amplified DNA fragment was inserted into a site of pCMA-G1 that had been cleaved with the restriction enzyme BIpI, so as to construct a human chimeric 151D heavy chain expression vector.

The nucleotide sequence of the human chimeric 151D heavy chain and the amino acid sequence of this heavy chain are shown in SEQ ID NO: 24 and SEQ ID NO: 25, respectively.

6)-3-4 Construction of Human Chimeric 151D Light Chain Expression Vector

Using, as a template, the cDNA encoding the variable region of a 151D light chain variable region obtained in Example 6)-1, PCR was carried out with primers designed for In-fusion cloning, so as to amplify a DNA fragment comprising cDNA encoding the light chain variable region. Using an In-Fusion HD PCR cloning kit (Clontech), the amplified DNA fragment was inserted into a site of pCMA-LK that had been cleaved with the restriction enzyme BsiWI, so as to construct a human chimeric 151D light chain expression vector.

The nucleotide sequence of the human chimeric 151D light chain and the amino acid sequence of this light chain are shown in SEQ ID NO: 26 and SEQ ID NO: 27, respectively.

6)-3-5 Construction of Human Chimeric 198D Heavy Chain Expression Vector

Using, as a template, the cDNA encoding the variable region of a rat antibody 198D heavy chain obtained in Example 6)-2, a human chimeric 198D heavy chain expression vector was constructed by the same method as that applied in Example 6)-3-3.

The nucleotide sequence of the human chimeric 198D heavy chain and the amino acid sequence of this heavy chain are shown in SEQ ID NO: 28 and SEQ ID NO: 29, respectively.

6)-3-6 Construction of Human Chimeric 198D Light Chain Expression Vector

Using, as a template, the cDNA encoding the variable region of a 198D light chain obtained in Example 6)-2, a human chimeric 198D light chain expression vector was constructed by the same method as that applied in Example 6)-3-4.

The nucleotide sequence of the human chimeric 198D light chain and the amino acid sequence of this light chain are shown in SEQ ID NO: 30 and SEQ ID NO: 31, respectively.

6)-4 Preparation of Human Chimeric Antibody

6)-4-1 Production of Human Chimeric Antibody

In accordance with the manual, FreeStyle 293F cells (Invitrogen) were cultured and passaged. 1×10⁸ FreeStyle 293F cells (Invitrogen) in the logarithmic growth phase were seeded on a 250-mL Fernbach Erlenmeyer Flask (CORNING), and were then diluted with FreeStyle293 expression medium (Invitrogen) at 2.0×10⁶ cells/mL.

Meanwhile, 20 μg of the heavy chain expression vector, 30 μg of the light chain expression vector and 150 μg of Polyethyleneimine (Polyscience #24765) were added to 5 mL of Opti-Pro SFM medium (Invitrogen), and the obtained mixture was gently stirred. After incubation for 5 minutes, the mixture was added to the FreeStyle 293F cells.

The cells were incubated in an incubator (37° C., 8% CO₂) with shaking at 125 rpm for 4 hours, and thereafter, 50 mL of EX-CELL VPRO medium (SAFC Biosciences), 0.36 mL of GlutaMAX I (GIBCO), and 2.5 mL of Yeastolate Ultrafiltrate (GIBCO) were added to the culture. The cells were further incubated in an incubator (37° C., 8% CO₂) with shaking at 125 rpm for 7 days. The culture supernatant was harvested and filtrated with a 250-mL Filter System (CORNING, #431096).

A human chimeric 151D antibody obtained by the combination of the human chimeric 151D heavy chain expression vector with the human chimeric 151D light chain expression vector was named “c151D,” whereas a human chimeric 198D antibody obtained by the combination of the human chimeric 198D heavy chain expression vector with the human chimeric 198D light chain expression vector was named “c198D.”

6)-4-2 Purification of Chimeric Antibody

The culture supernatant obtained in Example 6)-4-1 was purified by a one-stage process of rProtein A affinity chromatography. The culture supernatant was applied to a column (manufactured by GE Healthcare Bioscience) that had been filled with MabSelectSuRe equilibrated with PBS, and the column was then washed with PBS in an amount of two or more times the volume of the column. Subsequently, elution was carried out using a 2 M arginine hydrochloride solution (pH 4.0), so that a fraction containing an antibody was collected. This fraction was subjected to Centrifugal UF Filter Device VIVASPIN20 (molecular weight cutoff: UF30K, Sartorius), so that the buffer was replaced with PBS and the antibody was concentrated, thereby adjusting the antibody concentration to 1 mg/mL or more. Finally, the antibody was filtrated through Minisart-Plus filter (Sartorius) to obtain a purified sample.

6)-5 Evaluation of Binding Activity of Human Chimeric Antibody to Human GARP

The dissociation constant between the c151D or c198D produced in Example 6)-4 and human GARP was evaluated by using Biacore T200 (GE Healthcare Bioscience), according to a capture method, which comprises capturing the antibody as a ligand with the immobilized Protein A and then analyzing the dissociation constant using an antigen (recombinant human GARP: R&D Systems) as an analyte. HBS-EP+ (manufactured by GE Healthcare Bioscience) was used as a running buffer, and a Protein A Sensor Chip (manufactured by GE Healthcare Bioscience) was used as a sensor chip.

The human chimeric antibody (1 μg/mL) was added onto the chip at a rate of 10 μL/min for 20 seconds, and a dilution series solution (8 to 128 nM) of the antigen was then added at a flow rate of 30 μl/min for 120 seconds. Subsequently, the dissociation was monitored for 480 seconds. As a regeneration solution, Glycine 1.5 (manufactured by GE Healthcare Bioscience) was added at a flow rate of 20 μl/min for 30 seconds.

1:1 Fitting models were used in data analysis, and the association rate constant ka, the dissociation rate constant kd, and the dissociation constant (KD; KD=kd/ka) were calculated.

The results are shown in Table 1.

Table 1 Dissociation constant between c151D or c198D and human GARP

TABLE 1 Name KD (nM) 1 c151D 0.47 2 c198D 0.17

Example 7 Production of Humanized Antibody

7)-1 Molecular Modeling of c151D Antibody Variable Region

The molecular modeling of the variable region of the c151D antibody was carried out according to a method that had been generally known as homologous modeling (Methods in Enzymology, 203, 121-153, (1991)).

The primary sequence of the variable region of a human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res.28, 235-242 (2000)) (a three-dimensional structure inferred from an X-ray crystal structure is available) was compared with the variable region of the c151D antibody.

The three-dimensional structure of the variable region was produced by combining, with one another, the coordinates of the heavy chain and light chain of the c151D antibody and a model having high sequence homology to the interfaces, so as to obtain a “framework model.”

After that, the representative conformation of each CDR was incorporated into the framework model.

Finally, in order to eliminate atomic contact that was disadvantageous in terms of energy, an energy minimization calculation was carried out. The above described procedures were carried out using Discovery Studio (Dassault Systemes).

7)-2 Design of Amino Acid Sequence of Humanized 151D Antibody

A humanized 151D antibody was constructed according to a method generally known as CDR grafting (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)). An acceptor antibody was selected based on amino acid homology in the framework region.

The sequence of the framework region of the c151D antibody was compared with the framework region of a human subgroup consensus sequence determined by KABAT et al. (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service National Institutes of Health, Bethesda, Md. (1991)). As a result, the consensus sequence of human γ chain subgroup 3 and human κ chain subgroup 1 and 4 had high sequence homology, and based on this, they were selected as acceptors.

With regard to the consensus sequence of human γ chain subgroup 3 and the consensus sequences of human κ chain subgroup 1 and human κ chain subgroup 4, the amino acid residues in the framework regions were aligned with the amino acid residues of the c151D antibody, so that the positions, in which different amino acids were used, were identified. The positions of these residues were analyzed using the three-dimensional model of the c151D antibody constructed in the above 7)-1, and donor residues to be grafted onto the acceptor were selected based on the criteria given by Queen et al. (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)).

The thus selected several donor residues were introduced into an acceptor antibody, so as to construct the sequence of humanized h151D as in the manner described in the following examples.

7)-3 Design of Humanized 151D Heavy Chain h151D-H

7)-3-1 h151D-H1 Type Heavy Chain

A humanized 151D heavy chain designed by substituting the arginine residue at amino acid position 35 with a glycine residue, the lysine residue at amino acid position 37 with a leucine residue, the lysine residue at amino acid position 38 with an arginine residue, the serine residue at amino acid position 42 with an alanine residue, the threonine residue at amino acid position 61 with a glycine residue, the glutamine residue at amino acid position 62 with a lysine residue, the alanine residue at amino acid position 68 with a serine residue, the arginine residue at amino acid position 80 with an alanine residue, the alanine residue at amino acid position 94 with a serine residue, the serine residue at amino acid position 96 with an asparagine residue, the aspartic acid residue at amino acid position 103 with an asparagine residue, the serine residue at amino acid position 107 with an alanine residue, the threonine residue at amino acid position 112 with a valine residue, the valine residue at amino acid position 130 with a threonine residue, and the methionine residue at amino acid position 131 with a leucine residue in the c151D heavy chain shown in SEQ ID NO: 25 in the sequence listing, was named “h151D-H1 type heavy chain.”

In the nucleotide sequence (SEQ ID NO: 32) encoding the h151D-H1 type heavy chain, the mature heavy chain, from which a signal sequence has been removed, is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 1398, the variable region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 408, and the constant region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 409 to 1398. The aforementioned variable region has the nucleotide sequence consisting of the nucleotides at nucleotide positions 133 to 162 encoding CDRH1, the nucleotide sequence consisting of the nucleotides at nucleotide positions 205 to 234 encoding CDRH2, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 352 to 375 encoding CDRH3, in SEQ ID NO: 32 in the sequence listing.

In addition, in the amino acid sequence (SEQ ID NO: 33) of the h151D-H1 type heavy chain, the mature heavy chain, from which a signal sequence has been removed, is the amino acid sequence consisting of the amino acids at amino acid positions 20 to 466, the variable region is the amino acid sequence consisting of the amino acids at amino acid positions 20 to 136, and the constant region is the amino acid sequence consisting of the amino acids at amino acid positions 137 to 466. The aforementioned variable region has CDRH1 consisting of the amino acid sequence at amino acid positions 45 to 54 in SEQ ID NO: 33 in the sequence listing, CDRH2 consisting of the amino acid sequence at amino acid positions 69 to 78 therein, and CDRH3 consisting of the amino acid sequence at amino acid positions 118 to 125 therein.

Moreover, the sequences shown in SEQ ID NOS: 32 and 33 are also shown in FIGS. 31 and 21, respectively.

7)-3-2 h151D_H4 Type Heavy Chain

A humanized 151D heavy chain designed by substituting the arginine residue at amino acid position 35 with a glycine residue, the lysine residue at amino acid position 37 with a leucine residue, the lysine residue at amino acid position 38 with an arginine residue, the serine residue at amino acid position 42 with an alanine residue, the threonine residue at amino acid position 61 with a glycine residue, the glutamine residue at amino acid position 62 with a lysine residue, the alanine residue at amino acid position 94 with a serine residue, the aspartic acid residue at amino acid position 103 with an asparagine residue, the serine residue at amino acid position 107 with an alanine residue, the threonine residue at amino acid position 112 with a valine residue, the valine residue at amino acid position 130 with a threonine residue, and the methionine residue at amino acid position 131 with a leucine residue in the c151D heavy chain shown in SEQ ID NO: 25 in the sequence listing, was named “h151D₁₃ H4 type heavy chain.”

In the nucleotide sequence (SEQ ID NO: 34) encoding the h151D-H4 type heavy chain, the mature heavy chain, from which a signal sequence has been removed, is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 1398, the variable region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 408, and the constant region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 409 to 1398. The aforementioned variable region has the nucleotide sequence consisting of the nucleotides at nucleotide positions 133 to 162 encoding CDRH1, the nucleotide sequence consisting of the nucleotides at nucleotide positions 205 to 234 encoding CDRH2, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 352 to 375 encoding CDRH3, in SEQ ID NO: 34 in the sequence listing.

In addition, in the amino acid sequence (SEQ ID NO: 35) of the h151D-H4 type heavy chain, the mature heavy chain, from which a signal sequence has been removed, is the amino acid sequence consisting of the amino acids at amino acid positions 20 to 466, the variable region is the amino acid sequence consisting of the amino acids at amino acid positions 20 to 136, and the constant region is the amino acid sequence consisting of the amino acids at amino acid positions 137 to 466. The aforementioned variable region has CDRH1 consisting of the amino acid sequence at amino acid positions 45 to 54 in SEQ ID NO: 35 in the sequence listing, CDRH2 consisting of the amino acid sequence at amino acid positions 69 to 78 therein, and CDRH3 consisting of the amino acid sequence at amino acid positions 118 to 125 therein.

Moreover, the sequences shown in SEQ ID NOS: 34 and 35 are also shown in FIGS. 33 and 23, respectively.

7)-4 Design of Humanized 151D Light Chain h151D_L

7)-4-1 h151D-L1 Type Light Chain

A humanized 151D light chain designed by substituting the threonine residue at amino acid position 29 with an aspartic acid residue, the methionine residue at amino acid position 31 with a leucine residue, the phenylalanine residue at amino acid position 32 with an alanine residue, the isoleucine residue at amino acid position 33 with a valine residue, the valine residue at amino acid position 35 with a leucine residue, the aspartic acid residue at amino acid position 37 with a glutamic acid residue, the valine residue at amino acid position 39 with an alanine residue, the methionine residue at amino acid position 41 with an isoleucine residue, the threonine residue at amino acid position 60 with a proline residue, the threonine residue at amino acid position 83 with a serine residue, the asparagine residue at amino acid position 97 with a serine residue, the methionine residue at amino acid position 98 with a leucine residue, the leucine residue at amino acid position 103 with a valine residue, the threonine residue at amino acid position 120 with a glutamine residue, the leucine residue at amino acid position 124 with a valine residue, the leucine residue at amino acid position 126 with an isoleucine residue, the asparagine residue at amino acid position 127 with a lysine residue, and the alanine residue at amino acid position 129 with a threonine residue in the c151D light chain shown in SEQ ID NO: 27 in the sequence listing, was named “h151D_L1 type light chain.”

In the nucleotide sequence (SEQ ID NO: 36) encoding the h151D-L1 type light chain, the mature light chain, from which a signal sequence has been removed, is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 702, the variable region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 387, and the constant region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 388 to 702. The aforementioned variable region has the nucleotide sequence consisting of the nucleotides at nucleotide positions 130 to 162 encoding CDRH1, the nucleotide sequence consisting of the nucleotides at nucleotide positions 208 to 228 encoding CDRH2, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 325 to 351 encoding CDRH3, in SEQ ID NO: 36 in the sequence listing.

In addition, in the amino acid sequence (SEQ ID NO: 37) of the h151D_L1 type light chain, the mature light chain, from which a signal sequence has been removed, is the amino acid sequence consisting of the amino acids at amino acid positions 21 to 234, the variable region is the amino acid sequence consisting of the amino acids at amino acid positions 21 to 129, and the constant region is the amino acid sequence consisting of the amino acids at amino acid positions 130 to 234. The aforementioned variable region has CDRL1 consisting of the amino acid sequence at amino acid positions 44 to 54 in SEQ ID NO: 37 in the sequence listing, CDRL2 consisting of the amino acid sequence at amino acid positions 70 to 76 therein, and CDRL3 consisting of the amino acid sequence at amino acid positions 109 to 117 therein.

Moreover, the sequences shown in SEQ ID NOS: 36 and 37 are also shown in FIGS. 32 and 22, respectively.

7)-4-2 h151D-L4 Type Light Chain:

A humanized 151D light chain designed by substituting the threonine residue at amino acid position 29 with a serine residue, the methionine residue at amino acid position 31 with a leucine residue, the phenylalanine residue at amino acid position 32 with a serine residue, the isoleucine residue at amino acid position 33 with an alanine residue, the methionine residue at amino acid position 41 with an isoleucine residue, the threonine residue at amino acid position 60 with a proline residue, the glutamine residue at amino acid position 62 with a lysine residue, the threonine residue at amino acid position 83 with a serine residue, the asparagine residue at amino acid position 97 with a serine residue, the methionine residue at amino acid position 98 with a leucine residue, the alanine residue at amino acid position 100 with a proline residue, the leucine residue at amino acid position 103 with a phenylalanine residue, the valine residue at amino acid position 105 with a threonine residue, the threonine residue at amino acid position 120 with a glutamine residue, the leucine residue at amino acid position 124 with a valine residue, the leucine residue at amino acid position 126 with an isoleucine residue, the asparagine residue at amino acid position 127 with a lysine residue, and the alanine residue at amino acid position 129 with a threonine residue in the c151D light chain shown in SEQ ID NO: 27 in the sequence listing, was named “h151D-L4 type light chain.”

In the nucleotide sequence (SEQ ID NO: 38) encoding the h151D-L4 type light chain, the mature light chain, from which a signal sequence has been removed, is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 702, the variable region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 387, and the constant region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 388 to 702. The aforementioned variable region has the nucleotide sequence consisting of the nucleotides at nucleotide positions 130 to 162 encoding CDRL1, the nucleotide sequence consisting of the nucleotides at nucleotide positions 208 to 228 encoding CDRL2, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 325 to 351 encoding CDRL3, in SEQ ID NO: 38 in the sequence listing.

In addition, in the amino acid sequence (SEQ ID NO: 39) of the h151D_L4 type light chain, the mature light chain, from which a signal sequence has been removed, is the amino acid sequence consisting of the amino acids at amino acid positions 21 to 234, the variable region is the amino acid sequence consisting of the amino acids at amino acid positions 21 to 129, and the constant region is the amino acid sequence consisting of the amino acids at amino acid positions 130 to 234. The aforementioned variable region has CDRL1 consisting of the amino acid sequence at amino acid positions 44 to 54 in SEQ ID NO: 39 in the sequence listing, CDRL2 consisting of the amino acid sequence at amino acid positions 70 to 76 therein, and CDRL3 consisting of the amino acid sequence at amino acid positions 109 to 117 therein.

Moreover, the sequences shown in SEQ ID NOS: 38 and 39 are also shown in FIGS. 34 and 24, respectively.

7)-5 Molecular Modeling of Variation Region of c198D

Molecular modeling of the variable region of the c198D antibody was carried out according to a method generally known as homologous modeling (Methods in Enzymology, 203, 121-153, (1991)). The primary sequence of the variable region of a human immunoglobulin registered in Protein Data Bank (Nuc. Acid Res.28, 235-242 (2000)) (a three-dimensional structure inferred from an X-ray crystal structure is available) was compared with the variable region of the c198D antibody.

The three-dimensional structure of the variable region was produced by combining, with one another, the coordinates of the heavy chain and light chain of the c198D antibody and a model having high sequence homology to their interfaces, so as to obtain a “framework model.”

After that, the representative conformation of each CDR was incorporated into the framework model.

Finally, in order to eliminate atomic contact that was disadvantageous in terms of energy, an energy minimization calculation was carried out. The above described procedures were carried out using Discovery Studio (Dassault Systemes).

7)-6 Design of Amino Acid Sequence of Humanized 198D

A humanized 198D antibody was constructed according to a method generally known as CDR grafting (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)). An acceptor antibody was selected based on amino acid homology in the framework region.

The sequence of the framework region of the c198D antibody was compared with the framework region of a human subgroup consensus sequence determined by KABAT et al. (Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service National Institutes of Health, Bethesda, Md. (1991)). As a result, the consensus sequence of human γ chain subgroup 2 and human κ chain subgroup 1 had high sequence homology, and based on this, they ware selected as an acceptor. In addition, several residues in the consensus sequence of human γ chain subgroup 3 were introduced into the acceptor of the heavy chain.

With regard to the consensus sequence of human γ chain subgroup 2 comprising a portion of the consensus sequence of human γ chain subgroup 3 and the consensus sequence of human κ chain subgroup 1, the amino acid residues in the framework regions were aligned with the amino acid residues of the c198D antibody, so that the positions, in which different amino acids were used, were identified. The positions of these residues were analyzed using a three-dimensional model of the c198D antibody constructed in the above 7)-5, and donor residues to be grafted onto the acceptor were selected based on the criteria given by Queen et al. (Proc. Natl. Acad. Sci. USA 86, 10029-10033 (1989)).

The thus selected several donor residues were introduced into the acceptor antibody, so as to construct the sequence of humanized h198D as in the manner described in the following examples.

7)-7 Design of Humanized 198D Heavy Chain h198D-H

7)-7-1 h198D-H3 Type Heavy Chain

A humanized 198D heavy chain designed by substituting the glutamine residue at amino acid position 20 with a glutamic acid residue, the arginine residue at amino acid position 24 with a valine residue, the proline residue at amino acid position 28 with a glycine residue, the glutamine residue at amino acid position 32 with a lysine residue, the glutamic acid residue at amino acid position 61 with a glycine residue, the serine residue at amino acid position 80 with a proline residue, the alanine residue at amino acid position 81 with a serine residue, the leucine residue at amino acid position 86 with a valine residue, the serine residue at amino acid position 87 with a threonine residue, the serine residue at amino acid position 95 with an asparagine residue, the phenylalanine residue at amino acid position 98 with a serine residue, the methionine residue at amino acid position 101 with a leucine residue, the threonine residue at amino acid position 103 with a serine residue, the leucine residue at amino acid position 104 with a valine residue, the glutamine residue at amino acid position 105 with a threonine residue, the threonine residue at amino acid position 106 with an alanine residue, the glutamic acid residue at amino acid position 107 with an alanine residue, the methionine residue at amino acid position 111 with a valine residue, the phenylalanine residue at amino acid position 113 with a tyrosine residue, the alanine residue at amino acid position 133 with a threonine residue, and the serine residue at amino acid position 134 with a leucine residue in the c198D heavy chain shown in SEQ ID NO: 29 in the sequence listing, was named “h198D_H3 type heavy chain.”

In the nucleotide sequence (SEQ ID NO: 40) encoding the h198D-H3 type heavy chain, the mature heavy chain, from which a signal sequence has been removed, is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 1407, the variable region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 58 to 417, and the constant region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 418 to 1407. The aforementioned variable region has the nucleotide sequence consisting of the nucleotides at nucleotide positions 130 to 162 encoding CDRH1, the nucleotide sequence consisting of the nucleotides at nucleotide positions 205 to 231 encoding CDRH2, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 349 to 384 encoding CDRH3, in SEQ ID NO: 40 in the sequence listing.

In addition, in the amino acid sequence (SEQ ID NO: 41) of the h198D-H3 type heavy chain, the mature heavy chain, from which a signal sequence has been removed, is the amino acid sequence consisting of the amino acids at amino acid positions 20 to 469, the variable region is the amino acid sequence consisting of the amino acids at amino acid positions 20 to 139, and the constant region is the amino acid sequence consisting of the amino acids at amino acid positions 140 to 469.

Moreover, the sequences shown in SEQ ID NOS: 40 and 41 are also shown in FIGS. 35 and 25, respectively.

7)-8 Design of Humanized 198D Light Chain h198D-L

7)-8-1 h198D-L4 Type Light Chain

A humanized 198D light chain designed by substituting the alanine residue at amino acid position 29 with a serine residue, the glycine residue at amino acid position 33 with an alanine residue, the leucine residue at amino acid position 35 with a valine residue, the glutamic acid residue at amino acid position 37 with an aspartic acid residue, the threonine residue at amino acid position 38 with an arginine residue, the glutamine residue at amino acid position 42 with a threonine residue, the glutamine residue at amino acid position 65 with a lysine residue, the glycine residue at amino acid position 85 with a serine residue, the serine residue at amino acid position 92 with a threonine residue, the lysine residue at amino acid position 94 with a threonine residue, the methionine residue at amino acid position 98 with a leucine residue, the threonine residue at amino acid position 100 with a proline residue, the glutamic acid residue at amino acid position 103 with a phenylalanine residue, the glycine residue at amino acid position 104 with an alanine residue, the valine residue at amino acid position 105 with a threonine residue, the serine residue at amino acid position 120 with a glutamine residue, the leucine residue at amino acid position 124 with a valine residue, and the alanine residue at amino acid position 129 with a threonine residue in the c198D light chain shown in SEQ ID NO: 31 in the sequence listing, was named “h198D-L4 type light chain.”

In the nucleotide sequence (SEQ ID NO: 42) encoding the h198D-L4 type light chain, the mature light chain, from which a signal sequence has been removed, is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 702, the variable region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 61 to 387, and the constant region is encoded by the nucleotide sequence consisting of the nucleotides at nucleotide positions 388 to 702. The aforementioned variable region has the nucleotide sequence consisting of the nucleotides at nucleotide positions 130 to 162 encoding CDRL1, the nucleotide sequence consisting of the nucleotides at nucleotide positions 208 to 228 encoding CDRL2, and the nucleotide sequence consisting of the nucleotides at nucleotide positions 325 to 351 encoding CDRL3, in SEQ ID NO: 42 in the sequence listing.

In addition, in the amino acid sequence (SEQ ID NO: 43) of the h198D_L4 type light chain, the mature light chain, from which a signal sequence has been removed, is the amino acid sequence consisting of the amino acids at amino acid positions 21 to 234, the variable region is the amino acid sequence consisting of the amino acids at amino acid positions 21 to 129, and the constant region is the amino acid sequence consisting of the amino acids at amino acid positions 130 to 234.

Moreover, the sequences shown in SEQ ID NOS: 42 and 43 are also shown in FIGS. 36 and 26, respectively.

7)-9 Construction of Expression Vector for Humanized Antibody

7)-9-1 Construction of Expression Vector for Humanized Anti-human GARP Antibody h151D-H1L1

A DNA fragment comprising a sequence encoding the h151D-H1 type heavy chain consisting of the nucleotides at nucleotide positions 58 to 1398 of the nucleotide sequence of the h151D-H1 type heavy chain shown in SEQ ID NO: 32 in the sequence listing was synthesized (GENEART, artificial gene synthesis service). Using the synthesized DNA fragment, in accordance with the protocols of Potelligent(R) CHOK1SV Technology by BioWa and Lonza, an expression vector for the h151D-H1 type heavy chain was constructed. The constructed expression vector was named “GSV-h151D-H1.”

Subsequently, a DNA fragment comprising a sequence encoding the h151D-L1 type light chain consisting of the nucleotides at nucleotide positions 61 to 702 of the nucleotide sequence of the h151D-L1 type light chain shown in SEQ ID NO: 36 in the sequence listing was synthesized (GENEART, artificial gene synthesis service).

Using the synthesized DNA fragment, in accordance with the protocols of Potelligent(R) CHOK1SV Technology by BioWa and Lonza, an expression vector for the h151D-L1 type light chain was constructed. The constructed expression vector was named “GSV-h151D-L1.”

Subsequently, an MACA-1511a expression vector was constructed from the thus constructed expression vectors “GSV-h151D-H1” and “GSV-h151D-L1” in accordance with the protocols of Potelligent(R) CHOK1SV Technology by BioWa and Lonza. The obtained expression vector was named “DGV-h151D-H1L1-GS.”

7)-9-2 Construction of Expression Vector for Humanized Anti-human GARP Antibody h151D-H4L4

As in the case of Example 7)-9-1, a DNA fragment comprising a sequence encoding the h151D-H4 type heavy chain consisting of the nucleotides at nucleotide positions 58 to 1398 of the nucleotide sequence of an h151D-H4 type heavy chain shown in SEQ ID NO: 34 in the sequence listing, and a DNA fragment comprising a sequence encoding an h151D-L4 type light chain consisting of the nucleotides at nucleotide positions 61 to 702 of the nucleotide sequence of the h151D-L4 type light chain shown in SEQ ID NO: 38 in the sequence listing, were synthesized (GENEART, artificial gene synthesis service).

Using the synthesized DNA fragments, in accordance with the protocols of Potelligent(R) CHOK1SV Technology by BioWa and Lonza, an MACA-1514a expression vector was constructed. The obtained expression vector was named “DGV-h151D-H4L4-GS.”

7)-9-3 Construction of Expression Vector for Humanized Anti-human GARP Antibody h198D-H3L4

As in the case of Example 7)-9-1, a DNA fragment comprising a sequence encoding the h198D-H3 type heavy chain consisting of the nucleotides at nucleotide positions 58 to 1407 of the nucleotide sequence of the h198D-H3 type heavy chain shown in SEQ ID NO: 40 in the sequence listing, and a DNA fragment comprising a sequence encoding the h198D-L4 type light chain consisting of the nucleotides at nucleotide positions 61 to 702 of the nucleotide sequence of the h198D-L4 type light chain shown in SEQ ID NO: 42 in the sequence listing, were synthesized (GENEART, artificial gene synthesis service).

Using the synthesized DNA fragments, in accordance with the protocols of Potelligent(R) CHOK1SV Technology by BioWa and Lonza, an MACA-1983a expression vector was constructed. The obtained expression vector was named “DGV-h198D-H3L4-GS.”

7)-10 Preparation of Humanized Anti-human GARP Antibody

7)-10-1 Production of Cells that Produce Humanized Anti-human GARP Antibody

7)-10-1-1 Production of Cells that Produce Humanized Anti-human GARP Antibody h151D-H1L1

Potelligent CHOK1SV cells (BioWa and Lonza) were transfected with the humanized anti-human GARP antibody h151D-H1L1 expression vector, DGV-h151D-H1L1-GS, which had been constructed in Example 7)-9-1 in accordance with the protocols of Potelligent(R) CHOK1SV Technology by BioWa and Lonza, so as to construct a cell line producing the humanized anti-human GARP antibody h151D-H1L1. The obtained producing cell line was named “MAC1-1.”

7)-10-1-2 Production of Cells that Produce Humanized Anti-human GARP Antibody h151D-H4L4

As in the case of Example 7)-10-1-1, Potelligent CHOK1SV cells (BioWa and Lonza) were transfected with the humanized anti-human GARP antibody h151D-H4L4 expression vector, DGV-h151D-H4L4-GS, which had been constructed in Example 7)-9-2, so as to construct a cell line producing the humanized anti-human GARP antibody h151D-H4L4. The obtained producing cell line was named “MAC2-1.”

7)-10-1-3 Production of Cells that Produce Humanized Anti-human GARP Antibody h198D-H3L4

As in the case of Example 7)-10-1-1, Potelligent CHOK1SV cells (BioWa and Lonza) were transfected with the humanized anti-human GARP antibody h198D-H3L4 expression vector, DGV-h198D-H3L4-GS, which had been constructed in Example 7)-9-3, so as to construct a cell line producing the humanized anti-human GARP antibody h198D-H3L4. The obtained cell line was named “MAC3-1.”

7)-10-2 Culture of Cells that Produce Humanized Anti-human GARP Antibody

7)-10-2-1 Culture of Cells that Produce Humanized Anti-human GARP Antibody h151D-H1L1

The humanized anti-human GARP antibody h151D-H1L1-producing cell line “MAC1-1” produced in Example 7)-10-1-1 was cultured using a culture apparatus Wave reactor (GE Healthcare Japan). The producing cell line “MAC1-1” was thawed in Dsp04B (JX Energy) medium, and was then cultured in Dsp04B (JX Energy) medium at 120 rpm in an incubator (37° C., 5% CO₂). The obtained culture solution was diluted with C36 (JX Energy) medium, and was then expansively cultured at 120 rpm in an incubator (37° C., 5% CO₂).

The obtained culture solution was diluted with the C36 medium at 30×10⁴ cells/mL, and was then transferred into a WAVE CELLBAG (GE Healthcare Bioscience), followed by performing a culture at 37° C. in 5% CO₂, at an air-supplying rate of 0.3 L/min, at a rotation rate of 18-24 rpm, at an angle of 6-8° , for 13 days.

From the 3rd day after initiation of the culture, FM4Ae2 medium (self-prepared) was added to the culture in an amount of 6% of the initial culture volume per day. The obtained culture solution was roughly filtrated through a depth filter Millistak MC0HC054H1 (Merck Millipore), and was then filtrated through a 0.22-μm filter (Sartorius) attached to Flexboy Bags. This filtrate was named “MACA-1511a culture supernatant”.

7)-10-2-2 Culture of Cells that Produce Humanized Anti-human GARP Antibody h151D-H4L4

In the same manner as that applied in Example 7)-10-2-1, the humanized anti-human GARP antibody h151D-H4L4-producing cell line “MAC2-1” produced in Example 7)-10-1-2 was cultured and expanded, and thereafter, the cells were subjected to fed-batch culture using a culture apparatus Wave reactor (GE Healthcare Japan). The obtained culture was diluted with C36 medium at 30×10⁴ cells/mL, and was then transferred into a WAVE CELLBAG (GE Healthcare Bioscience), followed by performing a culture for 13 days. The obtained culture solution was filtrated, and the obtained filtrate was named “MACA-1514a culture supernatant.”

7)-10-2-3 Culture of Cells that Produce Humanized Anti-human GARP Antibody h198D-H3L4

In the same manner as that applied in Example 7)-10-2-1, the humanized anti-human GARP antibody h198D-H3L4-producing cell line “MAC3-1” produced in Example 7)-10-1-3 was cultured and expanded, and thereafter, the cells were subjected to fed-batch culture using a culture apparatus Wave reactor (GE Healthcare Japan). The obtained culture was diluted with C36 medium at 30×10⁴ cells/mL, and was then transferred into a WAVE CELLBAG (GE Healthcare Bioscience), followed by performing a culture for 13 days. The obtained culture solution was filtrated, and the obtained filtrate was named “MACA-1983a culture supernatant.”

7)-10-3 Purification of Humanized Anti-human GARP Antibody

7)-10-3-1 Purification of Humanized Anti-human GARP Antibody h151D-H1L1

The “MACA-1511a culture supernatant” obtained in Example 7)-10-2-1 was purified by a three-step process, namely, by rProtein A affinity chromatography, anion exchange chromatography, and cation exchange chromatography.

First, the culture supernatant was applied to rProtein A affinity chromatographic resin that had been equilibrated with PBS. After the entire culture solution had entered the column, the column was washed with PBS, a buffer containing arginine, and PBS. Subsequently, the remaining substance in the column was eluted with an acetate buffer, and an absorption peak at 280 nm was then collected. The collected solution was neutralized with a Tris buffer, and was then roughly filtrated through a glass fiber filter AP20 (Merck Millipore). The solution was filtrated through Stericup-GV (Merck Millipore) that was a 0.22-μm filter, and the resultant filtrate was defined as an rProtein A purified pool.

Subsequently, the rProtein A purified pool was applied to an anion exchange chromatographic resin that had been equilibrated with PBS. After the applied solution as a whole had entered the column, PBS was supplied. A flow-through fraction and the absorption peak at 280 nm at the time of the supply of PBS were collected. The pH of the collected solution was adjusted with acetic acid, and the solution was then roughly filtrated through a glass fiber filter AP20 (Merck Millipore). The solution was filtrated through Stericup-GV (Merck Millipore) that was a 0.22-μm filter, and the resultant filtrate was defined as an AEX purified pool.

Subsequently, the AEX purified pool was applied to a cation exchange chromatographic resin that had been equilibrated with an acetate buffer. After the applied solution as a whole had entered the column, the column was washed with an acetate buffer. Thereafter, elution was carried out using an acetate buffer containing a high concentration of NaCl, and the absorption peak at 280 nm was collected. The collected solution was roughly filtrated through a glass fiber filter AP20 (Merck Millipore), and was then filtrated through Stericup-GV (Merck Millipore) that was a 0.22-μm filter. The resultant filtrate was defined as a CEX purified pool.

The CEX purified pool was concentrated to an antibody concentration of 25 mg/mL with Pellicon 3 Cassette 30 kDa (Merck Millipore), and the buffer was then replaced with a histidine buffer (25 mM Histidine, 5% Sorbitol, pH 6.0). Finally, the solution was roughly filtrated through a glass fiber filter AP20 (Merck Millipore), and was then filtrated through Stericup-GV (Merck Millipore) that was a 0.22-μm filter, so as to obtain a purified sample. This purified sample was named “h151D-H1L1.”

7)-10-3-2 Purification of Humanized Anti-human GARP Antibody h151D-H4L4

In the same manner as that applied in Example 7)-10-3-1, the “MACA-1514a culture supernatant” obtained in Example 7)-10-2-2 was purified by a three-stage process, namely, by rProtein A affinity chromatography, anion exchange chromatography, and cation exchange chromatography. The purified sample was named “h151D-H4L4.”

7)-10-3-3 Purification of Humanized Anti-human GARP Antibody h198D-H3L4

In the same manner as that applied in Example 7)-10-3-1, the “MACA-1983a culture supernatant” obtained in Example 7)-10-2-3 was purified by a three-stage process, namely, by rProtein A affinity chromatography, anion exchange chromatography, and cation exchange chromatography. The purified sample was named “h198D-H3L4.”

7)-11 Evaluation of Binding Activity of Humanized Anti-human GARP Antibodies to Human GARP

The dissociation constant between each of the humanized anti-human GARP antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 produced in Example 7)-10 and GARP was evaluated by using Biacore T200 (GE Healthcare Bioscience), according to a capture method, which comprises capturing the antibody as a ligand by the immobilized Protein A and then analyzing the dissociation constant using an antigen as an analyte. HBS-EP+(manufactured by GE Healthcare Bioscience) was used as a running buffer, and a Protein A Sensor Chip (manufactured by GE Healthcare Bioscience) was used as a sensor chip.

The human chimeric antibody (1 μg/mL) was added onto the chip at a rate of 10 μL/min for 20 seconds, and a dilution series solution (8 to 128 nM) of the antigen was added at a flow rate of 30 μl/min for 120 seconds. Subsequently, the dissociation was monitored for 480 seconds. As a regeneration solution, Glycine 1.5 (manufactured by GE Healthcare Bioscience) was added at a flow rate of 20 μl/min for 30 seconds.

1:1 Fitting model was used in data analysis, and the association rate constant ka, the dissociation rate constant kd, and the dissociation constant (KD; KD=kd/ka) were calculated.

The results are shown in Table 2.

Table 2 Dissociation Constant of Humanized Anti-human GARP Antibodies

TABLE 2 Name KD (nM) 1 h151D-H1L1 1.8 2 h151D-H4L4 1.2 3 h198D-H3L4 0.088

Example 8 Binding to Antigen Gene-expressing Cells 8)-1 Binding to GARP

According to the method described in Example 2, an HEK-293T cell suspension, into which a human GARP expression vector or a control vector had been transfected, was prepared. h151D-H1L1, h151D-H4L4, h198D-H3L4, and control human IgG (human IgG: Eureka Therapeutics) were added to the cell suspension, and the cells were incubated at 4° C. for 15 minutes.

The cells were washed twice with FACS buffer (PBS (Invitrogen) supplemented with 3% FBS), and thereafter, R-Phycoerythrin (PE)-labeled anti-IgG antibody (Jackson ImmunoResearch Laboratories) and Horizon FVS450 (Becton Dickinson) were added and suspended. The cells were further incubated at 4° C. for 15 minutes. The flow cytometric analysis was carried out as described in Example 2, and a histogram of PE fluorescence intensity was generated (FIG. 37).

The histograms of fluorescence intensity for h151D-H1L1, h151D-H4L4, and h198D-H3L4 in HEK-293T cells transfected with control vector were similar to the histogram for control IgG (in the figure, the cells are referred to as “Mock vector-transfected HEK-293T”).

On the other hand, it was confirmed that the histograms of fluorescence intensity for h151D-H1L1, h151D-H4L4 and h198D_H3L4 shifted to the strong fluorescence intensity side in HEK-293T cells expressing GARP (which are referred to as “hGARP-transfected HEK-293T” in the figure) in comparison to the histogram for control human IgG.

From the aforementioned results, it was found that h151D-H1L1, h151D-H4L4 and h198D-H3L4 specifically bound to GARP.

8)-2 Binding to GARP-TGF β1

8)-2-1 Construction of Human GARP Mutant Expression Vector

Using a human GARP expression vector (Origene) as a template, and also using primer F (cacggcaacctgctggagcggctgctgggggagg) (SEQ ID NO: 44), primer R (caggctgttcccagacaggtccag) (SEQ ID NO: 45), and KOD-Plus-Mutagenesis Kit (Toyobo), YSG at amino acid positions 137-139 in the human GARP amino acid sequence (SEQ ID NO: 1) was converted to HGN, so as to construct a human GARP mutant expression vector. Then, the nucleotide sequence of this vector was confirmed.

8)-2-2 Co-expression of GARP-TGF β1

Using Lipofectamine 2000 (Invitrogen), HEK-293T cells were transfected with a human TGF β1 expression vector (Sino Biological), as well as a human GARP expression vector or a human GARP mutant expression vector.

The cells were cultured in DMEM medium (Invitrogen) supplemented with 10% FBS overnight in 5% CO₂ at 37° C., and the cells were then harvested from the plate by treating them with TrypLE Express (Invitrogen). The harvested cells were washed twice with FACS buffer and were re-suspended in the same solution.

The antibodies 105F, h151D-H1L1, h151D-H4L4 and h198D-H3L4 in the present invention, known antibodies (human IgG1 anti-GARP antibodies MHG8 and LHG10 which were produced based on the sequence information described in Patent Literature 1), and control human IgG (Eureka Therapeutics) were added to the cell suspension, and the cells were incubated at 4° C. for 15 minutes.

The cells were washed twice with FACS buffer, and PE-labeled anti-IgG antibody (Jackson ImmunoResearch Laboratories) and Horizon FVS450 (Becton Dickinson) were added and suspended. The cells were further incubated at 4° C. for 15 minutes. The flow cytometric analysis was carried out as described in Example 2, and histograms of PE fluorescence intensity were generated (FIG. 38).

It was confirmed that the histograms for all of the antibodies shifted to the strong fluorescence intensity side in HEK-293T cells co-transfected with TGF β1 and GARP in comparison to the histograms for the control IgG (FIG. 38).

On the other hand, the histograms for MHG8 and LHG10 did not shift and were similar to the histograms for the control IgG in HEK-293T cells co-transfected with TGF β1 and a GARP mutant, whereas the histograms for the antibodies 105F, h151D-H1L1, h151D-H4L4 and h198D-H3L4 shifted to the strong fluorescence intensity side in the cells. Thus, it was demonstrated that the antibodies MHG8 and LHG10 did not bind to the GARP mutant, as described in [Non Patent Literature 12].

From the aforementioned results, it was demonstrated that the antibodies 105F, h151D-H1L1, h151D-H4L4 and h198D-H3L4 bound to both GARP and the GARP mutant on cells co-expressing TGF β1, and it was found that these antibodies bound to regions different from those to which the MHG8 and LHG10 antibodies bound.

Example 9 Binding to Endogenous GARP-expressing Cells

9)-1 Flow Cytometric Analysis Using L428 Cells

L428 cells were washed twice with FACS buffer and suspended in the same solution. Thereafter, h151D-H1L1, h151D-H4L4, h198D_H3L4, and control human IgG (human IgG: Eureka Therapeutics) were added to the suspension, and the cells were incubated at 4° C. for 15 minutes. The cells were washed twice with FACS buffer, and PE-labeled anti-IgG antibody (Jackson ImmunoResearch Laboratories) was added and suspended. The cells were incubated at 4° C. for 15 minutes. Flow cytometric analysis was carried out as described in Example 3, and histograms of PE fluorescence intensity were generated.

As a result, the histograms for the antibodies h151D-H1L1, h151D-H4L4 and h198D_H3L4 shifted to the strong fluorescence intensity side in L428 cells in comparison to the histograms for the control IgG. Thus, it was confirmed that h151D-H1L1, h151D-H4L4 and h198D-H3L4 bound to endogenously expressed GARP (FIG. 39).

9)-2 Flow Cytometric Analysis Using Human Treg

Frozen human PBMC (Cellular Technology) was thawed in accordance with the protocols, and the PBMC was seeded at 2×10⁶ cells/mL in a 24-well plate (Sumitomo Bakelite Co., Ltd.) using RPMI1640 medium (Invitrogen) supplemented with 10% FBS.

Dynabeads Human T-Activator CD3/CD28 (Life technologies) was added to the plate, and the cells were cultured for 48 hours. Thereafter, the cells were suspended in FACS buffer, and the antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4, and control human IgG (human IgG: Eureka Therapeutics) were added. APC-labeled anti-CD4 antibody (Becton Dickinson) was also added to the suspension. The cells were incubated at 4° C. for 10 minutes.

The cells were washed with FACS buffer, and thereafter, FITC-labeled anti-IgG antibody (Jackson ImmunoResearch Laboratories) and Horizon FVS450 (Becton Dickinson) were added and suspended. The cells were further incubated at 4° C. for 15 minutes.

The cells were washed with FACS buffer again and re-suspended in solution using FoxP3 Staining Buffer Set (Miltenyi Biotec). After that, PE-labeled anti-Foxp3 antibody (Miltenyi Biotec) was added to the cells, and the cells were incubated at 4° C. for 30 minutes.

After the cells were washed, the cells were measured using a flow cytometer (FACS Canto II; Becton Dickinson). CD4-positive cells were analyzed using FlowJo (Tree Star) after dead cells were removed from the analysis by gating out cells stained with Horizon FVS450.

The results demonstrated that the antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 bound to FoxP3-positive Treg (FIG. 40).

Example 10 Properties of Anti-GARP Antibody 10)-1 ADCC activity

The antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4, known antibodies (human IgG1 anti-GARP antibodies MHG8 and LHG10 produced based on the sequence information described in Patent Literature 1), and control human IgG (Sigma) were analyzed for their ADCC activity according to the method described in Example 4.

The antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited cytolytic activity on L428 cells in an antibody concentration-dependent manner (FIG. 41A).

In contrast, as described in Example 4, MHG8 and LHG10 did not exhibit such cytolytic activity in the same way that the control human IgG did not (FIG. 41B).

From the aforementioned results, it was demonstrated that the antibodies h151D-H1L1, h151D-H4L4 and h198D-H3L4 had ADCC activity.

10)-2 Inhibitory Activity to Treg Function

The antibodies h151D-H1L1, h151D-H4L4, and h198D-H3L4 were analyzed for their inhibitory activity to Treg function according to the method described in Example 4. The inhibitory activity of h151D-H1L1, h151D-H4L4, and h198D-H3L4 to Treg function at a final concentration of 1 μg/mL is shown in FIG. 42 (inhibitory rate of h151D-H1L1: 81.5%; inhibitory rate of h151D-H4L4: 80.4%; and inhibitory rate of h198D-H3L4: 70.8%).

It was demonstrated that the antibodies h151D-H1L1, h151D-H4L4, and h198D-H3L4 had inhibitory activity to Treg function.

10)-3 Antitumor Activity (in Vitro)

10)-3-1 Preparation of Cytotoxic T Lymphocytes (CTL)

According to the protocol from Mie University, CTL cells having an NY-ESO-1-specific T cell receptor (MU28 CD8B35 Clone #7: obtained from Mie University) were incubated at 3×10⁵ cells in a 25 cm² flask (Sumitomo Bakelite Co., Ltd.) in the presence of an anti-CD3 antibody (OKT3: Imgenex), IL-2 (Novartis), and feeder cells in RPMI1640 medium (Invitrogen) supplemented with 10% Human male AB serum (Sigma) for 7 days.

With regard to the feeder cells, frozen human PBMC (Cellular Technology) was thawed and CD8-positive cells were removed from the PBMC using CD8 MicroBeads (Miltenyi Biotech) to obtain CD8-depleted PBMC (7.5×10⁶ cells/25 cm² flask) and the cells were X-ray irradiated. In addition, 103-LCL cells (obtained from Riken BioResource Center) (1.5×10⁶ cells/25 cm² flask) were also X-ray irradiated by using an X-ray irradiator (Hitachi Medical Corporation). These cells were used as feeder cells.

Treg obtained by the method described in Example 4)-2-1 were added upon initiation of culture (1.5×10⁵ cells/25 cm² flask) in order to evaluate the suppressive effect of Treg on CTL cell activity. In addition, Treg (7.5×10⁴ cells/25 cm² flask) obtained by the aforementioned method and the antibodies 105F, h151D-H1L1, h151D-H4L4, h198D-H3L4 and human IgG1 (Enzo) were added upon initiation of culture (10 μg/ml) in order to evaluate the antitumor activity of each antibody.

After completion of the culture, CD8-positive cells were purified and separated to prepare CTL cells using a CD8⁺ T Cell Isolation Kit (Miltenyi Biotech). Thereafter, the prepared CTL cells were used in the evaluation of activity.

10)-3-2 Preparation of Target Cells

A human melanoma cell line, namely, NY-ESO-1-expressing SK-MEL-52 cells (obtained from Mie University: Proc Natl Acad Sci U S A. 1980 July; 77(7): 4260-4) were cultured using RPMI1640 medium (Invitrogen) supplemented with 10% FBS. The labeling of the cells with ⁵¹Cr was carried out as described in Example 4)-1-2, and the cells were adjusted to 2×10⁴ cells/mL. The obtained cells were defined as target cells.

10)-3-3 ⁵¹Cr Release Assay

The target cells were dispensed in a 96-well U-bottom microplate (Costar) (50 μL/well).

Subsequently, CTL cells were added to the plate (100 μL/well), so that the number of CTL cells would be 16, 8, 4, or 2 times more than the number of target cells (CTL cells: target cells=16:1, 8:1, 4:1, or 2:1), and the cells were incubated in 5% CO₂ at 37° C. for 4 hours. After that, the cells were processed according to the method as described in Example 4)-1-3. It is to be noted that the inhibitory activity of a sample is calculated every time in each experiment. In addition, it was confirmed that the CTL cells do not exhibit cytolytic activity to cells that do not express NY-ESO-1.

The measurement results are shown in FIGS. 43 and 44.

The cytolytic activity of the CTL cells to SK-MEL-52 was suppressed by Treg (FIG. 43).

On the other hand, the cell lysis rates of CTL cells against SK-MEL-52 cells elevated as the number of the CTL cells increased in the CTL cells to which the antibodies 105F, h151D-H1L1, h151D-H4L4, or h198D-H3L4 had been added, and also, the cell lysis rates were clearly higher than that of the control CTL cells to which the control IgG had been added (FIG. 44) at any target-effector ratio.

Therefore, it was demonstrated that the antibodies 105F, h151D-H1L1, h151D-H4L4 and h198D-H3L4 inhibited the suppressive activity of Treg to CTL cells, and enhanced antitumor activity.

10)-4 Antitumor Activity (in Vivo)

It is known that the antitumor effects of a chimeric antibody having ADCC activity can be evaluated in NOD/Shi-scid, IL-2R ^(null) (NOG) mice into which L428 cells had been transplanted and human PBMC are administered (J Immunol. 2009 Oct. 1; 183(7): 4782-91).

L428 cells (DSMZ), which had been suspended in a mixed solution of RPMI1640 medium (Invitrogen) and Matrigel (Becton Dickinson) (1:1) at 1×10⁷ cells/mL, were transplanted in an volume of 0.1 mL into the subcutis of the axillary region of NOG mice (female, In vivo science). The day at which the L428 cells were transplanted was defined as Day 0. On Day 6, the mice were divided into groups based on the tumor volume value (n=6 in each group), and the groups of administration were set as follows.

PBS control 1: administered on Days 6, 10, 14, 18, 22 and 26, and also, human PBMC (Lot: 20140707) was administered on Days 6, 14 and 22

105F antibody: administered at a dose of 5 mg/kg on Days 6, 10, 14, 18, 22 and 26, and also, human PBMC (Lot: 20140707) was administered on Days 6, 14 and 22

PBS control 2: administered on Days 6, 10, 14, 18, 22, and also, human PBMC (Lot: 20150924) was administered on Days 6, 14 and 22

h151D-H1L1 antibody: administered at a dose of 1 mg/kg on Days 6, 10, 14, 18 and 22, and also, human PBMC (Lot: 20150924) was administered on Days 6, 14 and 22

h151D-H4L4 antibody: administered at a dose of 1 mg/kg on Days 0, 6, 10, 14, 18 and 22, and also, human PBMC (Lot: 20150924) was administered on Days 6, 14 and 22

h198D-H3L4 antibody: administered at a dose of 1 mg/kg on Days 0, 6, 10, 14, 18 and 22, and also, human PBMC (Lot: 20150924) was administered on Days 6, 14 and 22

Each antibody was diluted with PBS (Invitrogen) and administered to the mice through the tail vein (10 mL/kg).

Regarding human PBMC, frozen human PBMC (Cellular Technology) was thawed in accordance with the protocols and prepared at 1×10⁷ cells/mL. The prepared cells (0.2 mL) were administered to the mice through the tail vein.

The long diameter (mm) and short diameter (mm) of tumor were measured over time, using electronic digital calipers (Mitutoyo), and the volume of the tumor was then calculated according to the following expression. Tumor volume (mm3)=½×[long diameter of tumor]×[short diameter of tumor]×[short diameter of tumor]

A change in the mean value±standard error (SE) of the tumor volume in each group is shown in FIG. 45.

The antibodies 105F, h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited antitumor activity to the L428 cells, in comparison to the control group to which only PBMC was administered. Thus, a significant difference was observed with respect to the control group (105F: t-test; and h151D-H1L1, h151D-H4L4 and h198D-H3L4: Dunnett's multiple comparison test). The results of the significant difference test (P values) on the final measurement day of individual groups (105F: Day 31; and h151D-H1L1, h151D-H4L4 and h198D-H3L4: Day 25) are also shown in the figure.

Therefore, the antibodies 105F, h151D-H1L1, h151D-H4L4 and h198D-H3L4 exhibited antitumor activity in in vivo models.

Example 11 Epitope Analysis of Anti-GARP Antibody

The epitopes of anti-human GARP antibodies (105F, 110F, h151D-H1L1, and h198D-H3L4) were analyzed by hydrogen-deuterium exchange mass spectrometry.

A 7 mg/mL anti-human GARP antibody was mixed with 3 mg/mL human GARP (R&D Systems) or a blank buffer in equal amounts. To the obtained solution, 9 equivalents of light water or heavy water was added. After 30 seconds, 480 seconds, or 6000 seconds of the addition of the water, or after one night had passed, 100 mM phosphoric acid, 4 M Gdn-HCl and 150 mM TCEP (pH 2.5) were added in equal amounts to the sample, so that the obtained mixture was then subjected to deuterium substitution. The thus deuterium—substituted sample was injected into HPLC under cooling, and it was then supplied to an immobilized pepsin column with a 0.1% TFA solution.

A peptide fragment obtained by digestion of human GARP in the pepsin column was retained in a C18 trap column, was then eluted by linear gradient of water and acetonitrile to which 0.1% formic acid and 0.025% TFA had been added, and was then separated in a C18 analysis column. The separated peptide fragment was subjected to mass spectrometry using a time-of-flight mass spectrometer.

The deuterium substitution rate was calculated from the mass of each peptide. A peptide fragment, in which a significant reduction in the deuterium substitution rate was observed as a result of addition of the anti-human GARP antibody, was identified to be an epitope fragment.

In the case of 105F, suppression of the deuterium substitution rate was found in the amino acid residues at positions 366-377, 407-445, and 456-470 of the human GARP shown in SEQ ID NO: 1, and thus, they were identified to be an epitope.

In the case of 110F, suppression of the deuterium substitution rate was found in the amino acid residues at positions 54-112 and 366-392 of the human GARP shown in SEQ ID NO: 1, and thus, they were identified to be an epitope.

In the case of h151D-H1L1, suppression of the deuterium substitution rate was found in the amino acid residues at positions 352-392 of the human GARP shown in SEQ ID NO: 1, and thus, they were identified to be an epitope.

In the case of h198D-H3L4, suppression of the deuterium substitution rate was found in the amino acid residues at positions 18-112 of the human GARP shown in SEQ ID NO: 1, and thus, they were identified to be an epitope.

INDUSTRIAL APPLICABILITY

The anti-GARP antibody of the present invention has an antitumor activity caused by inhibitory activity to Treg function, which is mediated by an ADCC activity, and thus, a pharmaceutical composition comprising the anti-GARP antibody can be used as an anticancer agent.

Moreover, the excessive presence of Treg and the activation thereof in patients having malaria and HIV infection exhibit a correlation with the disease state, and the removal of Treg induces remission of each disease in murine models for the diseases. Accordingly, it can be expected that effective inhibition of Treg function will also have therapeutic effects on refractory infections such as malaria and HIV.

SEQUENCE LISTING FREE TEXT

-   SEQ ID NO: 1—Amino acid sequence of GARP -   SEQ ID NO: 2—Amino acid sequence of 105F antibody heavy chain -   SEQ ID NO: 3—Amino acid sequence of 105F antibody light chain -   SEQ ID NO: 4—Amino acid sequence of 110F antibody heavy chain -   SEQ ID NO: 5—Amino acid sequence of 110F antibody light chain -   SEQ ID NO: 6—Nucleotide sequence of 105F antibody heavy chain -   SEQ ID NO: 7—Nucleotide sequence of 105F antibody light chain -   SEQ ID NO: 8—Nucleotide sequence of 110F antibody heavy chain -   SEQ ID NO: 9—Nucleotide sequence of 110F antibody light chain -   SEQ ID NO: 10—Primer A -   SEQ ID NO: 11—Primer B -   SEQ ID NO: 12—Primer C -   SEQ ID NO: 13—Primer D -   SEQ ID NO: 149—Nucleotide sequence of cDNA encoding variable region     of 151D heavy chain -   SEQ ID NO: 15—Amino acid sequence of variable region of 151D heavy     chain -   SEQ ID NO: 16—Nucleotide sequence of cDNA encoding variable region     of 151D light chain -   SEQ ID NO: 17—Amino acid sequence of variable region of 151D light     chain -   SEQ ID NO: 18—Nucleotide sequence of cDNA encoding variable region     of 198D heavy chain -   SEQ ID NO: 19—Amino acid sequence of variable region of 198D heavy     chain -   SEQ ID NO: 20—Nucleotide sequence of cDNA encoding variable region     of 198D light chain -   SEQ ID NO: 21—Amino acid sequence of variable region of 198D light     chain -   SEQ ID NO: 22—Nucleotide sequence of DNA fragment comprising human     light chain signal sequence and sequence encoding amino acids in     human κ chain constant region -   SEQ ID NO: 23—Nucleotide sequence of DNA fragment comprising human     heavy chain signal sequence and sequence encoding amino acids in     human IgG1 constant region -   SEQ ID NO: 24—Nucleotide sequence of human chimeric antibody c151D     heavy chain -   SEQ ID NO: 25—Amino acid sequence of human chimeric antibody c151D     heavy chain -   SEQ ID NO: 26—Nucleotide sequence of human chimeric antibody c151D     light chain -   SEQ ID NO: 27—Amino acid sequence of human chimeric antibody c151D     light chain -   SEQ ID NO: 28—Nucleotide sequence of human chimeric antibody c198D     heavy chain -   SEQ ID NO: 29—Amino acid sequence of human chimeric antibody c198D     heavy chain -   SEQ ID NO: 30—Nucleotide sequence of human chimeric antibody c198D     light chain -   SEQ ID NO: 31—Amino acid sequence of human chimeric antibody c198D     light chain -   SEQ ID NO: 32—Nucleotide sequence of humanized antibody h151D-H1 -   SEQ ID NO: 33—Amino acid sequence of humanized antibody h151D-H1 -   SEQ ID NO: 34—Nucleotide sequence of humanized antibody h151D-H4 -   SEQ ID NO: 35—Amino acid sequence of humanized antibody h151D-H4 -   SEQ ID NO: 36—Nucleotide sequence of humanized antibody h151D-L1 -   SEQ ID NO: 37—Amino acid sequence of humanized antibody h151D-L1 -   SEQ ID NO: 38—Nucleotide sequence of humanized antibody h151D-L4 -   SEQ ID NO: 39—Amino acid sequence of humanized antibody h151D-L4 -   SEQ ID NO: 40—Nucleotide sequence of humanized antibody h198D-H3 -   SEQ ID NO: 41—Amino acid sequence of humanized antibody h198D-H3 -   SEQ ID NO: 42—Nucleotide sequence of humanized antibody h198D-L4 -   SEQ ID NO: 43—Amino acid sequence of humanized antibody h198D-L4 -   SEQ ID NO: 44—Primer F -   SEQ ID NO: 45—Primer R 

The invention claimed is:
 1. An antibody that specifically binds Glycoprotein-A Repetitions Predominant (GARP) comprising, a) CDRH1 consisting of the amino acid sequence at amino acid positions 45 to 54 of SEQ ID NO: 25, b) CDRH2 consisting of the amino acid sequence at amino acid positions 69 to 78 of SEQ ID NO: 25, c) CDRH3 consisting of the amino acid sequence at amino acid positions 118 to 125 of SEQ ID NO: 25, d) CDRL1 consisting of the amino acid sequence at amino acid positions 44 to 54 of SEQ ID NO: 27, e) CDRL2 consisting of the amino acid sequence at amino acid positions 70 to 76 of SEQ ID NO: 27 and f) CDRL3 consisting of the amino acid sequence at amino acid positions 109 to 117 of SEQ ID NO:
 27. 2. The antibody of claim 1, wherein the GARP is a molecule consisting of the amino acid sequence of SEQ ID NO:
 1. 3. The antibody of claim 1, comprising: a heavy chain variable region consisting of the amino acid sequence at amino acid positions 20 to 136 of SEQ ID NO: 25, and a light chain variable region consisting of the amino acid sequence at amino acid positions 21 to 129 of SEQ ID NO:
 27. 4. The antibody of claim 1, comprising a human constant region.
 5. The antibody of claim 1, comprising a heavy chain consisting of the amino acid sequence at amino acid positions 20 to 466 of SEQ ID NO: 25, and a light chain consisting of the amino acid sequence at amino acid positions 21 to 234 of SEQ ID NO:
 27. 6. The antibody of claim 1 which is humanized.
 7. The antibody of claim 6, comprising: a heavy chain variable region consisting of an amino acid sequence selected from the group consisting of: (a) the amino acid sequence at amino acid positions 20 to 136 of SEQ ID NO: 33, (b) the amino acid sequence at amino acid positions 20 to 136 of SEQ ID NO: 35, (c) an amino acid sequence having homology of at least 95% or more to the sequence of (a) or (b), and (d) an amino acid sequence comprising a substitution of one or more amino acids in the sequence of a framework region other than at each CDR sequence in the sequence of (a) or (b), and a light chain variable region consisting of an amino acid sequence selected from the group consisting of: (e) the amino acid sequence at amino acid positions 21 to 129 of SEQ ID NO: 37, (f) the amino acid sequence at amino acid positions 21 to 129 of SEQ ID NO: 39, (g) an amino acid sequence having homology of at least 95% or more to the sequence of (e) or (f), and (h) an amino acid sequence comprising a substitution of one or more amino acids in the sequence of a framework region other than at each CDR sequence in the sequence of (e) or (f).
 8. The antibody of claim 6, comprising: (1) a heavy chain variable region consisting of the amino acid sequence at amino acid positions 20 to 136 of SEQ ID NO: 33, and a light chain variable region consisting of the amino acid sequence at amino acid positions 21 to 129 of SEQ ID NO: 37, or (2) a heavy chain variable region consisting of the amino acid sequence at amino acid positions 20 to 136 of SEQ ID NO: 35, and a light chain variable region consisting of the amino acid sequence at amino acid positions 21 to 129 of SEQ ID NO:
 39. 9. The antibody of claim 6, comprising: (1) a heavy chain selected from the group consisting of a heavy chain having the amino acid sequence at amino acid positions 20 to 466 of SEQ ID NO: 33, and a heavy chain having the amino acid sequence at amino acid positions 20 to 466 of SEQ ID NO: 35, and (2) a light chain selected from the group consisting of a light chain having the amino acid sequence at amino acid positions 21 to 234 of SEQ ID NO: 37, and a light chain having the amino acid sequence at amino acid positions 21 to 234 of SEQ ID NO:
 39. 10. The antibody of claim 6, comprising: (1) a heavy chain having the amino acid sequence at amino acid positions 20 to 466 of SEQ ID NO: 33, and a light chain having the amino acid sequence at amino acid positions 21 to 234 of SEQ ID NO: 37, or (2) a heavy chain having the amino acid sequence at amino acid positions 20 to 466 of SEQ ID NO: 35, and a light chain having the amino acid sequence at amino acid positions 21 to 234 of SEQ ID NO:
 39. 11. The antibody of claim 10, comprising one or two or more modifications selected from the group consisting of N-linked glycosylation, O-linked glycosylation, N-terminal processing, C-terminal processing, deamidation, isomerization of aspartic acid, oxidation of methionine, addition of a methionine residue to the N-terminus, amidation of a proline residue, and a deletion of one or two amino acids at the carboxyl terminus of the heavy chain.
 12. The antibody of claim 11, wherein one or two amino acids are deleted at the carboxyl terminus of the heavy chain.
 13. The antibody of claim 11, wherein a proline residue at the carboxyl terminus of the heavy chain is further amidated.
 14. The antibody of claim 10, wherein sugar chain modification is regulated in order to enhance antibody-dependent cellular cytotoxicity.
 15. A pharmaceutical composition comprising an antibody of claim
 1. 16. A method for treating a tumor overexpressing GARP in an individual, which comprises administering an antibody of claim 1 to the individual.
 17. The method of claim 16, wherein the tumor is a cancer.
 18. The method of claim 17, wherein the cancer is lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, or blood cancer.
 19. An antibody that specifically binds Glycoprotein-A Repetitions Predominant (GARP) comprising, a heavy chain having the amino acid sequence at amino acid positions 20 to 466 of SEQ ID NO: 33, and a light chain having the amino acid sequence at amino acid positions 21 to 234 of SEQ ID NO:
 37. 20. The antibody of claim 19, wherein sugar chain modification is regulated in order to enhance antibody-dependent cellular cytotoxicity.
 21. The antibody of claim 20, wherein one or two amino acids are deleted at the carboxyl terminus of the heavy chain.
 22. An antibody that specifically binds Glycoprotein-A Repetitions Predominant (GARP) comprising, a heavy chain having the amino acid sequence at amino acid positions 20 to 466 of SEQ ID NO: 35, and a light chain having the amino acid sequence at amino acid positions 21 to 234 of SEQ ID NO:
 39. 23. The antibody of claim 22, wherein sugar chain modification is regulated in order to enhance antibody-dependent cellular cytotoxicity.
 24. The antibody of claim 23, wherein one or two amino acids are deleted at the carboxyl terminus of the heavy chain.
 25. A method for treating a tumor overexpressing GARP in an individual, which comprises administering an antibody of claim 19 to the individual.
 26. The method of claim 25, wherein the tumor is a cancer.
 27. The method of claim 26, wherein the cancer is lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, or blood cancer.
 28. A method for treating a tumor overexpressing GARP in an individual, which comprises administering an antibody of claim 20 to the individual.
 29. The method of claim 28, wherein the tumor is a cancer.
 30. The method of claim 29, wherein the cancer is lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, or blood cancer.
 31. A method for treating a tumor overexpressing GARP in an individual, which comprises administering an antibody of claim 21 to the individual.
 32. The method of claim 31, wherein the tumor is a cancer.
 33. The method of claim 32, wherein the cancer is lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, or blood cancer.
 34. A method for treating a tumor overexpressing GARP in an individual, which comprises administering an antibody of claim 22 to the individual.
 35. The method of claim 34, wherein the tumor is a cancer.
 36. The method of claim 35, wherein the cancer is lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, or blood cancer.
 37. A method for treating a tumor overexpressing GARP in an individual, which comprises administering an antibody of claim 23 to the individual.
 38. The method of claim 37, wherein the tumor is a cancer.
 39. The method of claim 38, wherein the cancer is lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, or blood cancer.
 40. A method for treating a tumor overexpressing GARP in an individual, which comprises administering an antibody of claim 24 to the individual.
 41. The method of claim 40, wherein the tumor is a cancer.
 42. The method of claim 41, wherein the cancer is lung cancer, kidney cancer, urothelial cancer, colon cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, stomach cancer, esophageal cancer, or blood cancer.
 43. A pharmaceutical composition comprising an antibody of claim
 19. 44. A pharmaceutical composition comprising an antibody of claim
 20. 45. A pharmaceutical composition comprising an antibody of claim
 21. 46. A pharmaceutical composition comprising an antibody of claim
 22. 47. A pharmaceutical composition comprising an antibody of claim
 23. 48. A pharmaceutical composition comprising an antibody of claim
 24. 